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Abstract
Uropathogenic Escherichia coli (UPEC) are the etiologic agent of more than 80% of
uncomplicated urinary tract infections (UTIs) in humans. Pyelonephritis-associated
pili (Pap) are fimbrial adhesins that facilitate binding of UPEC to Gala-(l,4)-Gal/i
moieties contained in membrane glycolipids on human uroepithelial cells and are
associated with acute kidney infection (pyelonephritis). Pap expression is phase
variable and the frequency with which phase transition occurs determines the
proportion of P-fimbriate bacteria in the population. In this study, pap phase
transition frequencies were measured in clinical isolates for the first time and were
shown to be markedly higher than the frequencies displayed by the same pap operons
measured in E. coli K-12. In this relevant regulatory context, phase variation
frequencies of homologous pap operons were found to be differentially affected by
culture conditions, indicating a hierarchy of expression depending on environmental
signals. Cross-talk between pap operons was also found to be dependent on culture
conditions. The molecular mechanism leading to different phase variation
frequencies between homologous pap operons was investigated by sequencing 82
pap regulatory regions and their regulators (papl and papB) from 54 UPEC isolates
of different clinical origin (asymptomatic vs. symptomatic UTI). One variable region
identified was a high affinity binding site for the pap autoregulatory protein PapB.
The site contained a variable number of 9 bp repeats with (T/A)3 sequences, which
affected PapB binding and the frequency of off-to-on phase transition, under
particular environmental conditions. Sequence diversification via point mutation was
also observed among papl genes, encoding for the pap transcriptional activator Papl,
and were shown to be under positive selection (dN/dS > 1) for functionally adaptive
xviii
amino acid replacements. Certain Papl variants correlated with symptomatic disease
and differed in their ability to activate pap operons. This study provided different
lines of evidence supporting the hypothesis that UPEC isolates have evolved
mechanisms to regulate the phase variation frequencies of homologous fimbrial
operons, potentially to achieve their differential activation and sequential expression.
The ability of UPEC to coordinate expression of multiple surface factors is critical
for the successful colonisation of the varied complex micro-environments






During our life we are continually interacting with microorganisms. Although not
visible to the naked eye, bacteria represent a major component of our bodies and
outnumber our tissue cells by 10 to 1. Bacteria live on our skin, in our mouth, nose,
throat, intestine and vaginal cavity without causing disease. Bacteria that are part of
our normal flora are termed commensals. The work of the French chemist Louis
Pasteur more than a century ago, provided strong support for the, until then
controversial, 'germ theory of disease' allowing bacteria to be considered as
causative agents of human disease. Further evidence was provided by the meticulous
work of Robert Koch, who isolated different types of bacteria and demonstrated their
direct role in known human diseases. Since then, much of scientific research has
focused in delineating the molecular basis of microbial pathogenesis and disease by
investigating both microbial and host factors that participate in these processes. This
thesis describes work that aims to further our understanding of microbial disease by
investigating the genetic regulation of pathogenicity factors utilised by Escherichia
coli during infection of the human urinary tract. In an era of increased microbial
resistance to antibiotics, understanding microbial pathogenicity is going to play a
crucial role in the design of new effective strategies for disease prevention and
treatment.
1.2 Escherichia coli
The bacterium Escherichia coli was first isolated in 1885 from the faeces of healthy
individuals and was named after the German paediatrician, Theodore Escherich, who
described it. E. coli are Gram negative rods and belong to the Family of
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Enterobacteriaceae. They live as commensals in the large intestine, or colon, of
humans and animals and represent approximately 1% of the total bowel flora of adult
humans. Populations of commensal bacteria are now considered to be phenotypically
and genetically diverse and to contain subpopulations that possess the genetic
potential to cause disease (Foxman, 2007). E. coli have demonstrated the ability to
act as multipotent pathogens that can cause disease in several body systems (Kaper et
al., 2004). Intestinal pathogenic E. coli strains with distinct genotypes, such as
enteropathogenic (EPEC), enterohaemorrhagic (EHEC), enteroinvasive (EIEC),
enterotoxigenic (ETEC), and enteroaggregative (EAgEC) are responsible for general
outbreaks of diarrhoeal disease causing significant morbidity and mortality through
several different mechanisms of pathogenesis (reviewed in Sussman, 1997).
Extraintestinal E. coli (ExPEC) are another varied subset of life-threatening
pathogens responsible for neonatal meningitis, septicaemia and urinary tract
infections (UTIs) (reviewed in Sussman, 1997).
Pathogenic strains were recognised as early as the start of the 20th century and their
discrimination from non-pathogenic strains was originally based on surface antigens.
Systematic studies of E. coli virulence were made possible with the development of
immunological serotyping originally proposed by Kauffman in 1944. According to
his scheme strains are seroytped on the basis of three antigens, somatic
lipopolysaccharide O-antigens, flagellar H-antigens and capsular K-antigens. The
scheme has since then expanded to include the analysis of fimbrial F-antigens
(Orskov and Orskov, 1990), which are however rarely included in the serological
formula of a strain.
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It soon became obvious that E. coli serogroups associate reproducibly with certain
clinical syndromes. It is not, however, the serological antigens per se that confer
virulence. Rather, they serve as easily identifiable chromosomal markers that
correlate with specific bacterial virulence and 'fitness' factors. A group of E. coli
strains sharing a defined set of virulence factors and causing a common disease
constitutes a pathotype (Kaper el al., 2004). Recent advances in whole-genome
sequencing and comparative genomics revealed major genetic differences between
commensal and pathogenic E. coli strains from different pathotypes, facilitating
research in established and novel virulence determinants (Blattner et al., 1997;
Hayashi et al., 2001; Perna et al., 2001; Oelschlaeger et al., 2002; Welch et al., 2002;
Glasner and Pema, 2004; Brzuszkiewicz et al., 2006; Chen et al., 2006; Willenbrock
et al., 2006; Johnson et al., 2007; Lloyd et al., 2007).
The focus of this thesis is uropathogenic E. coli (UPEC), which forms a group of
extraintestinal pathogens equipped with the necessary virulence and 'fitness' factors
to spread, adapt, and proliferate in the urinary tract, causing the majority of human
urinary tract infections (UTIs).
1.3 Urinary Tract Infections (UTIs)
Urinary tract infections (UTIs) are defined by the presence of organisms in the
urinary tract. Although normally sterile, the urinary tract is exposed to exogenous
microorganisms via its opening to the body surface (urethra) making UTIs a very
common problem, second in incidence only to bacterial respiratory infections.
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1.3.1 Epidemiology
It is estimated that UTIs affect 150 million people worldwide and cost more than $6
billion annually in direct health care expenditure (Kucheria et al., 2005). Just in the
United States the magnitude of UTIs, as judged by visits to physicians annually, is
estimated to be as high as 8 million and cost approximately $1.6 billion (Warren,
1996; Foxman, 2002). Most UTIs occur in otherwise healthy individuals with
normal, unobstructed urinary tracts (uncomplicated or community-acquired UTIs),
while infections occuring in patients with functional or anatomical abnormalities of
the urinary tract are referred to as complicated UTIs. Infection prevalence of
uncomplicated UTIs is influenced by age and sex. The incidence rate increases with
age, and due to anatomical differences women are significantly more likely to be
affected than men (Hooton et al., 1996), except at early infancy (Zorc et al., 2005).
UTI incidence in young healthy men is very rare. In contrast, one in three women are
estimated to have had at least one episode of acute uncomplicated UTI that requires
antibiotic treatment by the age of 24 years (Foxman et al., 2000) and 40-50% of all
women will experience one UTI episode in their lifetime (Kunin, 1994). Moreover,
of those affected, as many as 27% will suffer recurrent infections (RUTI) within six
months, despite receiving appropriate antibiotic therapy (Foxman, 1990) and RUTI
prevalence can increase to more than 40% within 12 months from the index UTI
episode (Ikaheimo et al., 1996).
Although acute uncomplicated UTIs are generally considered benign conditions that
normally resolve without significant long-term medical sequelae, they can have a
significant impact on quality of life, especially when recurrent (RUTI). Moreover,
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their high prevalence and associated short-term morbidity result in significant
financial ramifications (Foxman, 2002) signifying the need to understand the
molecular pathogenesis of UTI and design effective prevention strategies for their
clinical management.
1.3.2 Common uropathogens
Infecting organisms are most commonly bacteria however infections can also occur
due to viruses, fungi and parasites. Principal bacterial pathogens are enterics from the
host intestinal flora, predominantly Escherichia coli, which accounts for >80% of
uncomplicated UTIs and ~30% of nosocomial infections (Bouza et al., 2001). Other
Gram negative species, such as Proteus, Enterobacter, Klebsiella and Pseudomonas
are less common causes of uncomplicated cases, but are more prominent in
complicated UTIs involving either compromised patients or individuals with
functionally or anatomically defective urinary tracts. Gram positive organisms are
also responsible for UTIs, with Enterococcus and Staphylococcus spp. being the
commonest. In fact, Staphylococcus saprophyticus is the second most frequent cause
of acute uncomplicated UTIs after E. coli, affecting mainly young female outpatients
(Williams et al., 1976; Jordan et al., 1980; Latham et al., 1983).
1.3.3 Clinical syndromes
A positive urine culture defines all UTIs (uncomplicated and complicated), but
overall UTI clinical manifestations are diverse and typically range from
asymptomatic bacteriuria (ABU), to infections of the bladder (cystitis) or the renal
pelvis and kidneys (acute pyelonephritis). Asymptomatic bacteriuria is defined by the
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isolation of >105 colony forming units (cfu) per ml of urine and absence of local or
systemic symptoms (Rubin et al., 1992). The prevalence of ABU is estimated to be
around 5% in young women (Hooton et al., 2000), 1-2% in children (Jodal, 1987)
and is highest in the elderly (Boscia et al., 1986). Antibiotic treatment is not
necessary for ABU, except for specific subpopulations such as pregnant women, in
which if left untreated there is a 25% risk of progressing to acute pyelonephritis and
leading to complications in pregnancy (Cunningham and Lucas, 1994). Cystitis
accounts for the great majority of physician visits for UTIs and is characterised by
>103 cfu/ml of urine, frequency and urgency of urination, dysuria and occasionally
subrapubic pain (Rubin et al., 1992). In some cases, the infectious agent ascends
from the lower urinary tract to the kidneys via the ureters causing acute
pyelonephritis, a condition resulting from inflammation of the renal pelvis and
kidney. Acute pyelonephritis is clinically characterised by isolation of >104 cfu/ml of
urine, fever and flank pain. If left untreated, about 30% of acute UTIs can progress to
bacteraemia and become life threatening when the causative agent enters the blood
stream (Agace et al., 1996). Almost 25% of bacteraemia cases reported in an 18-year
prospective hospital survey in England and Wales involved E. coli originating from
the urinary tract (Gransden et al., 1990). Recent evidence suggests that persistent and
recurrent UTIs can also be associated with an invasive E. coli phenotype, even
though the clinical presentation is very different to acute UTI. Persistence of invasive
E. coli in the urinary tract is thought to be accomplished by strains being able to lie
quiescent for long periods in the bladder/urethral epithelium (Martinez et al., 2000;
Mulvey et al., 2001; Schilling et al., 2002; Anderson et al., 2003, 2004).
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1.3.4 Host susceptibility factors
Many years of intensive UTI research has identified certain host susceptibility and
risk factors associated with the varied clinical syndromes of the disease. Among
healthy adults, women represent 90% of patients with UTIs. Behavioural factors,
such as recent sexual intercourse and use of diaphragm with spermicide, have been
associated with increased risk of UTI in sexually active young women (Hooton et al.,
1996), whereas a history of recurrent infections (RUTI) is also a predisposition factor
(Foxman, 1990). Apart from demographic and behavioural factors, research is also
focusing on identifying genetic factors that predispose to UTIs. One early
observation was that nonsecretors of blood group antigens have a hereditary
predisposition to RUTI compared to secretors (Kinane et al., 1982; Navas et al.,
1994). Recently, acute pyelonephritis was suggested to be inherited through low
expression levels of the human IL-8 receptor CXCR1 (Lundstedt et al., 2007).
For the case of complicated UTIs, susceptibility mainly appears in two groups of
patients. One group comprises of those with functional or anatomical abnormalities
of the urinary tract. Instrumentation, such as urethral catheterisation, also causes an
obstruction in the urinary tract and predisposes patients to UTIs (Warren, 2001). In a
minority of children, structural defects of the bladder-ureter valve can lead to
vesicoureteral reflux (VUR), a condition that allows uropathogens to ascend from the
lower to the upper urinary tract. This condition was shown to be epidemiologically
associated with renal scarring and severe reduction in renal function or even
complete renal failure (Jakobsson et al., 1994). The second group includes
individuals with medical conditions that predispose them to a higher incidence or
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severity of UTI. For example, patients with spinal cord injuries (Cardenas and
Hooton, 1995) and neurogenic bladders (Matsumoto et al., 2001), acute coronary
syndrome (Sims et al., 2005), diabetes (Ronald and Ludwig, 2001) and human
immunodeficiency virus (HIV) (Schonwald et al., 1999) have increased UTI risk.
In many of these patient groups E. coli is not the predominant UTI cause. Such
epidemiological findings are important in the optimisation of risk assessment and
treatment of individual cases. Therefore, the optimal approach to UTI clinical
management requires not only the identification of susceptible individuals but most
importantly, the investigation of bacterial factors that contribute to pathogenesis.
1.4 Uropathogenic Escherichia coli (UPEC)
As the major causative agent of UTIs, uropathogenic E. coli (UPEC) has been
studied extensively. UPEC strains isolated from different UTI clinical syndromes
have served as model organisms for the identification and study of bacterial factors
that confer urovirulence, their evolution, epidemiology, interaction with the host,
genetic organisation and regulation of expression.
1.4.1 Virulence factors
During the course of bacterial infection, including urinary tract infection, the
pathogen is challenged to respond to several different environments within the host.
Different niches have different requirements. In order for a bacterial pathogen to be
successful, it has to possess and express different combinations of fitness factors.
Genomic research has revealed that the chromosome of different pathogenic E. coli
9
strains is composed of a conserved 'core' genome, which is shared with commensal
E. coli strains, and a 'flexible' gene pool, which contains additional traits that can be
advantageous under certain conditions (Oelschlaeger et al., 2002; Welch et al., 2002;
Glasner and Perna, 2004). This mosaic genome structure offers E. coli diverse
disease-causing potential and reflects the lifestyle of the bacterium.
Intensive research over the last decades has led to the accumulation of knowledge on
the virulence traits and mechanisms associated with uropathogenic E. coli (UPEC).
Even though UPEC strains originate from the host's own bowel flora and therefore
exist in the intestinal tract, they possess specific traits that promote their transition to
and survival in the urinary tract. The set of virulence factors defining the UPEC
pathotype can be divided into several functional groups, which include adhesins,
toxins, iron-uptake systems, capsule, serum resistance and invasins (reviewed in
Johnson, 1991). Adhesin factors facilitate attachment of bacteria to specific host cell
receptors and drive the pathogen's tissue tropism. UPEC adhesin factors, particularly
fimbriae, are the focus of this thesis and aspects of their biology are discussed more
thoroughly in sections 1.4.3 and 1.4.4. Other virulence factors commonly produced
by UPEC strains are toxins, which frequently associate with adhesin-encoding genes
in pathogenicity islands (PAIs) (Blanco et al., 1990, 1997; Blum et al., 1995). A
direct cytotoxic effect on host tissues has been demonstrated for haemolysin (Mobley
et al., 1990; Warren et al., 1995), cytotoxic necrotising factor 1 (CNF1) (Mills et al.,
2000) and the secreted autotransporter toxin (Sat) (Guyer et al., 2000, 2002;
Maroncle et al., 2006; Guignot et al., 2007). UPEC strains also possess multiple iron
acquisition systems to cope with the limited concentrations of soluble iron in the
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urinary tract during infection (Carbonetti et al., 1986; Snyder et al., 2004). One of
the most efficient siderophores, aerobactin, ensures sufficient iron solubilisation and
uptake, and was shown to enhance bacterial survival (Montgomerie et al., 1984).
Other virulence-associated factors encoded by UPEC PAIs, such as carbohydrate
capsules, outer membrane proteins and lipopolysaccharide, play a role in serum
resistance and bacterial protection from the host immune system (Cross et al., 1986;
Weiser and Gotschlich, 1991; Jann and Jann, 1997; Schembri et al., 2004).
Interestingly, a plethora of uropathogen-specific coding sequences localised in UPEC
PAIs have either no assigned function (hypothetical proteins) or have been assigned
putative functions, strongly indicating the existence of novel urovirulence
determinants (Welch et al., 2002; Lloyd et al., 2007).
1.4.2 Evolution of virulence
Most virulence traits are not encoded by the 'core' genome but are part of UPEC's
'flexible' gene pool. Early studies using UPEC isolates demonstrated a close linkage
of genes encoding E. coli virulence factors (Low et al., 1984; Welch et al., 1983) and
it was later shown that several of these linked virulence determinants were
spontaneously lost from UPEC isolates due to large chromosomal deletions (Hacker
et al., 1983, 1990; Blum et al., 1994, 1995; Ritter et al, 1995). This led to the
discovery of large genomic islands (GEIs), which were termed pathogenicity islands
(PAIs) since they associated with virulence traits in pathogenic variants but were
absent from closely-related non-pathogenic bacteria. PAIs are large mobile genetic
elements that spread among bacterial genomes through horizontal gene transfer
(HGT) (reviewed in Hacker et al., 1999). Acquisition of multiple virulence factors
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en-block by PAI HGT greatly contributes to the evolution of pathogenic microbes
and together with genome reduction, genome rearrangements and generation of point
mutations, HGT promotes bacterial genome plasticity. These mechanisms are
considered essential for the ecological adaptation of both pathogenic and
environmental microorganisms (reviewed in Dobrindt et al., 2004).
The spread of certain PAIs among E. coli genomes explains how a clonally
heterologous group of uropathogenic strains can be associated with the same type of
disease. It is now well accepted that certain virulence factors encoded by PAIs occur
more often in E. coli isolates from patients with UTI than among other E. coli strains
(Bidet et al., 2005; Parham et al., 2005). UPEC PAIs are the most-extensively
studied; they were originally discovered in UPEC strain 536 (Blum et al., 1994) and
have since been identified in the two other prototypic pyelonephritis strains J96
(Blum et al., 1995; Swenson et al., 1996; Melkerson-Watson et al., 2001) and
CFT073 (Kao et al., 1997; Guyer et al., 1998; Rasko et al., 2001), as well as the
recently sequenced cystitis isolate UTI89 (Chen et al., 2006). The genetic traits
encoded by UPEC PAIs enable bacterial adaptation to the hostile environment of the
urinary tract and evasion of the host immune defenses (reviewed in Hacker et al.,
1999). However, not all E. coli strains causing uncomplicated UTIs possess every
established virulence factor, indicating that the presence or absence of virulence
genes determines the probability and not the ability to cause disease in the urinary
tract. Moreover, although certain virulence determinants have been demonstrated to
increase the pathogenic potential of E. coli strains, many more factors encoded by
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genetic blocks unique to UPEC strains that could enhance urovirulence are yet to be
identified and functionally characterised (Lloyd et al., 2007).
1.4.3 Adhesin factors
Uropathogenic Escherichia coli strains carry the genetic potential to express several
distinct types of fimbrial and afimbrial adhesins that permit adherence of the
bacterium to a range of host cell receptors, thus determining host, tissue and target
cell specificity for each strain (reviewed in Soto and Hultgren, 1999). Adherence is
considered essential for initial establishment and persistence in the urinary tract, as
adhesins allow 'staging post' colonisation of the perineum and vagina and
attachment to the uroepithelium in the urethra and bladder, as well as the kidney
(reviewed in Krogfelt, 1991). Moreover, adhesin factors mediate bacterial cell-cell
interactions which are required in bacterial processes equally important for
successful infection, such as microcolony and biofilm formation, cellular invasion
and intracellular survival, as well as contact-dependent inhibition of growth (Pratt
and Kolter, 1998; Danese et al., 2000; Martinez et al., 2000; Anderson et al., 2003;
Aoki et al., 2005). Afimbrial adhesins are directly associated with the bacterial
surface, whereas fimbrial adhesins are located within or at the distal tip of the
fimbrial structure, which is a protein polymer extending from the bacterial surface.
This thesis is concerned with fimbrial adhesins as virulence factors of UPEC isolates
and in particular their regulation at the genetic level. For this reason, UPEC fimbriae
are discussed in greater detail in the following sections.
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1.4.4 Fimbriae
Fimbriae are hair-like protein fibers radiating from the bacterial cell surface (Fig.
1.1A). Their composite architecture consists of a rigid helical rod and a thinner
flexible tip fibrillum that carries the adhesin protein at its distal end (Fig. 1.1 B-C)
(Kuehn et al., 1992).
Fig. 1.1 Architecture of E. coli fimbriae. (A) Freeze-etch electron micrograph of E. coli cells
expressing P fimbriae. Multiple hair-like appendages can be seen radiating from the bacterial surface.
High-resolution quick-freeze deep-etch electron micrographs of (5) a single P and (C) type 1 fiber
showing their composite architecture. Both fimbrial types consist of a rigid rod, composed of the main
structural subunit (PapA for P and FimA for type 1 fimbriae), and a thin flexible fibrillum with the
adhesin localised at the tip. A substantial difference in the fibrillum length of P and type 1 fimbriae is
obvious (images adapted from Thanassi and Hultgren, 2000).
The term fimbriae originates from the Latin word for fringe or threads and is
synonymous to pili, which was introduced later (Brinton, 1959) but is also in
common use (Duguid and Anderson, 1967). Their discovery was directly linked to
their capacity to agglutinate human erythrocytes and adhere to uroepithelial cells
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(Svanborg-Eden and Hansson, 1978; Kallenius and Mollby, 1979; Kallenius et al.,
1980). The best-studied E. coli fimbriae are type 1 and P (or Pap for pyelonephritis-
associated pili), which will be used as paradigms in the following sections to
describe various aspects of fimbrial biology.
Type 1 fimbriae are by far the most prevalent fimbrial type among commensal and
pathogenic E. coli strains, (Brinton, 1959; Buchanan et al., 1985). They are encoded
by the fun operon (Fig. 1.2) and the tip adhesin FimH interacts with a variety of
mannose-containing glycoprotein receptors present in a number of different cell
types (Ofek et al., 1977; Connell et al., 1996; Mulvey et al., 1998; Martinez et al.,
2000). Studies over the last several years have identified natural FimH variants, with
alterations as small as a single amino acid residue, that confer distinct adhesive
properties to type 1 fimbriae and enhance the potential of E. coli to colonise the
urinary tract and cause disease (Sokurenko et al., 1994, 1995, 1997, 1998, 2004;
Schembri et al., 2000; Nilsson et al., 2006; Weissman et al., 2006).
P fimbriae are encoded by the pap (pyelonephiritis-associated pili) operon (Hull et
al., 1981) (Fig. 1.2) and are epidemiologically linked to pyelonephritis (Hagberg et
al., 1981; Plos et al., 1990; Blanco et al., 1997; Johnson, 1991; Guyer et al., 1998).
Several studies have indicated that expression of P fimbriae, and specifically the
PapG adhesin, is associated with pyelonephritis in mouse models of UTI (Hagberg et
al., 1983; O'Hanley et al., 1985; Svanborg-Eden et al., 1987; Hull et al., 1994;
Tseng et al., 2007), nonhuman primates (Roberts et al., 1994), and humans (Wullt et
al., 2000; 2001a, b; Bergsten et al., 2004), (reviewed in Lane et al., 2007). Consistent
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with this observation, the PapG adhesin was shown to bind to Gal(al-4)Gal moieties
present in the globoseries of glycolipids expressed by human erythrocytes and kidney
cells (Leffler and Svanborg-Eden, 1980, 1981; Korhonen et al., 1986b; Lund et al.,
1987). Glycolipid receptors with alterations in sugar composition (Gb03, Gb04, and
Gb05) have been shown to be differentially recognised by distinct classes of PapG
alleles (Stromberg et al., 1990, 1991; Manning et al., 2001), with papG allele II
predominating among E. coli isolates from acute pyelonephritis (Johanson et al.,
1993; Dodson et al., 2001; Sung et al., 2001).
Fewer uropathogenic E. coli strains carry S fimbriae encoded by the sfa operon,
which shares similar genetic organisation with both fim and pap operons (Fig. 1.2)
(Schmoll et al., 1990; Morschhauser et al., 1993; Jones et al., 1996). The SfaS tip
adhesin mediates binding to sialic acid-containing receptors present in human kidney
epithelium and vascular endothelium (Korhonen et al., 1986b; Moch et al., 1987;
Morschhauser et al., 1990), and S fimbriae are proposed to aid bacterial
dissemination across host tissues, as S-fimbriate E. coli strains are often associated
with pyelonephritis, newborn sepsis and meningitis (Korhonen et al., 1985; Ott et al.,
1986; Hacker et al., 1993). Studies using these strains have reported the presence of
other fimbrial structures highly homologous to S fimbriae but with distinct receptor
specificities, such as F1C fimbriae encoded by the foe operon (Ott et al., 1987,
1988). F1C fimbriae were shown to bind to GalNac(l,4)Gal epitopes (Khan et al.,
2000) found in glycolipids expressed by epithelial cells of the distal tubules and
collecting ducts of the kidney, as well as by bladder and kidney vascular endothelium
(Virkola et al., 1988). F1C fimbriae are encoded by approximately 14% of UPEC
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isolates with highest occurrence among pyelonephritis strains (Pere et al., 1985;
1987), including the sequenced pyelonephritis strain CFT073 (Welch et al., 2002).
The expression of F1C fimbriae has been implicated in UPEC colonisation and
persistence in the murine urinary tract, as well as in the induction of the
proinflammatory chemokine Interleukin (IL)-8 by human renal epithelial cells

























Fig. 1.2 Comparison of the genetic operons encoding for genes involved in the biogenesis of E.
coli P, S, and Type 1 fimbriae. The pap, sfa, and fim operons share organisational and functional
homologies. The location of genes is indicated by boxes. The first two genes in all three operons
(white boxes) encode for regulatory proteins that act synergistically with E. coli global transcriptional
regulators to determine the levels of fimbrial expression. Black boxes represent the main structural
subunits composing the rigid fimbrial rod. Downstream white boxes represent genes encoding for the
periplasmic chaperone and molecular usher that ensure the correct folding and translocation of
fimbrial subunits across the outer membrane. Grey boxes represent minor fimbrial subunit genes
encoding for the tip fibrillum, which carries the adhesin at its distal tip (image adapted from Jones et
al., 1996).
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It is important to note that the fimbrial genetic load of UPEC strains does not
necessarily associate with their fimbrial expression profile. In other words, a clinical
E. coli isolate that has the genetic potential to express different types of fimbriae,
does not necessarily express its entire repertoire during the course of infection. For
example, E. coli strain 83972 that was isolated from a girl with asymptomatic
bacteriuria who carried it for 3 years without adverse effects contains chromosomal
fimbrial operons homologous to fim, pap, uca, and foe (Andersson et al., 1991; Hull
et al., 1999). However, the strain does not express fimbriae or functional adhesins
after in vitro culture or when recovered from the urinary tract (Andersson et al.,
1991; Hull et al., 1999; Wullt et al., 2000). Examples like that demonstrate that
fimbrial genetic carriage in UPEC clinical isolates is different from fimbrial
expression potential, which is important to realise in studies of bacterial
pathogenicity in vivo.
1.4.4.1 Biogenesis of fimbriae
The biogenesis of the fimbriae described above, along with more than 30 other
adhesive structures from different Gram negative pathogenic bacteria, relies on the
synergistic action of highly conserved periplasmic chaperones and outer membrane
usher proteins (Hultgren et al., 1991; Thanassi et al., 1998a; Thanassi and Hultgren,
2000). In the chaperone-usher protein secretion pathway the unfolded polypeptides
are secreted through the cytoplasmic membrane in a Sec-dependent manner
(Thanassi et al., 2005) and are then bound by the periplasmic chaperone to allow
proper subunit folding and prevent premature interactions between fimbrial subunits
(Choudhury et al., 1999; Hung et al., 1999; Sauer et al., 1999, 2002; Bann et al.,
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2004; Vetsch et al., 2004). Chaperone-subunit complexes next target the N-terminal
region of the outer membrane (OM) usher (Nishiyama et al., 2003; Ng et al., 2004),
which serves as the OM platform for ordered fiber assembly and secretion to the cell
surface (Saulino et al., 1998; Thanassi et al., 1998b; Sauer et al., 2002; Nishiyama et
al., 2005; Vetsch et al., 2006) . The biogenesis of P fimbriae has served as a model
system for elucidating the molecular and structural basis of chaperon-usher protein
secretion and recent studies continue to unravel in impressive detail the mechanistic
steps by which the chaperone and usher proteins (PapD and PapC) orchestrate
fimbrial biogenesis (Li et al., 2004; Mu et al., 2005; Shu Kin So and Thanassi, 2006;
Verger et al., 2006; Vitagliano et al., 2007).
1.4.4.2 Host immune responses to fimbriae
Fimbriae are surface organelles that mediate pathogen-host interactions; it is thus
expected that they will be targeted by the host's defense mechanisms. Indeed, several
studies have provided evidence suggesting that fimbriae are pro-inflammatory (Wullt
et al., 2001a, b; reviewed in Hedlund et al., 2001a; Wullt et al., 2002; Chassin et al.,
2006) and therefore high proportions of fimbriate bacteria during infection may be
more likely to provoke a strong host immune response with resulting symptoms.
Conversely, an isolate that persists without fimbriae or with very low numbers of
fimbriate cells, is more likely to cause asymptomatic bacteriuria (Andersson et al.,
1991; Hull et al., 1998, 1999; Graham et al., 2001). This association between
bacterial virulence, inflammation and disease severity is particularly clear in UTIs.
Early epidemiological studies initially demonstrated that fimbriae-mediated
attachment to uroepithelial cells is more prevalent among pyelonephritis than
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asymptomatic E. coli isolates (Svanborg-Eden et al., 1976), and subsequently
showed an especially clear-cut association of P fimbriae with acute disease severity,
with 90% of pyelonephritis and <20% of asymptomatic bacteriuria E. coli strains
expressing P fimbriae (Leffler and Svanborg-Eden, 1981; Plos et al., 1990; Blanco et
al., 1997). Since then, expression of P fimbriae and the binding of the PapG tip
adhesin to glycosphingolipid receptors have been shown to trigger epithelial cell
responses in vitro (Hedges et al., 1992; Svensson et al., 1994; Godaly et al., 1998)
and in vivo, both in the mouse and human urinary tract (Linder et al., 1988, 1991; de
Man et al., 1989; Hedges et al., 1991; Wullt et al., 2001a, b). Human inoculation
studies demonstrated a direct role of P fimbriae in promoting the early establishment
but not persistence of E. coli in the human urinary tract and activating innate host
responses (Hagberg et al., 1983; Andersson et al., 1991; Wullt et al., 2000, 2001a, b;
Bergsten et al., 2004; Samuelsson et al., 2004; Bergsten et al., 2007). It was
demonstrated that bacterial adherence through P fimbriae initiates mucosal
inflammation at the site of infection through production and secretion of
inflammatory mediators, including tumour growth factor (TGF), interleukin (IL)-1,
IL-6, and IL-8/CXCL8, followed by recruitment of inflammatory cells (Shahin et al.,
1987; Linder et al., 1991; Agace et al., 1993a, b; Hedges et al., 1991, 1994; Godaly
et al., 1997, 2000). The pattern recognition receptor Toll-like receptor 4 (TLR4) of
the human innate immune system was proposed to control the signaling cascade
triggered by P fimbriae, in a lipopolysaccharide (LPS)-independent manner (Hedlund
et al., 1999; Frendeus et al., 2001; reviewed in Svanborg et al., 2001). It is also
possible that P fimbriae are inducing mucosal inflammation via other routes,
involving for example the newest TLR family member, TLR11, which was shown to
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be required for UPEC clearance from the mouse kidney (Zhang et al., 2004). The
ensuing neutrophil-mediated inflammation underlies disease pathology and links P
fimbrial expression to UTI disease severity.
The emerging picture for type 1 fimbriae is suggestive of a slightly different role in
induction of host immune responses. Firstly, there is no established epidemiological
link between type 1 fimbriae and symptomatic disease, as this fimbrial type, in
contrast to P fimbriae, occurs ubiquitously among pathogenic and commensal E. coli
strains, with no frequency differences observed even among E. coli isolates of
different UTI origin (Plos et al., 1991). However, expression of type 1 fimbriae has
been shown to enhance bacterial attachment and virulence in the urinary tract of
several mouse models of UTI (Hagberg et al., 1983; Hultgren et al., 1985; Svanborg-
Eden et al., 1987; Connell et al., 1996; Hedlund et al., 2001b; Snyder et al., 2004;
Bergsten et al., 2007). Moreover, type 1 fimbriae were shown to induce host
responses in vivo by adhering to bladder mast cells and evoking vigorous exocytic
and endocytic responses that were considered pivotal in determining both the
duration and pathophysiology of infection (Abraham et al., 2001). Lastly, interaction
of type 1-fimbriate E. coli with bladder epithelial cells was shown to result in the
rapid production of inflammatory mediators, including IL-6 and IL-8, through a
mechanism dependent on LPS and TLR4 (Hedlund et al., 2001b; Schilling et al.,
2001, 2003; Backhed et al., 2002b), while a role of FimH in activation of caspase-
dependent urothelial apoptosis has also been reported (Klumpp et al., 2006).
Recently however, a human inoculation study reported that type 1 fimbriae do not
appear to play a pro-inflammatory role in the human urinary tract mucosa, as E. coli
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asymptomatic strain 83972, reconstituted with a functional fim operon, failed to
promote cytokine secretion and neutrophil influx in human patients compared to the
isogenic pap+ 83972 variant (Bergsten et al., 2007). The role of type 1 fimbriae in
triggering the innate host immune response remains therefore less clear than for P
fimbriae. It is important to note however, that the severity of disease symptoms and
the ensuing tissue pathology are caused by the combined effect of E. coli virulence
factors, such as fimbriae and toxins, together with the ability of the host to activate
specific response pathways (reviewed in Svanborg et al., 2001; Wullt et al., 2003).
In addition to the inflammatory response, the host elicits antibody responses to
invading uropathogens, but the role of anti-fimbrial antibodies in protection against
UTI is not fully understood. Studies have shown that antibodies of the secretory IgA
type and IgG with specific activity against O and K antigens of the infecting E. coli
pathogen are produced locally in infected patients, while IgG and IgM are mainly
found in the serum of UTI patients (Hanson et al., 1977; Svanborg-Eden et al.,
1985). P-fimbriate E. coli was shown to induce production of specific anti-P
antibodies in the serum of patients with acute pyelonephritis, which however failed
to block fimbrial adherence in vitro (de Ree and van den Bosch, 1987). The role of
these antibodies in resistance to human infection in vivo requires further study.
Animal model studies have offered however some promising evidence by
demonstrating that the presence of anti-P IgG antibodies in the serum and urine of
mice immunized with purified Gal-Gal fimbriae correlated with their protection from
subsequent experimental infection with fimbriate E. coli strains (Pecha et al., 1989).
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1.4.4.3 Regulation of fimbriae
The expression of the majority of UPEC fimbriae is not constitutive, as the energy
cost associated with fimbrial biogenesis must be balanced with the benefits conferred
by each particular fimbrial adhesin to the pathogen's fitness in each different niche
colonised during UTI. Fimbrial expression in E. coli is in fact under tight regulatory
control by phase variation, environmental signals and cross-regulation by other
bacterial factors (reviewed in van der Woude and Baumler, 2004). The biological
significance of regulating fimbrial expression via these mechanisms has generally
been considered to facilitate bacterial evasion of host immune detection. It is also
possible that the regulation of UPEC fimbriae by phase variation could be facilitating
evasion of cross-immunity between E. coli serotypes, in a manner similar to that
demonstrated for the phase-variable Ipf operon encoding for long polar fimbriae in
Salmonella typhimurium (Norris and Baumler, 1999). Another proposed role for the
tight regulation of UPEC fimbrial expression is that it generates an ordered
programme of gene expression events at the single-cell level to ensure optimal
bacterial fitness in every spatial and temporal niche encountered during infection
(reviewed in Holden and Gaily, 2004; van der Woude, 2006).
1.4.4.3.1 Phase variation
Phase variation of fimbrial operons refers to a switch between on and off expressing
phases. Transitioning between the two phenotypic states is reversible and heritable
between generations and results in heterogeneous bacterial populations, in which
only a subset of cells express the fimbrial adhesin. These cells have either inherited
the on phase from the parent cell, or have switched from the off to the on expression
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phase. Transitioning between expression phases occurs at certain frequencies, which
are characteristic for each fimbrial operon, regulatory mechanism and bacterial
species (reviewed in van der Woude and Baumler, 2004; van der Woude, 2006).
These transition frequencies (off-to-on and on-to-off) determine the proportion of
fimbriate cells in the bacterial population. The genetic or epigenetic switch
mechanisms that dictate the heritable and reversible nature of phase variation have
been extensively studied at the molecular level and mechanistically, more is known
about the phase variation of type 1 and P fimbriae (reviewed in Blomfield, 2001).
Expression of both fimbrial types is regulated at the level of transcription but by
distinct phase variation mechanisms.
Phase variation of type 1 fimbriae is transcriptionally regulated and depends on the
inversion of a short DNA sequence (fimS) (Eisenstein, 1981; Abraham et al., 1985).
The 314 bp invertible element is positioned at the fimE-A intergenic region of the fim
operon (see Fig. 1.2) and contains the promoter pA directing transcription of the type
1 structural subunit fimA. The orientation of fimS and subsequently of the pA
promoter dictates the expression phase of the fim operon. Inversion of fimS is an
example of site-specific recombination and is catalysed by FimB and FimE
recombinases, which are encoded by the fimB and fimE genes located adjacent to
fimA (Klemm, 1986; Gaily et al., 1996). The activity and specificity of the two
recombinases is markedly different: FimB promotes fimS inversion in both
directions, whereas FimE promotes solely on-to-off switching at much higher
frequencies than FimB (McClain et al., 1991; Gaily et al., 1993). Recombination of
the fim switch also requires the accessory global regulatory proteins integration host
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factor (IHF) and leucine-responsive regulatory protein (Lrp) that are considered to
directly contribute to the overall DNA architecture of the fim switch, facilitating
inversion by the FimB and FimE recombinases (Eisenstein et al., 1987; Blomfield et
al., 1993, 1997; Gaily et al., 1994). The abundant nucleoide-associated protein FI¬
NS has also been implicated in the regulation of fim phase variation (Spears et al.,
1986; Schembri et al., 1998).
Phase variation of P fimbriae is also under transcriptional control, but unlike type 1
fimbriae, the mechanism does not involve changes in DNA sequence. Expression of
the pap operon was the first example of epigenetic gene regulation in bacteria
(reviewed in Casadesus and Low, 2006). The pap epigenetic switch involves the
formation of differential methylation patterns, which are generated by protein
complexes on either one of two GATC methylation sites present in the pap
regulatory region (papI-B intergenic region) (Blyn et al., 1990; reviewed in van der
Woude et al., 1996). Both GATC sites, denoted distal (GATCdlst) and proximal
(GATCprox) to the main operon promoter pBA, are methylation targets for DNA
adenine methylase (Dam) and overlap two binding sites for the global E. coli
regulator Lrp. Competition between Dam and Lrp for access to the overlapping sites
results in two different methylation patterns that determine the expression phase
(on/off) of the pap operon (Fig. 1.3) (Braaten et al., 1991, 1992, 1994; Nou et al.,
1993, 1995; van der Woude et al., 1992, 1995; Weyand and Low, 2000). Formation
of the pap phase on state also requires the /?«/?-encoded regulator Papl, which is
transcribed from a separate divergent promoter (p^ located upstream of the main
operon promoter pBA. Papl was shown to interact with Lrp-pap DNA complexes and
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favour Lrp binding to promoter distal sites when GATCprox is methylated by Dam,
thus promoting formation of the on phase (Kaltenbach et al., 1995; Nou et al., 1993,
1995; Hernday et al., 2003). A second local regulator, PapB, is encoded by the first
gene in the pap operon and has a dual role in the control of pap expression; it
activates papl transcription and is thus required for off-to-on pap phase transition,
but at high protein concentrations it acts as a transcriptional repressor of the pBA
promoter (Goransson et al., 1989b; Forsman et al., 1989). The autoregulatory
function of PapB is achieved by hierarchical binding to three DNA sites: a high
affinity activating site located near the pi promoter and two lower-affinity classical
repressor sites overlapping the pBA promoter and the papB coding sequence
(Forsman et al., 1989). PapB was shown to bind to the high-affinity site 1 in an
oligomeric fashion, through minor-grove interactions with AT-rich DNA (Xia et al.,
1998). Papl and PapB belong to separate families of homologous regulators encoded
by various methylation-dependent fimbrial operons with the potential of
complementation within the single cell (see section 1.4.4.3.3 below; Morschhauser et
al., 1994; Xia et al., 2000; Holden et al., 2001). The global E. coli regulator
catabolite activator protein (CAP), also termed cyclic AMP (cAMP) receptor protein
(CRP), is another essential regulator of pap transcription. Binding of CAP in a
cAMP-dependent manner to a single site in pap regulatory DNA was shown to
activate both pi and pBA divergent promoters (Goransson et al., 1989b; Forsman et




























Fig. 1.3 DNA-protein complex formation in the pap regulatory region in phase ON and phase
OFF bacteria. In phase ON cells a complex containing Lrp, Papl, CRP (or CAP) and PapB proteins
is formed on the pap DNA region containing GATC ,st methylation site, and transcription from both
Pba and pi promoters is activated. GATCd,sl is protected from Dam methylation, whereas GATCprox is
methylated (adenine marked with *). In phase OFF cells Lrp binding to sites 1, 2, 3 protects GATCprox
site from Dam methylation and inhibits the initiation of transcription at the pBA promoter probably by
exclusion of RNA polymerase. In contrast, the adenine in GATCdlst is methylated (*) by Dam. Loss of
methylation requires DNA synthesis, which is therefore also required for pap phase variation. The on-
to-off phase transition frequency (thick arrow) is higher than the off-to-on frequency (thin arrow).
Off-to-on phase switching requires Papl and is stimulated by CRP, whereas Lrp plays a dual role in
pap phase variation, binding as an activator at sites 4, 5 in phase ON cells and as a repressor at sites 1,
2, 3 in OFF cells. (Image adapted from Blomfield. 2001).
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1.4.4.3.2 Environmental conditions
In order for bacterial pathogens to be successful in colonising varied environments it
is important that gene expression is regulated in response to environmental
conditions. Especially for fimbriae, which are both metabolically-expensive and
immunogenic, it is crucial that expression occurs only under optimal growth
conditions and is repressed promptly when fimbriation is detrimental to bacterial
survival. Environmental signals that regulate fimbrial expression in E. coli include
temperature, pH, osmolarity, carbon source, and nutrient availability, as well as the
presence of iron and aliphatic amino acids (Blyn et al., 1989; Goransson et al., 1990;
Gaily et al., 1993; White-Ziegler et al., 2000; Schwan et al., 2002; reviewed in
Henderson et al., 1999; Blomfield, 2001; van der Woude and Baumler, 2004).
Environmental sensing is mediated by global regulatory proteins that modify fimbrial
biogenesis either by influencing the frequency of phase variation or by having an
epistatic effect on the phase variation mechanism. Temperature was shown to
modulate phase variation of type 1 fimbriae by increasing the frequency of fimE-
promoted on-to-off switching at 28°C, while the frequency of /imB-promoted
recombination increased with temperature, being optimal within the range of
physiological mammalian body temperatures (Gaily et al., 1993). The presence of
aliphatic amino acids in growth media also modulated type 1 phase transition
frequencies and the effect was shown to be dependent on the global regulator Lrp
(Gaily et al., 1993; Blomfield et al., 1993). Lrp is also essential for pap phase
variation (van der Woude et al., 1995), but the expression of P fimbriae seems to be
unaffected by the presence of leucine in the growth medium (Braaten et al., 1992). P
fimbrial expression is also subject to thermoregulation with pap expression repressed
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at low temperatures (below 26°C) by a mechanism involving the global regulator FI¬
NS (Goransson et al., 1989a, 1990; White-Ziegler et al., 1990, 1998), which was
subsequently shown to be an important environmental regulator of pap expression
responsive to additional environmental signals, including osmolarity, carbon source
and growth medium composition (White-Ziegler et al., 2000). Expression of P
fimbriae is also subject to repression in the presence of glucose (Baga et al., 1985;
Blyn et al., 1989) with the phase variation mechanism being directly affected due to
lack of the cAMP-CAP regulator, which is an essential activator of papBA and papl
transcription (Goransson et al., 1989b; Weyand et al., 2001).
An important part of environmental sensing for bacteria involves being able to detect
and respond to physical changes caused by bacterial processes, such as adhesion. For
example, E. coli adherence mediated by P fimbriae was shown to be monitored by
attachment-induced changes in the bacterial cell envelope, which activated the Cpx
two-component regulatory system (Hung et al., 2001). P fimbrial phase variation
frequencies were directly modulated in response to bacterial adherence by the CpxR
regulator, which inhibited pap off-to-on phase transition and expression of P
fimbriae (Hernday et al., 2004). A growing body of evidence is indicating that
bacteria monitor fimbrial adherence to surfaces or specific receptors and regulate
gene expression accordingly (Hung et al., 2001; Otto and Silhavy, 2002; DiGiuseppe
and Silhavy, 2003). It therefore appears that the Cpx system is not only modulating
fimbrial expression in response to environmental cues, but also integrates the
regulation of fimbrial expression into a wider regulatory network that includes other
E. coli surface and virulence factors (Dorel et al., 2006).
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1.4.4.3.3 Cross-talk
Fimbrial expression in E. coli is integrated into the cell's regulatory network, which
not only ensures that fimbrial production is responsive to the environmental signals
described above, but also that it is subject to cross-regulation (also termed cross-talk)
by other bacterial factors (Holden and Gaily, 2004). Fimbrial operons can cross-talk
to coordinate their expression and this can be advantageous for the uropathogen, as it
limits physical interference between surface structures and permits sequential
fimbrial expression, which is considered to aid colonisation of multiple niches. Early
studies using E. coli strain KS71 demonstrated that although the strain has the
potential to express type 1, P and type 1C fimbriae only a small proportion of cells in
the bacterial population expressed two fimbrial types simultaneously (Nowicki et al.,
1984, 1985). Similarly, E. coli strain C1212 that contains two operons encoding for
antigenically-distinct P fimbriae (pop-17 and pap-21) was shown to express only one
P fimbrial variant on individual cells, with co-expression limited to only a small
fraction of the bacterial population (Low et al., 1987). A later study reported that a P-
fimbriate uropathogenic E. coli strain was attenuated in the murine urinary tract due
to inactivation of a second fimbrial type (Connell et al., 1996). The molecular
mechanism of regulatory cross-talk between type 1 and P fimbriae was the first
example of fimbrial cross-talk to be elucidated (Xia et al., 2000; Holden et al., 2006).
The mechanism involved the pap-encoded regulator PapB inhibiting type 1
expression by acting on the type 1 phase variation mechanism in a dual fashion: it
increased FimE expression and therefore the on-to-off phase transition frequency and
also blocked the activity of FimB on the Jim switch preventing type 1 expression
from switching on (Xia et al., 2000). This regulatory cross-talk ensures that
30
expression of type 1 and P fimbriae in the bacterial surface is mutually exclusive,
which is consistent with the distinct receptor specificities of the two fimbrial
adhesins. A similar inhibitory effect on type 1 fimbrial expression was demonstrated
by the PapB homologue SfaB of the sfa fimbrial operon, but not by DaaA, FaeB,
FanA, FanB, ClpB, and PefB which are PapB homologues encoded by other pap-like
operons found in E. coli or Salmonella typhimurium (Pef) (Holden et al., 2001). The
observation that the ability to cross-talk to a certain fimbrial operon is limited only to
some members of a regulator family raises the possibility of a hierarchy in fimbrial
expression. Expression of type 1 fimbriae was also shown to coordinately affect
expression of P fimbriae in an inverse manner in a study investigating the
transcriptome profile of type 1 phase-locked mutants in E. coli strain CFT073
(Snyder et al., 2005).
Complementation has also been demonstrated between homologous fimbrial
regulators of P and S fimbriae (Morschhauser et al., 1994). Early work using the
uropathogenic E. coli strain 536 demonstrated that deletion of pathogenicity island II
(PAIII) resulted in failure of S fimbriae expression due to a block in the transcription
of s/a-encoded genes (Knapp et al., 1986). PAI II of E. coli 536 was later shown to
contain the prf operon encoding for P-related fimbriae (Hacker et al., 1990), while
the sfa operon encoding for S fimbriae was localised within PAI III (Dobrindt et al.,
2001). The prf-encoded regulators prjT and prfB are homologous to sfaC and sfaB
from the sfa operon (Goransson et al., 1988) and were shown to complement
mutations in sfaC and sfaB and have a positive effect on the expression of S fimbriae
in E. coli strain 536. The same study demonstrated that mutants for prfl and prfB
31
repressed sfaA transcription in vitro and attenuated the virulence of E. coli 536 in
vivo (Morschhauser et al., 1994). Similarly, studies by other investigators
demonstrated that mutations in the pa/?-encoded regulator Papl are complemented by
the Papl homologues SfaC and DaaF encoded by the sfa and daa fimbrial operons
found in E. coli (Goransson et al., 1988; van der Woude and Low, 1994), as well as
Pefl, the regulator of Plasmid-encoded fimbriae (Pef) expressed by Salmonella
typhimurium (Nicholson and Low, 2000). A possible outcome of this positive
regulatory cross-talk is an increase in the probability of sequential fimbrial
expression at the single cell level and possibly subtle changes in the total fimbriation
level of UPEC isolates that contain multiple related fimbrial operons.
Regulatory cross-talk in E. coli is not restricted between fimbrial operons but
expands to other surface structures that are important for bacterial fitness in varied
specialised niches. Examples of cross-regulation have been described between
fimbriae and the phase-varying antigen 43 (Ag43) autotransporter protein (Hasman
et al., 1999; Schembri and Klemm, 2001), as well as between phase-varying fimbriae
and flagella. Ag43 is a self-recognising adhesin associated with E. coli aggregation
and biofilm formation (Danese et al., 2000) and was recently shown to promote
UPEC long-term persistence in the murine urinary bladder (Ulett et al., 2007). Ag43
expression is controlled by an epigenetic phase variation mechanism involving Dam
and the global regulator OxyR, which represses agn43 transcription by binding to
three GATC methylation sites present in the promoter region (Henderson and Owen,
1999; Haagmans and van der Woude, 2000). The molecular mechanism of Ag43
repression by fimbrial expression in E. coli has been proposed to occur by a
32
fimbriation-induced increase in the reduced form of OxyR, which will repress agn43
transcription (Schembri and Klemm, 2001), although recent evidence suggests that
OxyR can act as agn43 repressor in both the reduced and oxidised state (Wallecha et
al., 2003), posing a problem as to how, under the proposed model, Ag43 synthesis is
relieved when fimbrial expression is switched off. A suggested alternative for a
cross-talk mediator between the two phase-varying surface structures is the Cpx two-
component signal-transduction pathway (van der Woude and Baumler, 2004). The
Cpx system monitors stress in the bacterial cell envelope, including cell-surface
interactions (Otto and Silhavy, 2002), the biogenesis of P fimbriae (Hung et al.,
2001) and its activation was recently shown to repress pap operon transcription by
inhibiting phase transition from off-to-on (Hernday et al., 2004). Another example of
coordinated expression was recently identified between flagella and type 1 fimbriae
in an invasive E. coli isolate (Barnich et al., 2003). Deletion of the flagellin-encoding
gene fliC resulted in downregulation of type 1 fimbriae and the molecular
mechanism of this cross-talk appeared to act on type 1 phase variation. Additionally,
a gene encoded terminally by some E. coli P and S fimbrial operons (papX and sfaX;
Marklund et al., 1992; Dobrindt et al., 2001) reduced the motility of Proteus
mirabilis by repressing flagella expression and was proposed to be a functional
homologue of the MprJ regulator, which also represses transcription of the flagella
regulon when expressed by the manose-resistant Proteus-like (MR/P) fimbrial
operon in Proteus mirabilis (Li et al., 2001). Several studies are reporting novel
examples of cross-regulation between phase-varying or not phase-varying factors in
E. coli and other bacterial species (Schembri et al., 2004, 2005; Aoki et al., 2005;
Schwan et al., 2005; Ulett et al., 2006; Bryan et al., 2006) and although some of the
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molecular mechanisms still remain unknown, the data supports the presence of local
regulatory networks that control expression of bacterial fitness and virulence factors
in a coordinated or sequential manner (Fig. 1.4).
Stage 1: Environmental signals
switch on expression of flagellal
genes
Stage 2: FIIC promotes type 1
fimbrial expression.
Stage 3: FimE represses type 1
fimOrial expression and possibly
promotes Pap expression
Stage 4: PapB maintains type 1
repression and at high level
represses Pap expression. PapX
rcfxesscs flagcllal expression and
Papl promotes S (imbhal
expression.
Stage 5: SfaB also maintains
partial repression of type 1 and
like PapB. represses S fimbrial
expression at higher levels SfaX
possibly represses flagellal
expression.
Finn Pap j I Fla
7~A
y i!
Fim Pap Sfa Fla
Fig. 1.4 Diagrammatic representation of one possible scenario of sequential virulence factor
expression in a single E. coli bacterium. Type I fimbriae are denoted Fim and are coloured in blue,
P fimbriae (Pap) in red, S fimbriae (Sfa) in green and flagella (Fla) in black. Arrows indicate positive
regulation and blocked lines negative regulation. Filled lines represent cross-regulation examples
supported by strong experimental evidence, while broken lines are used when some evidence is
available. (Diagram adapted from Holden and Gaily, 2004).
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1.5 Research hypotheses and aims
As P fimbriae prove to be important in enhancing UPEC virulence and generating
pro-inflammatory responses in the host, it is natural to hypothesise that the regulation
of their expression must be critical for the progression of urinary tract infection and
the clinical outcome. For example, fimbrial expression is more likely to be repressed
in asymptomatic infections that persist for long periods in the host (Andersson et al.,
1991; Hull et al., 1998; Hull et al., 1999; Graham et al., 2001), than in symptomatic
infections, in which the proportion of fimbriated bacteria is likely to be higher. In
this study it was hypothesised that the proportion of P-fimbriate bacteria, as
determined by pap phase variation, is itself an important virulence determinant with
the potential to affect the magnitude of host immune responses and disease severity.
Therefore, the major aim was to investigate P fimbrial phase transition frequencies in
uropathogenic E. coli isolates, as these frequencies will determine the proportion of
P-fimbriate cells in the bacterial population.
To date, pap phase transition frequencies have been mainly measured using
lysogenic reporter constructs integrated into the chromosome of£. coli K-12 (Blyn et
al., 1989, 1990; White-Ziegler et al., 1990), but little is known about pap phase
variation frequencies in clinical isolates. It is becoming increasingly evident that
fimbrial expression in pathogenic E. coli strains is part of a cellular regulatory
network controlling expression of several virulence determinants and bacterial fitness
factors, suggesting that commensal E. coli strains do not provide a relevant genetic
background for measuring phase variation frequencies of P fimbrial operons from
UPEC clinical isolates. The initial research objective of this study was to establish a
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system for measuring P fimbrial phase transition frequencies in a clinical isolate
background.
In many isolates the combined transition frequencies (on-to-off and off-to-on) result
in a predominately phase off population that allows a minor subset of bacteria to
express fimbriae and colonise by binding to the uroepithelium, while the majority of
bacteria are present in the urine without adhering (Hultgren et al., 1985; Pere et al.,
1987). Previous findings in this laboratory however, suggest that some UPEC
isolates have higher pap phase transition frequencies resulting in the majority of the
population expressing P fimbriae (Miss L. Dixon, unpublished data). It was
hypothesised that the differences in pap phase variation frequencies observed among
different isolates reflect differences in pap regulatory DNA sequence and/or
regulatory protein sequences. It was proposed that such mechanisms would allow
modification of pap phase variation frequencies and play a role in coordinating the
regulation and expression of different pap operons present in the same UPEC isolate.
In order to investigate this hypothesis a number ofpap regulatory regions belonging
to UPEC isolates of distinct clinical origin were sequenced. Identified regions of
nucleotide diversity would serve as candidates for molecular analyses in their effects
on pap phase variation frequencies. Ultimately, the aim was to interpret sequence
diversity and its effect on pap phase variation in the context of the clinical isolate,
i.e., in a genetic background containing fimbrial operons and other virulence factors
that can cross-talk.
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It was finally hypothesised that if differences in pap regulation hold true in vivo, then
E. coli strains capable of higher P-fimbriate proportions are likely to be far more
inflammatory and aggressive in nature, not least because a much higher number will
be interacting with epithelial cells lining the urinary tract. Host factors, such as
receptor profiles and immune response, will certainly influence the clinical outcome
of UTI but their effects are likely to be dependent on bacterial virulence factors. The
final aim of this study was to assess the virulence potential of isogenic P fimbrial
regulatory variants in a mouse model of UTI in vivo. The alternative hypothesis
would predict that modulating pap phase variation frequencies and consequently P-
fimbriate proportions in the bacterial population will not affect the symptoms and
severity of infection and that isolates with differences inpap regulatory sequence and
P-fimbriate proportions are equally likely to trigger the same host immune response.
In summary, the three original aims of this research study were:
1. To measure pap phase variation frequencies from different UPEC isolates in a
clinical isolate genetic background.
2. To determine the genetic basis to differences in pap phase transition frequencies
and assess whether this information can be predictive of cross-regulation scenarios
coordinating virulence factor expression in UPEC isolates.
3. To determine whether UPEC isolates with different levels of P fimbrial




2.1 Bacterial strains and plasmids
All bacterial strains and plasmids used in this study are listed in Tables 2.1A-C and
2.2. Unless otherwise stated, all bacterial strains and plasmids were constructed as
part of this thesis.
2.1.1 Reference E. coli strains
Section (A) of Table 2.1 lists all reference E. coli K-12 strains and UPEC isolates
used in this study. E. coli strain MG1655 (Guyer et al., 1981) does not naturally
contain pap operons and was frequently used as a negative control in P fimbriation
experiments and PCR reactions. All genetic cloning steps were carried out with E.
coli AAEC185 (Blomfield et al., 1991).
UPEC isolates CFT073, J96, 536, and 83972 were included in this study as reference
strains, as they have been studied extensively. CFT073 is a pathogenic E. coli strain
isolated from the blood of a woman with acute pyelonephritis (Mobley et al., 1990).
The genome of CFT073 was the first complete UPEC genome to be sequenced and
analysis revealed the presence of two pap operons, PI and P2, encoding P fimbriae
and one foe operon encoding F1C fimbriae (Guyer et al., 1998; Welch et al., 2002).
Strain J96 belongs to an early extraintestinal E. coli isolate collection (Minshew et al.,
1978) and was isolated from a patient suffering from pyelonephritis. The virulence
profile of this strain has been studied extensively (Hull et al., 1981; Low et al., 1984;
Korhonen et al., 1985; Blum et al., 1995; Swenson et al., 1996) and the presence of
two pap operons, termed pap and prs (pap-related sequence) was demonstrated (Hull
et al., 1986; Karr et al., 1989, 1990). E. coli 536 is another well-studied
39
pyelonephritis wild-type isolate, originally obtained from the Institute for Hygiene
and Microbiology, Wurzburg, West Germany (Berger et ah, 1982). It contains P-
related fimbrial adhesin-encoding genes (prf), as well as S-fimbriae-encoding genes
(,sfa), located in distinct pathogenicity islands (Hacker et al., 1985; Janke et al., 2001;
Middendorf et al., 2004) and its genome was recently sequenced (Brzuszkiewicz et
ah, 2006). A collection of 536 isogenic fimbrial mutants (Holden et ah, 2006) was
also included in this study. Strain 83972 is a prototype asymptomatic bacteriuria E.
coli isolate identified by Andersson et ah, 1991 for its capacity to colonise the human
bladder asymptomatically and persist for a long-time. Despite the presence of DNA
sequences related to four fimbrial families (fim, pap, foe, uca), no functional adhesin
expression was detected in vitro and in vivo (Hull et ah, 1999). This was later shown
to be due to attenuating mutations in genes encoding type 1, P and F1C fimbriae
(Klemm et ah, 2006; Roos et ah, 2006b). The strain has been used for prophylactic
purposes and several trials have demonstrated its capacity to prevent other
uropathogens from causing infection in the human urinary tract (Wullt et ah, 1998;
Hull et ah, 2000; Darouiche et ah, 2001; Trautner et ah, 2002, 2003). The molecular
mechanism of this inhibition was investigated by genome-wide expression profiling
and was attributed to the strain's optimized growth properties in human urine (Roos
et ah, 2006a, c; Roos and Klemm, 2006).
2.1.2 UPEC isolates
Section (B) of Table 2.1 lists all E. coli isolates from different clinical UTI cases that
were used in this study.
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2.1.2.1 Asymptomatic bacteriuria (ABU) isolates
In total, seventeen E. coli isolates from cases of asymptomatic bacteriuria (ABU)
were obtained. Strains U43-U151 were isolated from pregnant women screened for
significant urine cultures (>103 cfu per ml of urine) (Graham et al., 2001). E. coli
asymptomatic strain BR2-V1 was isolated from a female patient subjected to ileum
enterocystoplasty (augmentation), BR10-V8 from a male patient that had undergone
ileocaecum orthotopic bladder replacement, and BR20-V1 from a male patient
subjected to ileocaecum enteroplasty (substitution) (Keegan et al., 2003). E. coli
strains HU1690-1761 were isolated from patients with asymptomatic bacteriuria and
neuropathic bladders due to spinal cord and brain injuries (Hull et al., 1998) and
were kindly provided by R. Hull. All ABU strains included in this study were
specifically selected as they contained at least one P fimbrial gene cluster (pap+).
However, it is important to note that pap+ ABU strains represent the minority of
ABU isolates, as epidemiological studies report that less than 20% express P
fimbriae (Leffler and Svanborg-Eden, 1981; Blanco et al., 1997).
2.1.2.2 Cystitis isolates
Fifteen E. coli strains isolated from cystitis cases were obtained from a Ph.D study
performed by Dr. S. Keegan at the University of Newcastle (Keegan, 2001). Patients
admitted to the Royal Victoria Infirmary and Freeman Hospital were diagnosed with
community acquired (uncomplicated) cystitis when presenting with a combination of
the following symptoms: dysuria, smelly urine, white blood cell count above >100
mm"3, subrapubic pain and in more severe cases haematuria (Keegan, 2001). All
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strains selected had been previously screened for the presence of various virulence
determinants and were shown to be pap*.
2.1.2.3 Pyelonephritis isolates
A total of 25 E. coli strains isolated from cases of pyelonephritis were collected for
this study from distinct geographical locations. Strains AUTI 8, 11 and 20 were
isolated from blood cultures of pyelonephritis cases (invasive strains) and strains
AUTI 67-71 were isolated from urine cultures. All AUTI isolates were selected from
the Keegan, 2001 study (Newcastle upon Tyne, UK) and have been characterised as
pap*. The rest of the pyelonephritis isolates were kindly provided by Prof. T.
Korhonen and were collected in Helsinki, Finland. Isolate KS71 was originally used
to demonstrate phase-variable expression of fimbriae in UPEC (Nowicki et al., 1984).
Strains AP4, AP5, AP7 and AP18 were selected from a study of P-fimbrial
expression levels (Pere et al., 1987). Isolates IHE 1041, 1049, 1086, 1106, 1152,
1190, 1268, 1402, and 1431 were used in a study of novel E. coli fimbriae by Pouttu
et al., 2001.
2.1.3 ZAP E. coli strains
The recombinant strains used in this study are listed in the order of ZAP number
designations in Table 2.1C. They mainly consist of E. coli MG1655 and CFT073
derivatives with reporter gene fusions inserted in single-copy into the bacterial
chromosome and were generally constructed by allelic exchange (see sections
2.3.14-16).
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Table 2.1 Bacterial strains. (A) Reference E. coli strains (B) UPEC isolates (C) ZAP E. coli strains.
E. coli strains Description/Relevant Genotype Source/Reference
MG1655 K-12 F" X Guyer et al., 1981
AAEC185 F" X supE44 hsdRl 7 mcrA endA I thi-1 Blomfield et al., 1991
NfimBEACDFGH) ArecA
AAEC90A Intermediate allelic exchange strain with sacB-neo cassette Blomfield et al., 1991
inserted in the lac locus ofMG1655
NEC 11 BL21 (DE3) him82::TnlO (tef) Irp::mTnlO (katf) Gaily et al., 1996
83972 Asymptomatic bacteriuria (ABU) strain (serotype Andersson et al., 1991
OR:K5:H"),fim,pap+,foc+, uca+
CFT073 UPEC pyelonephritis strain (serotype ()6:K2:H 1),fim , Mobley et al., 1990
papl* (P\),pap2+ (P2),foc+ (F1C)
J96 UPEC pyelonephritis strain (serotype 04:K6),fim',pap+, Minshew et al., 1978
536
prs
UPEC pyelonephritis strain (serotype 06:H15:K31), fun , Berger et al., 1982
prf, sfa+
536 prf 536 strain with complete prfoperon deleted Holden et al., 2006
536 sfa 536 strain with complete sfa operon deleted
M
536 fun 536 strain with complete fun operon deleted
536 prfsfa 536 strain with complete prfand sfa operons deleted
536 prffun 536 strain with complete prfandfim operons deleted
U
536 sfafun 536 strain with complete sfa and fim operons deleted
((
536 prfsfa fun 536 strain with complete prf, sfa, and fim operons deleted
It
Clinical origin UPEC isolates Source/Reference
Asymptomatic U43, U68, U105, U113, U126, U151 Graham et al., 2001
Bacteriuria (ABU) BR2-V1, BR10-V8, BR20-V1 Keegan et al., 2003
HU1690, HU1691, HU1740, HU1751, HU1756, Hull et al., 1998
HU1757, HU1758, HU1761
Cystitis AUTI3, AUTI4, AUT17, AUTI12, AUT116, AUTI19, Keegan, 2001
AUTI31, AUTI36, AUTI43, AUT147, AUT148,
AUTI62, AUTI64, AUTI66, AUT172
Pyelonephritis AUTI 8, AUTI 11, AUTI 20, AUTI 67, AUT1 68, Keegan, 2001
AUTI 69, AUTI 70, AUTI 71
AP4, AP5, AP7, API 8 Pere et al., 1987
KS71 Nowicki et al., 1984
I HE 1041, IHE1049, IHE1086, IHE1106, IHE1152, Pouttu et al., 2001
IHE1190, IHE1268, IHE1402,1HE1431
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Table 2.1 Bacteria strains (continued)
ZAP strains Description/Relevant Genotype Source/Reference
ZAP589 Allelic exchange ofpapA m¥n::egfp fr°m pLD2 in ZAP1164 Laboratory stocks
ZAP593 Allelic exchange ofpapA 196¥l3::lacZ from pLD7 in ZAP1164 Holden et al., 2007
ZAP594 Allelic exchange ofpap j96fi3 complete operon from pLDl in "
AAEC090A
ZAP595 Allelic exchange ofpapA cfto73 n'.'AacZ from pMT06 in ZAP964 "
ZAP596 Allelic exchange ofpapA AUTI72.i-' :lacZ from pMT07 in ZAP964 This study
ZAP597 Allelic exchange ofpapA hui76i.2-' :lacZ from pMT08 in ZAP964
"
ZAP598 Allelic exchange ofpapA mEm62::lacZ from pMT09 in ZAP964
((
ZAP610 Allelic exchange ofpapl S96En::gfp' from pMT35 in ZAP1164 u
ZAP611 Allelic exchange ofpapl cfto73 pi-'-'gfp from pMT34 in ZAP1164
it
ZAP612 Allelic exchange ofpapl cfto73 n-'-Sfp fr°m pMT36 in ZAP1164
it
ZAP613 Allelic exchange ofpapl AVTm.i-'-'gfp+ from pMT37 in ZAP1164 tt
ZAP614 Allelic exchange ofpapl ypu\16\.2::gfp^ from pMT38 in ZAP1164 a
ZAP615 Allelic exchange ofpapA cfto73 p2-'-gfp from pMT19 in ZAP1164
u
ZAP616 Allelic exchange ofpapl iheio86.2 -'-'gfp from pMT39 in ZAP1164
"
ZAP714 Allelic exchange ofpapA cfto73Pi ''sgfp from pMTOl in ZAP1164 Holden et al., 2007
ZAP715 Allelic exchange offocA cvum-'^gfp fr°m pMT03 in ZAP1164
u
ZAP833 Allelic exchange ofpapA cfto73 pi ■'■gfp from pMT32 in ZAP957
11
ZAP834 Allelic exchange ofpapA cfto73 n'-gfp from pMT22 in ZAP957
"
ZAP838 Allelic exchange ofpapA cfto73pi ::lacZ from pMT31 in ZAP957
"
ZAP843 Allelic exchange ofpapA cfto73 pi ::lacZ from pMT31 in ZAP964
"
ZAP955 Allelic exchange ofpapA cfto73 vi-'-egfp from pKCIO in ZAP1164
"
ZAP957 Intermediate allelic exchange strain with sacB-kan cassette inserted
"
in the lac locus of CFT073
ZAP964 Intermediate allelic exchange strain with sacB-kan cassette inserted
It
in the lac locus ofZAP965
ZAP965 CFT073 ApapI-B cfto73 pi ApapI-B cfto73 p2
II
ZAP966 Intermediate allelic exchange strain with sacB-kan cassette inserted
"
in the papl-B cfto73 p2 ofZAP969
ZAP969 CFT073 Apapl-B cfto73 pi
"
ZAP972 Intermediate allelic exchange strain with sacB-kan cassette inserted
"
in the papl-B cfto73 pi ofCFT073
ZAP992 Allelic exchange ofpapA cfto73 pp-'-lacZ from pKC41 in ZAP1164
"
ZAP996 Allelic exchange ofpapA ]96Fi3::lacZ from pKC37 in ZAP957
II
ZAP1000 Allelic exchange ofpapA Awvm.P :lacZ from pMT07 in ZAP957 This study
ZAP 1002 Allelic exchange ofpapA hutoi i--lacZ from pMT08 in ZAP957
it
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ZAP1003 Allelic exchange ofpapA iheio86.2::lacZ from pMT09 in ZAP957 This study
ZAP1137 Allelic exchange ofpapA omra P2::lacZ from pMT06 in ZAP957 Holden et al., 2007
ZAP1164 Intermediate allelic exchange strain, with sacB-kan cassette inserted Porter et al., 2004
in the lac locus ofMG1655
2.1.4 Plasmids
All plasmids used in this study are listed in Table 2.2. Commercial vectors were
obtained from laboratory stocks, except for pCR®4-TOPO® vector that was supplied
with the TOPO TA Cloning® Kit for sequencing (Invitrogen). Plasmid pHMG98 was
kindly provided by Prof. B. E. Uhlin and plasmids pIB307 and pIB462 were a gift
from Dr. I. Blomfield. All remaining plasmids were either constructed as part of this
study (pMTs) or were kindly provided by other investigators in the research
laboratory that this study was carried out in (pAJRs were constructed by Dr. A. J.
Roe, pKCs by Miss K. Catherwood, pLDs by Miss L. Dixon and pNJHs by Dr. N. J.
Holden).
Table 2.2 Plasmids
Plasmids Relevant features Source/Reference
pACYC184 Commercial cloning vector, Cm8 TcR (NEB) Rose, 1988
pBAD18 Pbad expression vector, ApR Guzman et al., 1995
pBR322 Commercial cloning vector, ApR TcR (NEB) Bolivar et al., 1977
pETll Commercial expression vector, ApR (NEB) Studier et al., 1990
pUC18 commercial cloning vector, ApR (NEB) Yanisch-Perron et al.,
1985
pCR®4-TOPO® Commercial cloning vector for sequencing, TOPO® cloning Invitrogen™
site, T3 and T7 priming sites, ApR KnR,
pPap5 pBR322 with pap j96fi3 operon on 9.6 kb EcoRl-BamYH Lindberg et al., 1984
fragment, ApR
pAJR25 pIB307 with MG1655 lacIA flanking regions Porter et al., 2004
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Table 2.2 - continued
pAJR28 pAJR25 with promoterless egfp cloned between MG1655
lacIA
Holden et al., 2006
pAJR36 pAJR25 with promoterless lacZ cloned between MG1655
lacIA
Porter et al., 2004
pAJR145 pACYC184 with rpsM::gfp+ transcriptional fusion, CmR Roe et al., 2004
pHMG98 pACYC184 with inducible paplm, TcR Forsman et al., 1989
pIB307 Allelic exchange temperature-sensitive vector, pSClOl
replicon, CmR
Blomfield et al., 1991
pIB462 pIB307 with MG1655 lac flanking regions
((
pKCl pBAD18 with inducible paplcfto73 pi Laboratory stocks
pKC2 pBAD18 with inducible paplamm p2
"
pKC8 pIB307 with CFT073 lacIA flanking regions Holden et al., 2006
pKCIO pAJR28 withpapl-A' cfto73 P2.'.' egfp translational fusion
cloned between MG1655 lacIA
Holden et al., 2007
pKCll pKC8 with sacB-kan cassette cloned between CFT073 lacIA Holdcn et al., 2006
pKC26 pAJR145 with rpsM removed Holden et al., 2007
pKC29 pKC8 with promoterless lacZ cloned between CFT073 lacIA
<(
pKC37 pKC29 with papI-A J96 F13::ZacZ translational fusion cloned
between CFT073 lacIA
u
pKC41 pAJR36 with papI-A crrn73 t\::lacZ translational fusion
cloned between MG1655 lacIA
pKC47 pKC8 with promoterless gfp+ cloned between CFT073 lacIA u
pKC48 pKC8 with promoterless gfp* cloned between MG1655 lacIA Laboratory stocks
pLDl pIB462 with pap J96 Fi3 operon from pPap5 sub-cloned into
EcoR\-Bam\A\
Holden et al., 2007
pLD2 pAJR28 with papI-A' J96 Fi2"egfp translational fusion cloned
between MG1655' lacIA
Laboratory stocks
pLD7 pAJR36 with papI-A' J96 F13;.7acZ translational fusion cloned
between MG1655 lacIA
Holden et al., 2007
pMTOl pAJR28 with papI-A' cfito pi '~:egfp translational fusion
cloned between MG1655 lacIA
((
pMT03 pAJR28 with sfaC-focA' crnm-'-'egfp translational fusion
cloned between MG1655 lacIA
This study
pMT06 pKC29 with papI-A' cfito p2::lacZ translational fusion
cloned between CFT073 lacIA
Holden et al., 2007




pMT08 pKC29 withpapI-A' hui76i.2'-'.lacZ translational fusion cloned
between CFT073 lacIA
pMT09 pKC29 with papI-A' mEi086.2-'-'lacZ translational fusion
cloned between CFT073 lacIA
pMTIO pIB307 with PI paplA (UP and DOWN) flanking regions
from CFT073
pMTll pMTIO with sacB-kan cassette cloned between CFT073 PI
paplA
pMT16 pIB307 with P2 paplA (UP and DOWN) flanking regions
from CFT073
pMT17 pMT16 with sacB-kan cassette cloned between CFT073 P2
paplA
pMT19 pKC48 with papI-A' cfto73 p2■'■'gfp+ transcriptional fusion
cloned between MG1655 lacIA
pMT22 pKC47 with papI-A' cram P2-'-gfp+ transcriptional fusion
cloned between CFT073 lacIA
pMT24 pKC26 with paplcfto73 pi promoter;:gfp+ transcriptional
fusion
pMT31 pKC29 with papI-A enrra pi::lacZ translational fusion cloned
between CFT073 lacIA
pMT32 pKC47 with papI-A cfto73 pi:-'gfp+ transcriptional fusion
cloned between CFT073 lacIA
pMT34 pKC48 with with papl cfto73 pi promoter;:gfp+ transcriptional
fusion cloned between MG1655 lacIA
pMT35 pKC48 with with paplj96 Fi3 promoter;:gfp+ transcriptional
fusion cloned between MG1655 lacIA
pMT36 pKC48 with with papl cfto73 p2 promoter;:gfp+ transcriptional
fusion cloned between MG1655 lacIA
pMT37 pKC48 with with paplauttc.i promoter;:gfp+ transcriptional
fusion cloned between MG1655 lacIA
pMT38 pKC48 with with papl nui76i.2 promoter;:gfp+ transcriptional
fusion cloned between MG1655 lacIA
pMT39 pKC48 with with papliheio86.2 promoter;;#))/ transcriptional
fusion cloned between MG1655 lacIA
pNJH20 pBAD18 with papBS96 cloned at EcoRl, AmpR
pNJH36 pETll papB
pNJH107 pUC18 with PI paplA (UP and DOWN) flanking regions
from CFT073
pNJH117 pUC18 with P2 paplA (UP and DOWN) flanking regions
from CFT073
This study
Holden et al., 2007
This study
Holden et al., 2007
This study
Holden et al., 2001
Laboratory stocks
Holden et al., 2007
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All chemicals were obtained from Sigma-Aldrich, UK, unless otherwise stated.
2.2 Bacterial culture conditions and media
Bacterial strains were routinely cultured at 37°C in Luria-Bertani (LB) broth1 or
agar2 (BDH Merck) supplemented with 25 pg ml"1 tetracycline, 25 pg ml"1
chloramphenicol, 25 pg ml"1 kanamycin, or 50 pg ml"1 ampicillin when necessary.
All UPEC isolates were originally confirmed by plating on McConkey agar3.
Colonisation factor antigen (CFA) medium4'5 was used for promoting expression of P
fimbriae (Evans et al., 1977). In switching assays, M9 medium was used containing
M9 salts supplemented with 2 mM magnesium sulphate (MgS04.7H20), 0.1 mM
calcium chloride (CaCl2.H20), 20 mM thiamine (Ci2Hi7N4OS), and 0.2% glycerol or
glucose. Essential and non-essential amino acids (Sigma-Aldrich) were added to
generate rich defined (RD) medium. Human urine was obtained from eight healthy
volunteers, with no history of UTI or antibiotic usage in the last six months. The
urine was pooled, filtered sterilised, stored in aliquots at -20°C and used within two
weeks. Urine was added to agar to make plates at a final concentration of 0.5-fold, or
used neat for static growth experiments.
XLB broth: For 1 L, 10 g tryptone, 5 g yeast extract, 5 g NaCl.
2LB agar: as for LB broth with 15 g bacto agar added.
3McConkey agar: prepared according to manufacturer's instructions.
3CFA broth: For 1 L, 10 g casein hydrolysate, 1.5 g yeast extract. Following sterilisation by
autoclaving, filter-sterile solutions of magnesium sulphate (MgS04.7H20) and manganese chloride
(MnCl2.4H20) were added to a final concentration of400 pM and 40 uM, respectively.
5CFA agar: as for CFA broth with 15 g bacto agar added.
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2.3 DNA analysis and genetic manipulation methods
Unless otherwise stated, all methods were performed as for Sambrook et al., 1989.
2.3.1 Genomic DNA extraction from E. coli strains
Genomic DNA was extracted from E. coli strains using the CTAB method as
described by Murray and Thompson, 1980. This method is based on the selective
precipitation properties of hexadecyltrimethylammonium bromide (CTAB), which
removes cell debris, proteins and polysaccharides and leaves high-molecular weight
DNA that can be recovered by isopropanol precipitation. Briefly, a 1.5 ml aliquot of
an overnight bacterial culture was microcentrifuged (13,400 g, 1 min) and the cell
pellet was suspended in 567 pi TE buffer [10 mM Tris (pH 8.0), 1 mM EDTA].
Three pi proteinase K (20 mg/ml) and 30 pi 10% sodium dodecyl sulphate (SDS)
were added, and the mix was incubated at 37°C for 1 hour. A volume of 100 pi of 5
M solution of sodium chloride (NaCl) was added and mixed thoroughly, followed by
addition of 80 pi 10% CTAB solution in 0.7 M NaCl. The mix was incubated at 65°C
for 10 min. An equal volume of chloroform:isoamyl alcohol (24:1) was added and
the samples were microcentrifuged (13,400 g, 5 min). The aqueous supernatant was
then subjected to two rounds of phenol-chloroform extraction. DNA was precipitated
with 0.6 volumes of isopropanol, pelleted by microcentrifugation at 4°C (13,400 g,
10 min), and the resulting DNA pellet was washed with 0.5 ml 70% ethanol. Lastly,
DNA pellets were suspended in 50 pi TE buffer and stored at -20°C.
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2.3.2 Preparation of crude DNA extracts from E. coli strains
Crude DNA preparations were used as templates for PCR screens mainly in cloning
experiments. A single bacterial colony from overnight growth on LB agar was
suspended in 100 pi MQ water (Sigma-Aldrich). Bacterial suspensions were heated
to 100°C for 5 min, microcentrifuged (13,400 g, 1 min) and stored at -20°C for one
week. One pi supernatant volume was used as DNA template in PCR screens.
2.3.3 Plasmid DNA extraction from E. coli strains
Medium and high copy-number plasmids (eg. pACYC184, pBAD18, pBR322,
pETll, or pCR4®-TOPO and derivatives) were extracted from bacteria cultured
overnight in 5 ml LB broth supplemented with the appropriate antibiotic. The
QIAprepIM spin plasmid miniprep kit (QIAGEN) was used according to
manufacturer's instructions and all buffers were supplied with the kit. Plasmid DNA
was eluted in 50 pi MQ water, yielding approximately 300 ng pi"1, as determined by
quantitative analysis on an agarose gel. For low copy-number plasmids (eg. pIB307
and derivatives) the plasmid contents of four 5 ml culture aliquots were pooled
through a single QIAGEN spin column of the QIAGEN miniprep kit and eluted in 35
pi MQ water to achieve a yield of -150 pg ml"1. Alternatively, the QIAGEN plasmid
midi and maxi kit was used according to manufacturer's instructions with expected
yields of 20-100 ng low-copy plasmid DNA.
2.3.4 DNA amplification by PCR
Polymerase chain reaction (PCR) was carried out in sterile thin-wall tubes in 50 pi
reaction volumes, containing 1 pi template DNA (1:50 dilution for genomic DNA),
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0.5 [xM primer (Table 2.3), 0.5 U Taq DNA polymerase (Roche) and 5 pil 10 x PCR
reaction buffer (Roche) [100 mM Tris-HCl (pH 8.3 @ 20°C), 15 mM MgCl2, 500
mM KC1], 0.4 mM mixture of dNTPs (Roche) and filter-sterile MQ water to the final
volume. Amplification was performed in a Thermo-Hybaid PCR Express cycler
programmed for an initial 4-minute DNA denaturing step at 94°C, followed by 25
cycles of 45 sec at 94°C, 45 sec at primer-optimal annealing temperature, and then 1
min 30 sec at 72°C, with a final 10-min extension step at 72°C. Amplification
products were resolved by agarose gel electrophoresis, as described in the following
section. Negative controls, in which all reagents but template DNA were added
(DNA blank), were performed in every PCR run and all reactions were repeated if
the controls contained amplification products (faint bands). Positive and negative
controls were also performed for every primer combination using DNA template
from positive and negative reference E. coli strains. Test strains were regarded as
positive if they contained amplification products of the correct size (bp) and negative
if they failed to give correct-size products in two independent PCR repeats.
For cloning and sequencing purposes, high-fidelity amplification of genomic DNA
fragments was achieved using the Expand Long Template PCR System (Roche)
according to manufacturer's instructions. This system is based on the same PCR
principles as described above, but contains an enzyme mix of Taq DNA polymerase
and Tgo DNA polymerase with inherent proofreading activity, ensuring a lower error
rate than PCR using Taq DNA polymerase alone.
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Table 2.3 Oligonucleotide primers for PCR. The primer name and associated sequence (5'-3') is
listed, together with the optimal annealing temperature (Ta) for each primer pair. Primer tail sequence
is shown in lower case and any included restriction sites are underlined. The table is sectioned to
group primers used for similar purposes: top - amplification of pap regulatory regions, second -
construction of E. coli strain ZAP965, third - amplification of papl promoter regions, last - gene
screening and other.
Primer ID DNA Sequence (5'-3^ Ta (°C) Comment Reference
PI 480 cqcqqatccGAAGTTTATGGCGTTTGTATTTTG 66 P1cfto73 regulatory Holden et al.,
papAPI 1910 cqqqtaccCCCCTGAGGAATAGTTGG region 2007
P2 52 cqcqqatccCTGATTCGTCATTCTATTCTTATTGA 66 P2cfto73 regulatory ((
papAP2 1507 cqqqtaccGCCTTGAGGGATAGATGCA region
F1C 74 cqcqqatccGGAGGTTACAGGATTTGCTTTTGTA 66 F1Ccfto73 regulatory This study
focA 1689 cqqqtaccGTTAACCGTGGTGACAGCAG region
J96 P for cqcqqatccGGCCATGCAGTAAAACCGG 53 Papj96 regulatory Holden et al.,
J96 P rev cqqqtaccCCCCTGTGGAATAGTTGGAG region 2007
CFTP1+2 for cqcqqatCcGTTTCAGTGAAGCATGCCCAC 58 Generic pap <(
CFTP1+2 rev cqqqtaccCATAAATAACAACCTCTTTTTCATTAC regulatory region
PlUPfor qctqaqctcCGGTTCAGTAATATCTGA 56 (PI) P1,2cft073 upstream Holden et al.,
P2UPfor qctqaqctcGTGCCGACGATCCCCTGA 57 (P2) flanking region 2007
P12SUPrev qctqqatccTTCACTGAAACAGATAAAWGT3
P12DNfor cqqqatccatqqtaccTCGGTTATTGCCGGTGCG 59 (PI) P1)2cFT(i73
PIDNrev cqctctaqaCCATCTTTTCTGACGGCAGC 55 (P2) downstream
11
P2DNrev cqctctaqaCTATTATCTTTCTTAACAAATGC flanking region
papIPlfor cqctCtaqaCATATATTCACTCATCTCACTG 55 PI papl promoter Holden et al.,
papIPlrev cqctCtaqaGTTTCCCCCTTCTGTCGGGC region 2007





PfamA GTGCAGATTAACATCAGGGG 60 papF screen Keegan, 2001
PfamB ATGCTCATACTGGCCGTGGT
papBl CCGGAATTCTATATCCAGGGGCCC 54 papB screen Holden et al.,
papB2 CCAGAATTCCCGGAATGCCATAAT 2001
sacB 5' CAGCTCTTTGAACATCAACGG 56 sacB screen Emmerson et
sacB 3' CTTGGTAGCCATCTTCAGTTCC al., 2006
pIB 5' AGACAAATGGATCTCGTAAGCG 55 pIB307 backbone K
pIB 3' GCTGTAACAAGTTGTCTCAGGTGT sequence screen
PapB sitel_F CTCACTGTAACAAAGTTTCTTCG 58 PapB binding This study
PapB sitel R CAGCATAAAAGATCGTCTAAATG site 1 variants
seq papB (F) GCGAGAAATACCAGATGAATAATGG 53 Internal primers for u
seq papB (R) CCATTATTCATCTGGTATTTCTCGC sequencing
a W: A+T, M: A+C, R: A+G
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2.3.5 DNA electrophoresis
DNA fragments were resolved by electrophoresis in gels containing 0.8-1.5%
agarose in 1 x Tris-borate/EDTA (TBE) buffer [89 mM trishydroxymethyl
aminomethane (Fisher), 89 mM boric acid, 2 mM ethylenediamine tetraacetic acid
(EDTA)] and 1 pi of 1 M ethidium bromide for DNA staining. Electrophoresis was
typically performed in 1 x TBE buffer at constant voltage (100 V) using Bio-Rad
systems. DNA samples contained 10 x DNA loading buffer (Invitrogen) and
fragment sizes were determined by comparison to molecular markers (1 Kb, 100 bp
or X Hindlll ladder; Invitrogen). DNA fragment visualisation was performed with
UV illumination in a Flowgen Multilmage™ light cabinet (Shenstone, England) and
gel images were captured and analysed using Chemilmager 4000i v.4.04 software.
2.3.6 DNA enzymatic digestion
All restriction endonucleases were purchased from New England BioLabs (NEB, UK)
and were used according to manufacturer's instructions. Typically, an appropriate
concentration of genomic or plasmid DNA was mixed with 4 pi 10 x appropriate
NEB buffer, 2 pi restriction endonuclease (NEB), 4 pi 10 x bovine serum albumin
(BSA; NEB), if required, and filter-sterilised water to a final volume of 40 pi.
Incubation at the recommended temperature was carried out for approximately 2
hours.
2.3.7 DNA fragment purification
DNA fragments from PCR (100 bp -
purified from contaminants using the
10 Kb) and other enzymatic reactions were
QIAquick PCR purification kit (QIAGEN)
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following manufacturer's instructions. Extraction of DNA fragments from agarose
gels in TBE buffer was performed using the QIAquick gel extraction kit (QIAGEN)
according to manufacturer's instructions. All buffers were supplied with the kits.
Purified DNA fragments were reconstituted in 30-50 pi filter-sterilised MQ water.
2.3.8 DNA fragment ligation
To generate recombinant DNA plasmids, vector and insert DNA was digested with
appropriate restriction endonucleases and purified as described in section 2.3.7. If
required, the linearised vector was treated with shrimp alkaline phosphatase (SAP;
NEB) to dephosphorylate 5' restricted termini and prevent vector religation. The
DNA concentration of the digested vector and insert were determined by quantitative
analysis on an agarose gel and the amount of insert (ng) used in a ligation reaction
with 50-100 ng of vector DNA was calculated using the following equation:
ng of vector * bp of insert
Insert (ng) = x lnsert:Vector ratio
bp of vector
where Insert: Vector ratio used was 3:1. The DNA fragments were mixed with 1 pi
T4 DNA ligase (NEB) and 1 pi 10 x ligase reaction buffer (NEB) [50 mM Tris-HCl
(pH 7.5 @ 25°C), 10 mM MgCh, 1 mM ATP, 10 mM dithiothreitol (DTT), 25 pg/ml
BSA] in a final volume of 10 pi. For ligation of complementary ends the mixture was
incubated at 16°C overnight.
2.3.9 Southern blotting and hybridisation
The number of pap operons present in each E. coli isolate used in this study was
detected by Southern hybridisation. Reference E. coli strains CFT073, J96, 536 and
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AAEC185 (Table 2.1A), and pPap5 plasmid (Table 2.2), were used as controls for
probe specificity. Genomic DNA from each isolate and plasmid DNA were digested
overnight with Hindlll or BgUl restriction endonucleases, resolved on 1% agarose
gels and blotted onto a positively-charged nylon membrane (Hybond™-N+,
Amersham Biosciences) using the capillary transfer method described in Sambrook
et al., 1989. Briefly, gels were prepared for DNA transfer by firstly soaking in 0.25
M HC1 for 10 min with gentle agitation at room temperature, to depurinate DNA, and
then washed in dHaO followed by soaking in 0.5 M NaOH, 1.5 M NaCl for 25 min,
to denature DNA. Finally, gels were washed in dH^O and neutralised by soaking in
0.5 M Tris-HCl (pH 7.5), 1.5 M NaCl for 30 min. Treated gels were then placed
upside down onto a strip of 3MM Whatman paper that was pre-soaked in transfer
buffer and rested on a solid support with its ends dipped into a reservoir of transfer
buffer [10 x SSC buffer: 1.5 M NaCl, 0.15 M trisodium citrate (Na3C6H507)]. A
piece of nylon membrane (Hybond™-N+, Amersham Biosciences) was placed on top
of the gel and covered by 3 pieces of 3MM Whatman paper. Lastly, a stack of dry
paper towels was secured with a weight on top of the blotting papers to facilitate the
upward flow of liquid necessary for the capillary transfer of DNA from the gel onto
the nylon membrane. Transfer was allowed to occur overnight and the retrieved
membranes were exposed to UV light for 2 min to cross-link DNA onto the
membrane. Membranes were then pre-hybridised in 0.3 ml cm" pre-heated
hybridisation buffer [5 x SSC buffer, 0.1% SDS, 1:20 liquid block (Amersham
Biosciences), 5% dextran sulphate] for 2 hours at 60°C. Fifty ng of denatured
hybridisation probes were added and hybridisation was allowed to occur overnight at
60°C. The hybridisation probe used for detecting all pap operons present in each
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isolate was complementary to the papB gene and was amplified using primers papBl
and papB2 (Table 2.3). The amplified product was labelled with fluorescein-dUTP
using the ECF Random Prime Labelling kit (Amersham Biosciences) according to
manufacturer's instructions. Following hybridisation, the membrane was washed
with high stringency buffers [Wash Solution 1: 1 x SSC buffer, 0.1% SDS and Wash
Solution 2: 0.5 x SSC buffer, 0.1% SDS] at 60°C and the signal was amplified using
an ECF Signal Amplification System (Amersham Biosciences) according to
manufacturer's instructions. The fluorescence signal was detected with a Fuji FLA-
2000 scanner with a 580 nm filter.
2.3.10 Transformation of competent E. coli
E. coli strains were made competent for transformation with plasmid DNA following
methods described in Sambrook et al., 1989.
2.3.10.1 Preparation and transformation of chemically-competent E. coli cells
E. coli K-12 strains were cultured in 5 ml LB broth shaking at 200 rpm at 37°C
overnight. The following day the culture was diluted 1:100 in LB broth and cultured
under the same conditions until bacterial growth reached an optical density OD6oo =
0.4-0.6. Cultures were incubated on ice prior to centrifugation at 4°C (3220 g, 8 min).
Cell pellets were gently suspended in 0.4 volumes (of the original culture volume) of
ice-cold transformation buffer I [TFBI: 30 mM potassium acetate (KC2H3O2), 10
mM CaCl2.2H20, 100 mM KC1, 15% glycerol, 45 mM MnCl2] and incubated on ice
for 15 min. Cells were harvested as above and gently suspended in 0.04 volumes of
ice-cold TFBII [75 mM CaCl2, 10 mM KC1, 15% glycerol, 10 mM Na-MOPS (pH
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7.0)]. Cells were incubated on ice for 15 min prior to aliquoting in 100 pi volumes
and storing at -70°C.
Typically, 100 pi of chemically-competent E. coli cells were transformed with 1 pi
plasmid DNA or 10 pi ligation reactions (see section 2.3.8) by mixing, incubating on
ice for 30 min and heat-shocking in a 42°C waterbath for 45 sec. Reactions were
incubated on ice for 2 min immediately after heat-shocking and then 350 pi of salt-
optimised and carbon medium (SOC; Invitrogen) was added. Transformants
containing pIB307-based temperature-sensitive vectors were cultured at 28°C,
shaking at 80 rpm for 2 hours. For all other plasmids, transformants were recovered
after one hour incubation at 37°C. A 200 pi culture aliquot was plated on LB agar
supplemented with the appropriate antibiotics and incubated overnight at the
appropriate temperature.
2.3.10.2 Preparation and transformation of electro-competent E. coli cells
All plasmid transformations in wild-type UPEC isolates and derivatives were
performed by electroporation. E. coli cultures for preparation of electro-competent
cells were prepared in a similar manner to those for chemically-competent cells.
Culture pellets were initially washed with 0.5 volumes of ice-cold 10% glycerol and
harvested by centrifugation at 4°C (3220 g, 8 min). A second wash in ice-cold 10%
glycerol followed and cells were finally suspended in 0.005 volumes of ice-cold 10%
glycerol and incubated on ice prior to aliquoting in 100 pi volumes and storing
at -70°C.
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Typically, 100 pi of electro-competent E. coli cells were transformed with 1 pi
purified plasmid DNA by gentle mixing, incubating on ice for 30 min and
electroporating at 2.5 KV in a 1.5 ml electroporation cuvette (Flowgen, UK). A
volume of 1 ml of SOC medium was immediately added, and the suspension
transferred to a 1.5 ml Eppendorf tube. Transformants containing pIB307-based
temperature-sensitive vectors were cultured at 28°C, shaking at 200 rpm for 2 hours.
For all other plasmids, transformants were recovered after one hour incubation at
37°C. A 200 pi culture aliquot was plated on LB agar supplemented with the
appropriate antibiotics and incubated overnight at the appropriate temperature.
2.3.11 TOPO TA cloning
The TOPO TA cloning® kit for sequencing (Invitrogen) provides a highly efficient
cloning strategy for the direct insertion of PCR products into the pCR4®-TOPO®
vector and their sequencing. PCR products amplified by Taq DNA polymerase
contain poly-A 3' overhangs, created by the addition of single deoxyadenosine (A) to
the 3' end of PCR products during amplification, by Taq's non-template dependent
terminal transferase activity. Amplification products generated using the Expand
Long Template system (Roche) are lacking poly-A 3' overhangs, as they are
removed by Tgo DNA polymerase. For inserting these products into the pCR4 -
TOPO® vector, PCR reactions were incubated post-amplification with 1 U of Taq
DNA polymerase at 72°C for 10 min. TOPO TA cloning® relies on ligating the
linearised pCR4®-TOPO® vector containing poly-T 3' overhands with the PCR
products carrying poly-A 3' overhangs and was carried out according to
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manufacturer's instructions. Ligation reactions were subsequently transformed into
One shot® TOPIO chemically-competent E. coli cells (Invitrogen).
All pap regulatory regions, amplified by Expand Long Template PCR (Roche) using
primers [CFTP1+2 for and rev] (Table 2.3), were cloned into pCR4®-TOPO® vector
according to manufacturer's instructions. The use of generic primers ensured
amplification of all pap regulatory regions present in the same UPEC isolate and
meant that PCR reactions potentially contained more than one type of amplification
products. Preliminary evidence for this was provided by screening several TOPO-
clones from the same cloning reaction for insert size (bp) by EcoRl diagnostic
digestion (see Fig. 4.7). Typically, two TOPO®-clones were screened for UPEC
isolates with one pap operon, five for isolates with two pap operons and eight for
isolates with three pap operons (the number of pap operons per isolate was
determined by Southern blotting, as described in section 2.3.9). The high efficiency
of TOPO® cloning ensured that almost all selected clones contained inserts and
hence, the excess number of screened clones was sufficient for obtaining different
amplification products.
2.3.12 DNA Sequencing
All DNA sequencing for this study was performed by MWG-Biotech (Single Read
DNA sequencing services), according to the company's guidelines. Each sequencing
reaction was guaranteed to contain up to 900 bp of good-quality sequence (PHRED
20).
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All pap regulatory regions examined in this study were cloned into pCR4®-TOPO®
vector by TOPO TA cloning® (section 2.3.11) and sequenced using 1 pg plasmid
DNA as template, and T3 and T7 primers that initiate sequencing reactions at
priming sites flanking the TOPO® cloning site. A second pair of internally-situated
primers [seq papB (F) and (R), Table 2.3] was used in order to achieve 100% double-
stranded sequence coverage of good-quality bases for the ~1.2 Kb inserts. To ensure
sequencing of all pap regulatory regions present in each UPEC isolate, two TOPO-
clones were sequenced for isolates with one pap operon, five for isolates with two
pap operons and eight for isolates with three pap operons.
A double-stranded DNA sequence for each pap regulatory region was assembled by
aligning four contigs obtained from the four individually-primed sequencing
reactions and covering both directions. Contig alignment was performed using
ContigExpress, a component of Vector NTI Suite 8.0. Sequence chromatograms
were viewed with CodonCode Aligner v.1.3.4 and were visually inspected for all
singleton mutations to ensure consistency between contigs and strands.
2.3.13 DNA sequence analysis
The assembled DNA sequences for all pap regulatory regions were aligned using
ClustalX 1.83 (Thompson et al., 1997). The multiple sequence alignment (msa) of all
sequenced clones aided in two tasks: firstly, identifying clones from each UPEC
isolate that carried pap regulatory sequences from the same or different operons, and
secondly, identifying polymorphic base positions across the complete sequenced
region. For this study, all point mutations were considered real sequence variation if
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they occurred in all sequenced clones representing the same operon from the same
isolate or in several clones from different UPEC isolates. Singleton mutations that
occurred in only one clone out of the ~200 sequenced clones were assumed to be
errors, potentially incorporated by PCR, and were converted to the base observed in
99.5% of the sequences.
DNA polymorphism analyses and mean diversity estimates were performed with
DnaSP 4.0 software (Rozas et al., 2003). Construction of phylogenetic trees of Papl
protein variants was performed with MEGA v.3.1 software (Kumar et al., 2004)
using the neighbor-joining distance method (Saitou and Nei, 1987) and support for
predicted tree nodes was provided by the bootstrap method (1000 replicates)
(Felsenstein, 1988). Synonymous (dS) and nonsynonymous (dN) mean pairwise
diversities were calculated with MEGA v.3.1 software (Kumar et al., 2004) using the
Nei-Gojobori method (Nei and Gojobori, 1986) and differences between
synonymous and nonsynonymous distances were compared with a codon-based Z-
test to test for positive selection (hypothesis tested: dN>dS).
2.3.14 Allelic exchange
All chromosomal deletions and gene replacements in E. coli K-12 and CFT073 were
performed by a temperature-sensitive allelic exchange plasmid system, as described
in Blomfield et al., 1991, Porter et al., 2004 and Emmerson et al., 2006.
The method relies on the initial construction of an intermediate strain in which the
sacB-kan cassette is inserted into the chromosome replacing the desired wild-type
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chromosomal sequence (eg. ZAP1164, ZAP957 and ZAP964 in Table 2.1C). The
sacB-kan cassette contains the sacB gene from Bacillus subtilis and the neomycin
(knR) gene from Tn5. Chromosomal insertion of the sacB-kan cassette firstly
involves cloning of the sacB-kan cassette between homologous flanking regions of
DNA in a temperature-sensitive, chloramphenicol-resistant plasmid (pIB307-based).
This plasmid is transformed into the desired E. coli genetic background and selection
for plasmid chromosomal integration occurs at 42°C in the presence of
chloramphenicol, while plasmid backbone excision occurs at 28°C in the presence of
kanamycin. Successful integrants are identified by growth in kanamycin-containing
media but not chloramphenicol. PCR screens for the presence of sacB gene and
absence of pIB307 plasmid backbone and/or wild-type sequence replaced by the
sacB-kan cassette were also carried out for confirmation of successful integrants.
For generation of clean chromosomal deletions or gene replacements the
intermediate allelic exchange strain carrying the sacB-kan cassette was transformed
with the temperature-sensitive plasmid containing either the homologous flanking
regions alone or DNA cloned between the flanking regions. Growth at 42°C in the
presence of chloramphenicol selected for plasmid chromosomal integration, and was
followed by growth at 28°C in the absence of antibiotics to promote excision of the
plasmid together with the sacB-kan cassette that was exchanged with the desired
target sequence. Elimination of unsuccessful integrants was achieved by culturing on
LB agar containing 6% sucrose, which is cleaved by the product of the sacB gene
(levansucrase) and results in levels of levans that are toxic for many E. coli strains.
Successful integrants were sucrose tolerant, kanamycin and chloramphenicol
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sensitive, and were confirmed by PCR screens for absence of the sacB gene and
pIB307 backbone sequence (for primers see Table 2.3) and presence of the
exchanged sequence or a 'scar' region resulting from the clean chromosomal deletion.
2.3.15 Construction of E. coli strains containing chromosomal single-copy
reporter fusions
Plasmids and strains for all single copy reporter fusions were constructed using a
similar strategy. For reporter fusions to the pBA promoter (main pap operon
promoter), the pap regulatory region including papl and papB genes was firstly
amplified by PCR using primers listed in the top panel in Table 2.3. For reporter
fusions to the pi promoter, the regulatory region downstream the first proposed
translational start site of papl, including PapB site 1 and the CAP binding site, was
amplified by PCR using primers [papl 15_KpnI (F)] and [papl promoter_CAP_BglII
(R)] (Table 2.3). The amplified promoter regions were subsequently cloned into
BamHl-Kpnl sites in allelic exchange vectors containing either lacZ (pAJR36 and
pKC29), egfp (pAJR28) or gfp+ (pKC47 and pKC48) reporter genes, flanked by
DNA sequences homologous to K-12 (pAJR36, pAJR28 and pKC48) or CFT073
(pKC29 and pKC47) chromosomal lacl and lacA. This directional cloning step
placed the reporter gene under the control of either pBA or pi promoter. The plasmids
were then transformed into intermediate allelic exchange strains ZAP1164, ZAP597
and ZAP964 that contained the sacB-kan cassette in the chromosomal lac locus of
MG1655, CFT073 wild-type and ZAP965, respectively. Using the strategy of allelic
exchange (section 2.3.14) the reporter fusions were integrated into the E. coli
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chromosome in single-copy, generating the majority of the ZAP strains listed in
Table 2.1C.
2.3.16 Construction ofE. coli CFT073 fimbria! mutants
Strain ZAP965 was generated through a series of intermediate strains (see Table
2.1C) to delete the regulatory region from the 3' end ofpapl to the 5' end ofpapA of
both PI and P2 operons of E. coli CFT073. The flanking regions incorporating papl
were amplified by PCR using primers PlUPfor (PI) or P2UPfor (P2) together with
P12SUPrev (both) and the flanking regions incorporating papA were amplified by
PCR using P12DNfor (both) and PIDNrev (PI) or P2DNrev (P2) (for primer
sequences see Table 2.3). The flanking regions were sequentially cloned by Dr. N. J.
Holden into the Sacl-BamHl (papl) and BamHl-Xbal (papA) sites in pUC18 to
generate pNJH107 (PI) and pNJH117 (P2). Both upstream and downstream flanking
regions were then sub-cloned into the Sacl-Xbal sites in pIB307 generating pMTIO
(PI) and pMT16 (P2). Subsequently, the sacB-kan cassette was cloned in the BamRl
site of pMTIO and pMT16 to generate the allelic exchange vectors pMTll (PI) and
pMT17 (P2) (for plasmids see Table 2.2). E. coli CFT073 was transformed with
pMTll by electroporation and the sacB-kan cassette was integrated into the
regulatory region of PI operon by homologous recombination and counter selection,
as described in section 2.3.14. The resulting strain ZAP972 was transformed with
pMTIO and the chromosomal sacB-kan cassette was excised from the PI region,
resulting in strain ZAP969 with papIB (PI) deleted. ZAP969 was subsequently
transformed with pMT17 to insert the sacB-kan cassette in the regulatory region of
the P2 operon. The resulting strain ZAP966 was transformed with pMT16 to excise
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the sacB-kan cassette, deleting the papIB P2 region and generating strain ZAP965, a
CFT073-derivative with both pap regulatory regions deleted (for confirmation of
strain ZAP965 see Fig. 3.4).
2.4 Indirect immunofluorescence staining of P fimbriae
For labelling P-fimbriae on the bacterial cell surface, CFA agar streak plates of
UPEC isolates cultured overnight at 37°C were washed with 3 ml of phosphate
buffered saline [137 mM NaCl, 10 mM Na2HPC>4, 2.7 mM KC1, 1.4 mM K2HPO4,
adjusted to pH 7.4] (PBS; Oxoid). Bacterial suspensions adjusted to OD60o = 0.6
were prepared from the bacterial slurry and washed twice in 1 ml PBS and then
mixed with the appropriate primary anti-P rabbit polyclonal serum diluted 1:50 in
PBS and incubated for 30 min at room temperature. For detection of J96 F13 P
fimbriae an anti-PapA antibody supplied by Prof. B.E. Uhlin was used (Nilsson et al.,
1996), whereas for detection of the E. coli CFT073 PI and P2 fimbriae polyclonal
OM12 serum provided by Prof. T. Korhonen was used (Pere et al., 1987). Different
primary antibodies were used reflecting the different P fimbrial variants being
detected. Excess primary antibody was removed with three washes in 1 ml PBS and
cells were then mixed with the secondary goat Alexa Fluor 488 conjugate to anti-
rabbit IgG (1: 500 in PBS; Molecular Probes) for 30 min at room temperature.
Excess secondary antibody was removed with three washes in 1 ml PBS.
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2.5 Methods for fluorescence detection
2.5.1 Flow cytometry (FC)
Fluorescence either from serum-labelled P-fimbriate bacteria (section 2.4) or strains
possessing a single-copy fluorescent reporter fusion was detected using a
FACSCalibur flow cytometer (Becton Dickinson). Samples of antibody-labelled P-
fimbriate bacteria were prepared as described in 2.4, whereas fusion strains were
collected with 3 ml PBS from CFA agar plates, adjusted to OD600 = 0.6 and washed
twice in 1 ml PBS. Acquisition and analysis of flow cytometry data was performed
using the CELLQuest software. The selected R1 region was optimized in order to
exclude small particles and debris using sized beads (Becton Dickinson) and multiple
E. coli strains. The gate for the detection of fluorescence signals was set such that
cells under investigation were considered positive when their fluorescence intensity
(FL-1 height) exceeded that of all but a very small fraction (0.5%) of the negative
control population of the same UPEC strain grown under the same conditions but
labelled only with the secondary antibody or the non-fluorescent parent strain of a
fusion strain. Typically, a population of 20,000 bacterial cells (events) was assessed
in every sample run.
2.5.2 Fluorescence microscopy
Visualisation of serum-labelled P-fimbriate bacteria and strains containing
fluorescent reporter fusions was performed using fluorescence microscopes by Leica
Microsystems and image acquisition and analysis was performed using Improvision
OpenLab software. Bacterial samples were prepared as described above, fixed onto
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glass slides with 4% paraformaldehyde (PFA) and mounted with fluorescence
mounting medium (Dako).
2.5.3 Whole population fluorescence measurements
To investigate papl::gfp+ expression in different genetic backgrounds, E. coli strains
AAEC185, CFT073 and ZAP965 (Table 2.1A&C) were transformed with plasmids
pKC26 and pMT24 (Table 2.2) and single transformants cultured in CFA medium
supplemented with 25 pg ml"1 chloramphenicol at 37° overnight. Samples were
diluted to ODeoo =1.0 and three replicate aliquots of 200 pi per well were assayed in
a Flurostar fluorimeter (FLUOstar Optima), using 485 nm absorbance and 520 nm
emission, at a gain of 1500. The results, expressed in relative fluorescence units (rfu),
were corrected for background auto-fluorescence by subtraction of pKC26 levels at
the equivalent optical densities.
2.6 Switching assays
To determine phase transition frequencies of pap operons fused to the lacZ reporter
under a number of different conditions the following strategy was used: fusion
strains were cultured on CFA agar at 37°C from which at least three individual
colonies were picked, serially diluted in PBS and plated onto the appropriate medium
containing 40 pg ml"1 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-gal).
After overnight growth on the relevant induction medium, at least six colonies, either
blue (mostly phase on) or white (mostly phase off), were then picked, serially diluted
in PBS and plated onto RD M9 medium with glycerol and X-gal to allow
quantification of the proportions of phase on and phase off colonies (measuring
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plates). Colonies containing blue colour in >50% of their surface area were scored as
on and all others were scored as off. The frequency of phase transition was calculated
using the formula (M/N)/g, as described in Blyn et al., 1989. 'M/N' is the ratio of
cells that underwent phase transition to total cells, and 'g' is the number of
generations of growth from a single cell to the number of cells in the colony assessed.
In all frequency calculations it was assumed that an on or off colony resulted from a
single on or off parent cell. The various induction conditions tested were as follows:
for phase transition on rich undefined media, CFA agar containing X-gal was used;
for different environmental conditions minimal M9 medium with glycerol and X-gal,
RD M9 medium with glycerol and X-gal or RD M9 medium with glucose and X-gal
were used; for temperature effects, induction on RD M9 medium with glycerol and
X-gal was performed at 37°C or 28°C; for phase transition in urine, urine agar plates
containing X-gal were used. To determine off-to-on phase transition in static urine
single off colonies were selected from RD M9 medium containing glucose and X-gal,
diluted to approximately 5 cfu ml"1 in PBS and paired samples cultured statically in 5
ml urine or 5 ml RD M9 medium with glycerol at 37°C for 24 hours. Bacterial
cultures were then serially diluted and plated onto RD M9 medium with glycerol and
X-gal to determine the proportions of phase on and phase off bacteria (measuring
plates). The starting phase of the initial off colonies was confirmed on measuring
plates and colonies containing >2% phase on cells were excluded from the analysis,
as they were probably not true phase off colonies but rather phase on under catabolite
repression.
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2.7 Electrophoretic Mobility Shift Assays (EMSAs)
EMSA analysis of PapB on PapB site 1 variants was performed as described in
Forsman et al., 1989. Radiolabeled DNA fragments containing different site 1
variants were obtained by PCR using 20 pCi [32P]-dATP, sequenced TOPO®-clones
as templates and primers [PapB site 1 (F) and (R)] (Table 2.3). The relative
concentrations of the radiolabeled amplification products were determined by
electrophoresis in 4% polyacrylamide (acrylamide:bisacrylamide 37.5:1) gels in TBE
buffer. Binding reactions contained 1 pi radiolabeled DNA of appropriate dilution,
0.5 pg poly-(dl-dC) as non-specific competitor DNA and 50 mM KC1 in buffer B [30
mM Tris-HCl (pH 7.9), 0.1 mM EDTA, 1 mM dithiothreitol (DTT), 5% glycerol].
One pi of whole cell protein extract prepared as described in section 2.8.1 was added
in serial two-fold dilutions and binding reactions were incubated at room temperature
for 20 min. Free DNA and protein-DNA complexes were separated by
electrophoresis in 4% polyacrylamide-bis (37.5:1) gels in TBE buffer at constant
voltage (160 V) for 2 hours. Gels were transferred onto 3MM Whatman paper, dried
at 80°C for 45 min and autoradiographed using BioMax MR Film (KODAK).
Radioactive signals were also detected using the Molecular Imager® system (Bio-
Rad) and quantified using MULTI-ANALYST software v.1.1 (Bio-Rad).
2.8 Methods for protein analysis
2.8.1 Whole-cell protein extracts
In papl expression experiments, E. coli strains containing single-copy pi::gfp+
fusions (ZAP610-614/616, Table 2.1C) were cultured in 50 ml CFA broth at 37°C.
For strains containing pBAD18 or pNJH20 plasmids, CFA broth was supplemented
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with ampicillin and 0.2% arabinose. Bacterial cells were harvested at stationary
phase by centrifugation (3220 g, 30 min at 4°C) and pellets were frozen-thawed once
and suspended in 0.5 ml sonication buffer [100 mM NaCl, 50 mM Tris-HCl (pH 7.6),
1 mM EDTA, 0.1 mM DTT, 1 pM phenylmethylsulphonyl fluoride (PMSF)]. Cell
suspensions were subjected to three 15-sec sonication rounds at 5 microns amplitude
using a Soniprep 150. Cell debris was removed by microcentrifugation (13400 g, 15
min at 4°C) and the volume of the supernatant containing the cytoplasmic proteins
was adjusted with sonication buffer to account for ODeoo differences in the original
bacterial cultures. Protein samples were aliquoted and stored at -20°C.
For PapB and control protein preparations used in EMSAs, E. coli NEC11
transformed with pNJH36 or pETll plasmids was cultured in 25 ml LB broth
supplemented with ampicillin at 37°C. Cultures were induced during mid-
exponential growth with 1 mM isopropyl [3-D-l-thiogalactopyranoside (IPTG) for 3
hours and subsequently cells were harvested, sonicated and protein extracts prepared
as described above. Cleared lysates were stored with 50% glycerol at -20°C.
2.8.2 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-
PAGE)
Protein samples obtained from whole-cell lysis were separated by SDS-PAGE using
the BIO-RAD Mini-protean II gel apparatus (Bio-Rad, UK). A sample volume of 12
pi was mixed with 8 pi SDS loading buffer [50 mM Tris-HCl (pH 6.8), 4% sodium
dodecyl sulphate (SDS), 12% glycerol, 2% (3-mercaptoethanol, 0.1% bromophenol
blue] and heated to 100°C for 5 min to denature the proteins. For analysis of pi::gfp+
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fusion expression, protein samples were loaded in a 5% stacking gel [5% acrylamide-
bisacrylamide (37.5:1), 0.125 M Tris-HCl (pH 6.8), 0.1% SDS, 0.1% ammonium
persulfate (APS), 0.001% N,N,N',N'-Tetramethylethylene diamine (TEMED)] and
resolved in a 12% resolving gel [12% acrylamide-bisacrylamide (37.5:1), 0.375 M
Tris-HCl (pH 8.8), 0.1% SDS, 0.1% APS, 0.001% TEMED] by electrophoresis in
running buffer [25 mM Tris-HCl (pH 8.3), 250 mM glycine, 0.1% SDS] at constant
voltage (100 V) for approximately 2 hours. Molecular weight markers (Rainbow
marker, Amersham Phamacia Biotech) were used for protein size (KDa)
determination.
2.8.3 Colloidal Blue Staining of SDS-PAGE Gels
Proteins separated in polyacrylamide gels were stained with Colloidal blue
(Invitrogen) according to manufacturer's instructions. Gels were de-stained in dH20
overnight and transferred onto 3MM Whatman paper. Gel images were captured
using a Flowgen Multilmage™ Light cabinet and subsequently gels were dried at
50°C for 90 min.
2.8.4 Western blotting
Detection of reporter proteins expressed from pi promoter fusions was performed
using the method of Western hybridisation. Separated proteins were transferred from
polyacrylamide gels onto nitrocellulose membranes (Amersham Phamacia Biotech)
using the Bio-Rad transfer apparatus (Bio-Rad, UK). Briefly, the gel and membrane
were placed between 4 pieces of 3MM Whatman paper, which were in turn placed
between two sponge pads, pre-soaked in Transfer buffer [39 mM glycine, 48 mM
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Tris, 20% methanol] and held together in a plastic clamp. The transfer of proteins
was performed in cold transfer buffer at constant voltage (60 V) for 100 min.
Nitrocellulose membranes were subsequently blocked in 8% dried milk (Marvel)
solution in PBS at 4°C overnight. Excess blocking buffer was removed by three 10-
min washes with washing buffer [1% dried milk (Marvel), 0.05% Tween® 20
(polyoxyethylenesorbitan monolaurate) in PBS]. Membranes were mixed with
primary antibody solution (mouse anti-GFP, clone JL-8, BD Biosciences), prepared
at a 1:2000 dilution in washing buffer, and incubated for 1 hour at room temperature
on a rocking platform. Excess primary antibody was removed with three 10-min
washes in washing buffer. Membranes were then suspended in secondary antibody
solution [Rabbit anti-mouse HRP (horseradish peroxidase) conjugate, Dako],
prepared at 1:4000 in washing buffer, and incubated for 1 hour at room temperature
on a rocking platform. Excess secondary antibody was removed with three 10-min
washes in washing buffer. Membranes were finally incubated in 10 ml ECL Solution
1 [100 mM Tris-HCl (pH 8.5), 2.5 mM Luminol (C8H7N3O2) , 0.4 mM /?-Coumaric
acid (C9H803)] mixed with 10 ml ECL Solution 2 [100 mM Tris-HCl (pH 8.5),
0.02% H2O2] for 5 minutes at room temperature on a rocking platform.
Chemiluminescence was detected using Hyperfilm™ ECL chemiluminescence film
(Amersham Phamacia Biotech), developed in a Protec automatic film processor
(Optimax).
2.8.5 Protein structure
The structure of the Papl protein (Kawamura et al., 2007) was obtained from the
RCSB Protein Data Bank (PBD ID 2HTJ) (Berman et al., 2000) and molecular
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viewing and analysis was performed using the MBT Protein Workshop software
(Moreland et al. 2005).
2.9 Statistical methods
Associations between observation data were tested using the chi-square test or
Fisher's exact test if data sets contained a small number of observations. Regression
analysis was used to determine the relationship between explanatory and dependent
variables. Equality of mean values between populations of normally distributed data
was tested by analysis of variance (ANOVA). For non-normally distributed
continuous data, median values were compared by the non-parametric Kruskal-
Wallis test. All statistical analyses were performed using MINITAB (r.12) and
Genstat 5 (r. 4.1) packages.
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Chapter 3
Regulation of P fimbrial phase transition frequencies in
uropathogenic Escherichia coli CFT073
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Adhesion of uropathogenic Escherichia coli (UPEC) to host tissues via P fimbriae is
required for colonisation and infection of the urinary tract (Wullt et al., 2000; Tseng
et al., 2007). Expression of P fimbriae is regulated by phase variation and its
transition frequencies are important as they determine the proportion of P-fimbriate
bacteria in the population and govern expression of other surface factors at the
single-cell level through positive and negative cross-talk (Xia et al., 2000; Holden et
al., 2001, 2004, 2006). To date, measurements of P fimbrial phase variation
frequencies have been performed in the E. coli K-12 background using lysogenic
reporter constructs (Blyn et al., 1989, 1990; White-Ziegler et al., 1990). Laboratory
E. coli strains do not naturally possess pap operons and are potentially less suitable
genetic backgrounds for studying P-fimbrial phase variation than clinical UPEC
strains. Moreover the reported frequencies in E. coli K-12 are not predictive of the
high proportion of P-fimbriate bacteria reported for several UPEC clinical isolates
(Nowicki et al., 1984; Low et al., 1987; Pere et al., 1987). The aim of this work was
to measure P-fimbrial phase variation frequencies in their relevant genetic
background for the first time. This chapter describes the methods employed for
measuring P fimbriation and associated pap phase transition frequencies in two
UPEC clinical isolates, including the sequenced strain CFT073, and comparing them
to levels and frequencies for homologous pap constructs in E. coli K-12. Phase
variation frequencies in the isolate background were also investigated under different
environmental conditions, including human urine, the closest physiological
environment to human UTI.
N.B. The results of this study were published in a peer-reviewed journal (Holden et
al., 2007, Appendix A). The work presented in this chapter was performed as part of
this thesis and contribution from co-authors is stated in the appropriate sections.
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3.1 Comparison of the proportion of P-fimbriate bacteria in populations of
UPEC clinical isolates with a cloned pap operon in E. coli K-12
The proportion of P-fimbriate bacteria was measured in populations of two well-
characterised UPEC clinical isolates that both contain two homologous pap operons;
isolates J96 (Hull et al., 1981) and CFT073 (Mobley et al., 1990), and compared to
P-fimbriate proportions in an E. coli K-12 derivative containing a complete pap
operon. Measurements were obtained from single colonies cultured on CFA medium,
a culture condition known to promote expression of P fimbriae (Evans et al., 1977;
Holden et al., 2006). Colonies of the pyelonephritis E. coli isolate J96 (Fig. 3.1A-C)
were shown by flow cytometry to contain an average of 18% ± 2% P-fimbriate
bacteria, as determined by immunofluorescence labelling with a polyclonal anti-
PapA serum specific for F13 P fimbriae (Nilsson et al., 1996). In E. coli CFT073
(Fig. 3.1D-F), the positive proportion determined by flow cytometry was 4.8% ±
0.4% using the polyclonal anti-P serum OM12 (Pere et al., 1987). This percentage is
however an underestimate as this polyclonal serum caused a degree of bacterial
aggregation which resulted in a substantial fraction of labelled cells being
incorporated into large particles and hence being missed by flow cytometry due to
the imposed size limitations (see section 2.5.1). To obtain a more accurate proportion
for CFT073 colonies, P-fimbriate bacteria were counted by immunofluorescence
microscopy and produced proportions of between 10% and 20% depending on the
colony measured (Fig. 3.1D-E). As a comparison to assessing fimbriation
proportions in E. coli clinical isolates, the complete F13 pap operon (papI-papG)
from E. coli J96 (Lindberg, et al., 1984; Marklund et al., 1992) was exchanged into
the E. coli K-12 chromosome at the lac locus, generating strain ZAP594 (Table
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2.1C). In this strain, only 0.26% ± 0.02% of the bacterial population was P-fimbriate
as determined by flow cytometry using the anti-PapA serum (Fig. 3.11 - the
associated micrograph is depicted in Fig. 3.1G-H). The results demonstrated an
effect of genetic background on proportion ofP-fimbriate cells.
Fig. 3.1 P fimbriation in different E. coli strains examined by immunofluorescence microscopy
and flow cytometry. Phase-contrast images in panels A, D & G and fluorescence images in panels B,
E & H. Example flow cytometry histograms (C, F & I). The gate for fluorescence detection is
indicated by Ml and was set as defined in section 2.5.1. The proportion of fluorescent events is
indicated in the upper right corner of each histogram. E. coli J96 (A, B & C); E. coli CFT073 (D, E &
F); E. coli ZAP594 (G, H & I). For panel H multiple fields had to be scanned to detect a single P-
fimbriate bacterium.
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3.2 Reporter fusions to GFP reflect fimbriation proportions in clinical isolates
and the E. coli K-12 backgrounds
Green fluorescent protein (GFP) reporter fusions were constructed to both pap
operons (PI and P2) from E. coli CFT073 and inserted into both E. coli CFT073 and
K-12 chromosomes at lac, generating strains ZAP833/834 and ZAP714/955,
respectively (Table 2.1C). The pap regulatory regions used in the fusions included
both papl and papB and the first codon ofpapA. The proportions of GFP-expressing
bacteria under P-optimal growth conditions (CFA medium, 37°C) were then
determined by flow cytometry. The proportions of CFT073 expressing PI and P2
operon fusions were 24% ± 1.9% and 32% ± 3.6%, respectively. In contrast, the
proportions of K-12 expressing PI and P2 operon fusions were 0.23% ± 0.04% and
0.37% ± 0.13%, respectively. These results confirmed marked differences in P-
fimbriate proportions between the CFT073 and K-12 genetic backgrounds.
3.3 Measurement ofpap phase transition frequencies in E. coli CFT073
Differences in P-fimbriate proportions were proposed to result from different pap
phase variation frequencies in the CFT073 and K-12 backgrounds. In order to
measure phase transition frequencies in a clinical isolate background, fusions of the
CFT073 PI, P2 and J96 F13 pap regulatory regions were made to lacZ and
exchanged into the CFT073 chromosome at lac, generating strains
ZAP838/1137/996, respectively (Table 2.1C). Phase transition frequencies were
determined under P-optimal growth conditions (CFA medium, 37°C) using switching
assays, as described in section 2.6. The J96 pap operon fusion phase varied at a high
off-to-on frequency, >1 x 10"2 per cell per generation. The off-to-on phase transition
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frequencies of the CFT073 PI and P2 operon fusions were 4.4 x 10"3 ± 0.3 and 6.1 x
10 " ± 0.6 per cell per generation, respectively (Table 3.1). As a comparison, a fusion
to PI was constructed in E. coli K-12 (ZAP992) and the off-to-on frequency
determined was <1 x 10"5 per cell per generation (data contributed by Miss K.
Catherwood), confirming the observed differences in P expression and proportions of
P-fimbriate bacteria between the isolate and K-12 backgrounds. Phase transition was
also measured in the opposite (on-to-off) direction and was 3.3 x 10"2 ± 0.08 and 3.5
x 10~2 ± 0.02 per cell per generation for PI and P2, respectively, in the CFT073
background (Table 3.1). These on-to-off frequencies were found to be consistent
when measured under a number of different conditions and were at least 10-fold
higher than off-to-on transition frequencies measured for the same operon fusions.
3.4 Correlation of P-flmbriate proportions and pap phase transition frequencies
In the current study the frequencies ofpap phase variation were determined together
with the proportion of P-fimbriate bacteria in both the E. coli K-12 and clinical
isolate backgrounds. As these two parameters are linked, the proportion of P-
fimbriate bacteria in the population can be calculated from phase transition
frequencies and vice versa. Figure 3.2 (contributed by Prof. D. L. Gaily) shows the
expected proportions of phase on (fimbriate) bacteria in colonies plotted against the
number of generations. These were calculated using a range of off-to-on transition
frequencies and a single on-to-off frequency of 3 xlO"2 per cell per generation that
was based on the measurements obtained in this study. From this correlation, it can
be estimated that the two pap operons in J96 switch on at a combined frequency of
>1 x 10"2 per cell per generation, while the pap operons in CFT073 vary from off-to-
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on at a frequency between 3 x 10" and 1 x 10' per cell per generation. In
comparison, the estimated frequency for the single J96-derived operon in the E. coli
K-12 background is 1 x 10 4 per cell per generation based on 0.26% fimbriation.
These frequency estimates based on P-fimbriate proportions are in agreement with
the actual transition frequencies measured using the papAwlacZ fusions.
Generations
Fig. 3.2 Correlation between the proportion of phase on bacteria in a population and phase
transition frequencies. Different frequencies of phase off-to-on transition were plotted against the
number of generations, using a constant frequency of on-to-off transition of 3 x 10"2 per cell per
generation. The resultant proportions of the population that are phase on are expressed as percentages
of the total population. The phase on transition frequencies (per cell per generation) used for the
correlation are indicated as follows (with the expected percentage of phase on bacteria at equilibrium
shown in parentheses): •, 1 x 10"2 (25%); *, 6x 10° (16.7%); x , 3 x 10"3 (9.09%); ▲, 1 x 10*''
(1.2%); ■, 5 x 10"4 (1.64%); ♦, lxl0"4 (1.33%). All cultures would reach an apparent steady state in
more than 200 generations. (Figure contributed by Prof. D. L. Gaily).
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3.5 Environmental signals have differential effects on off-to-on transition
frequencies of PI and P2 pap operons from E. coli CFT073
Previous research has shown that pap regulation is responsive to a number of
environmental signals in an E. coli K-12 background, such as carbon source and
temperature (Blyn et al., 1989). In addition, recent studies have suggested differential
regulation of these pap clusters in human urine and during murine UTI (Snyder et al.,
2004). In light of the genetic background effect on pap expression, it was interesting
to investigate the effect of environmental signals on pap transition frequencies in the
context of the clinical isolate background. Frequencies were determined using the PI
and P2 lacZ reporter fusions in the CFT073 background (ZAP838 and ZAP1137
respectively, Table 2.1C). Table 3.1 shows the phase transition frequencies for
CFT073 PI and P2 pap operons in the off-to-on orientation cultured under different
conditions (part of the data was contributed by Dr. N. J. Holden). In contrast to the
results obtained with a complex medium (CFA), off-to-on transition frequencies
were lower in defined media. As expected from previous studies (Baga et al., 1985;
Blyn et al., 1989), both operons were catabolite repressed to similar extents; the
decrease was highly significant for both PI and P2 papA::lacZ fusions (p < 0.001).
The frequencies were also higher in the presence of amino acids, although PI was
more responsive (four-fold) than P2 (two-fold) (p < 0.001 and p = 0.03, respectively).
A temperature decrease from 37°C to 28°C only moderately affected the PI transition
frequency and had no effect on P2.
The effect of human urine on phase transition frequencies of E. coli CFT073 PI and
P2 was measured on plates at 37°C and in static liquid urine at 37°C. On urine plates
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the off-to-on frequencies for PI were equivalent to those on CFA, whereas the
frequency for P2 was approximately five-fold lower. The frequency was significantly
higher for PI (p < 0.001). In liquid urine the frequencies were slightly lower than on
plates, although the differential between PI and P2 was still evident. On-to-off phase
transition frequencies were also determined on urine plates and were similar to those
measured on CFA medium (~ 3 x 10"2 per cell per generation). Phase off transition
2 2
on urine plates was marginally higher for P2 (1.5 x 10") than for PI (1 x 10" ).
Taken together these results indicate that PI is expressed at higher levels in human
urine compared to P2.
Table 3.1 Phase transition frequencies of PI and P2 pap operons from E. coli CFT073, measured
under different environmental conditions. Switching assays were performed using strains ZAP838 (PI)
and ZAP1137 (P2) and several growth media, as described in section 2.6. Mean frequencies (103 per
cell per generation) are listed, together with the estimated standard error of the mean (± s.e.). ND: not
determined.
Mean off-to-on transition Mean on-to-off transition
Condition frequency x 10"3 (±s.e.) frequency x 10"3 (±s.e.)
PI P2 PI P2
RD M9 glycerol, 37°C 1.92 (0.14) 1.01 (0.12) ND ND




37°C 0.79 (0.19) 0.60 (0.11)
RD M9 glycerol, 28°C 1.25 (0.20) 1.02 (0.08)
(t u
static urine, 37°C 2.55 (0.31) 1.25 (0.14)
(( «
urine plates, 37°C 4.31 (0.53) 1.28 (0.22) 10.16 (2.02) 14.74 (1.00)
CFA, 37°C 4.4 (0.3) 6.1 (0.6) 32.60 (0.79) 35.30 (1.77)
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3.6 Papl in trans can increase the pap off-to-on transition frequency in the E.
coli K-12 background
Papl is an established positive regulator ofpap off-to-on phase transition (Baga et al.,
1985; Kaltenbach et al., 1995; Nou et al., 1995; Hernday et al., 2003). Changes in
the amount of Papl may explain the background differences reported in this study
and in a clinical isolate background this may arise as a consequence of either the
presence of multiple pap operons (i.e., gene copy number), and/or differences in the
regulatory network that differentially affect expression from each pap operon. To
determine whether increasing papl expression in E. coli K-12 could increase pap off-
to-on phase transition frequencies and fimbriation proportions, plasmid-based papl
(pHMG98; Forsman et al., 1989) was transformed into two E. coli K-12 strains; one
containing the integrated single-copy fusion of the J96 F13 pap regulatory region to
lacZ (ZAP593) and the other containing the complete J96 F13 pap operon (ZAP594;
for strains see Table 2.1C). The off-to-on transition frequency increased 34-fold in
the presence of induced Papl (Fig. 3.3A). This correlated well with a 53-fold increase
in the proportion of P-fimbriate bacteria detected using immunofluorescence staining
with anti-papA serum and flow cytometry (Fig. 3.3B). Taken together these data
suggest that low Papl levels in the E. coli K-12 background could in part explain the










Fig. 3.3 Effect of papl addition in trans on pap phase variation and P fimbriation in the E. coli
K-12 genetic background. (A) Off-to-on phase transition frequency (per cell per generation) of strain
ZAP593. (B) Percentage of P-fimbriate bacteria in ZAP594 populations stained with anti-PapA
antibody and determined by flow cytometry. In both cases the strains were transformed with
pACYCl 84 (control) or pHMG98 (papl). Mean values (± s.e.) are shown.
3.7 Effect of multiple pap operons on pap phase transition frequencies in E. coli
CFT073
To investigate whether the presence of two papl gene copies in the CFT073
chromosome is responsible for the higher pap expression observed in this isolate, a
CFT073 mutant strain was constructed, in which both PI and P2 regulatory regions
were deleted (ZAP965; Table 2.1C). E. coli strain ZAP965 was constructed as
described in section 2.3.16 and deletions were confirmed genotypically by PCR and
phenotypically by immunofluorescence labelling using the OM12 anti-P polyclonal
serum (Fig. 3.4).
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Fig. 3.4 Genotypic and phenotypic characterisation of E. coli strain ZAP965. (A) PCR screens
using ZAP965 genomic DNA to confirm the absence of pIB307 backbone sequence and of the sacB
gene, as well as deletion of the paplB region from both PI and P2 operons. The sequence of
associated primers is listed in Table 2.3 Plasmid pMT17 (Table 2.2) served as a positive control in
pIB and sacB PCR screens, and genomic DNA from CFT073 w.t. was used as a positive control for
amplification of the 1.43 Kb PI and 1.45 Kb P2 papIBA' regions. Deletion of the paplB region in
strain ZAP965 left a 200-300 bp 'scar' in both PI and P2 operons. PCR negative controls (DNA blank
samples) were performed in each amplification reaction. (B) Phase-contrast and fluorescence
microscopy images of E. coli CFT073 {top) and ZAP965 {bottom) populations stained for P fimbriae
using the OM12 anti-P polyclonal serum (Pere et al„ 1987) and the secondary Alexa Fluor 488 IgG-
conjugate (Molecular Probes), as described in sections 2.4 and 2.5.2. No P-fimbriate ZAP965 cells
were detected in several scanned fields or under longer fluorescence exposure times.
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The PI and P2 lacZ reporter fusions were then assayed in the ZAP965 background
(ZAP843 and ZAP595, respectively; Table 2.1C). The off-to-on transition frequency
on CFA medium for PI was reduced slightly from 4.4 x 10~3 per cell per generation
in the CFT073 wild-type background to 3.3 x 10"3 per cell per generation in the
CFT073 mutant background, while for P2 there was a 2.4-fold reduction from 6.1 x
10~3 to 2.6 x 10"3 per cell per generation (p < 0.001). When the PI and P2 lacZ
reporter fusions in the CFT073 mutant background were assayed under alternative
conditions (28°C, RD M9 medium containing glycerol) the impact of the genetic
background was again more evident in the P2 fusion. The off-to-on transition
frequency for the P2 fusion was reduced eight-fold, while the PI frequency was
reduced two-fold. While these data indicate some cross-regulation occurring due to
homologous regulators, they cannot account for the marked background differences
between the E. coli K-12 and CFT073 strains demonstrated in this study.
To investigate whether the background affected papl expression per se, a plasmid-
based transcriptional fusion of the PI papl promoter region to gfp (pMT24; Table 2.2)
was transformed in E. coli K-12, wild-type CFT073 and the CFT073 pap regulatory
region mutant strain (ZAP965). Expression of papl was higher (4.4-fold) in both
wild-type strain CFT073 and the pap regulatory region mutant of CFT073 than in E.
coli K-12 (Fig. 3.5). It was concluded that increased activation ofpapl in the clinical
isolate background in combination with cross-regulation from homologous operons










Fig. 3.5 Expression of papl::gfp plasmid-based fusion in different E. coli genetic backgrounds.
The pACYC184-based construct pMT24 was transformed into E. coli K-12, CFT073 and ZAP965
strains and whole population GFP expression from the plasmid-based fusion (pMT24) was measured,
as described in section 2.5.3. The background fluorescence levels determined from transformation of
pKC26 (control) in each strain was subtracted from the pMT24 corresponding level. Mean relative
fluorescence units (rfu) are presented (± s.e.).
3.8 Discussion
P fimbriae are an established virulence factor utilised by uropathogenic E. coli to
promote colonisation of urinary and gastrointestinal tracts (Pere et al., 1987; Tuilus
et al., 1992; Hull et al., 2002; Roberts et al., 2004). Like expression of most fimbrial
adhesins produced by E. coli, expression of the pap operon is phase variable. The
mechanism underlying this variation and the genetic and environmental inputs that
affect it have been the focus of many years of research. The majority of these studies
have been carried out on regulatory regions cloned into the E. coli K-12 chromosome
and the frequencies of phase transition have been determined using lacZ fusions in
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this non-native background, (i.e., one that does not normally support expression of a
pap operon). The current study reports for the first time the regulation of P-fimbrial
phase transition frequencies in a uropathogenic E. coli strain and demonstrates the
importance of the genetic background for these frequencies. In particular, high off-
to-on transition frequencies may be accounted for by elevated papl expression levels.
Early studies using immunoelectron microscopy and indirect immunofluorescence
reported high proportions of P-fimbriate bacteria in UPEC isolate populations
cultured in vitro and demonstrated that phase variation was extremely rapid, although
no actual frequency measurements were performed. The pyelonephritis E. coli isolate
KS71 possesses two pap operons and when cultured on CFA agar produced a P-
fimbriate subpopulation of 17% (Nowicki et al., 1984). A different UPEC strain,
C1212, also carrying two pap operons, produced colonies in which 84% of the
bacteria expressed P-fimbriae, although in this case one cluster (pilin-21) was
dominant (Low et al., 1987). Pere and colleagues showed that P-fimbriate
proportions in populations of E. coli strains found in urine from patients with
symptomatic UTI were between 0.01 and 95% (Pere et al., 1987). Overall, the
reported high proportions of P-fimbriate cells would predict that pap off-to-on
transition frequencies in UPEC strains are higher than the frequencies determined in
the E. coli K-12 background (Blyn et al., 1989). These studies report pap frequencies
of one cell in 10,000 transitioning from phase off to phase on in each generation.
This frequency would generate a phase on sub-population of less than 1% (Fig. 3.2)
which is not sufficiently high to account for the P-fimbriate subpopulations reported
in the studies described above (Nowicki et al., 1984; Low et al., 1987).
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To address this question in detail, phase transition frequencies were measured for the
two pap operons present in E. coli CFT073 using lacZ and gfp fusions to the papl-
papBA regulatory regions. As anticipated (Baga et al., 1985; Blyn et al., 1989;
Goransson et al., 1989a; White-Ziegler et al., 1990), the frequencies were dependent
on culture conditions but ranged from 6 x 10"4 per cell per generation on minimal M9
glycerol medium to 6 x 10"3 per cell per generation on CFA medium. On-to-off
transition frequencies were also measured and remained fairly constant at 3 x 10~2 per
cell per generation. Based on these frequencies the expected proportion of fimbriate
bacteria cultured on CFA medium would be between 10% and 30% depending on the
amount of cross-regulation between the two operons and the rate with which bacteria
that turn off expression lose fimbriae from their surface. The predicted proportion of
fimbriate bacteria, based on the measured frequencies, was entirely consistent with
that detected for E. coli CFT073 in the present study (10-20%, Fig. 3.1D-E). It
should be noted that construction of the chromosomally-integrated reporter fusions
does introduce an extra copy of the regulatory region into E. coli CFT073 but that the
phase transition frequencies and levels of expression were consistent with
fimbriation under the conditions tested.
PI and P2 are homologous pap operons in E. coli CFT073 both encoding a PapG
class II adhesin. Here it was demonstrated that these operons are differentially
regulated by certain environmental conditions. The PI operon was more responsive
to amino acids and temperature. By contrast, both operons showed the same level of
catabolite repression. Urine has been shown to contain levels of amino acids
sufficiently high to support bacterial growth, and the increased off-to-on phase
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transition frequency of PI relative to P2 may be due to an amino acids response
(Asscher et al., 1966). In addition, the P2 on-to-off transition frequency was higher,
indicating that the overall proportion of PI-fimbriate cells was higher in human urine.
This is the first time that phase transition frequencies have been measured in a UPEC
isolate cultured in human urine, the closest physiological environment to human UTI.
The present study has shown that pap operons exhibit significantly reduced
frequencies of phase variation when measured in an E. coli K-12 background. This
background difference was confirmed using a complete pap operon exchanged into
the E. coli K-12 chromosome at lac. Fimbriate proportions in populations of this
strain were 100-fold lower than for the parental isolate strain, J96 (Fig. 3.1). Based
on the current understanding of the pap phase variation mechanism (van der Woude
et al., 1996; Blomfield, 2001) all the required regulators are present in both
backgrounds. The higher frequency in the clinical isolate must be explained by
altered levels of one or more of the established regulators or novel regulators of the
system. While off-to-on transition frequencies were much higher in the isolate
background, transition frequencies in the opposite direction were equivalent. This
indicates that the difference is due to a factor or factors that promote only phase off-
to-on transition. A key candidate is the positive regulator, Papl. Higher total levels of
Papl could be achieved by increased expression from individual papl promoters
and/or by the presence of multiple homologous pap operons and therefore an
increased papl copy number. To determine the significance of cross-activation in the
clinical isolate background, the two papIB regulatory regions from PI and P2 in E.
coli CFT073 were deleted and expression of pap was examined from a regulatory
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region fusion engineered into the lac locus. Deletion of the pap regulatory regions
made no significant difference to the off-to-on phase transition frequency of PI but
did reduce the P2 transition frequency. These results indicate that cross-activation
between P-related operons alone cannot account for the frequency differences in the
different backgrounds. Subsequently, papl expression was measured in the two
backgrounds and was shown to be higher in the clinical isolate than in E. coli K-12.
Furthermore,papl expression was the same in the papIB double deletion strain which
suggests that signals over and above native pap regulators influence papl expression
in the clinical isolate. While plasmid copy number or GFP stability differences may
account for the higher apparent expression level in E. coli CFT073, elevated papl
expression would explain the higher phase off-to-on transition frequencies and P-
fimbriate proportions observed in the clinical isolate background. Not surprisingly,
the results also indicate that the regulatory network controlling papl expression is
different in a clinical isolate and this is likely to be due to both the evolution of
common signal transduction systems as well as regulatory cross-talk with other
specifically acquired virulence determinants and their regulators. At present there is
little published research on the regulation ofpapl and further work is required in this
area.
Phase variable expression of P-fimbriae has two proposed roles in aiding UPEC
colonisation of the human urinary tract. As P-fimbriae are surface antigens, phase
variation is considered to limit immune exposure of the specific antigen and assist in
evasion of innate and adaptive host responses (Kantele et al., 2003; Snyder et al.,
2006). At the same time, phase variation generates a heterogeneous bacterial
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population with a subpopulation of P-fimbriate bacteria that are equipped to colonise
cells expressing Gala-(l,4)-Gal/?-containing receptors (Leffler and Svanborg-Eden,
1981; Lindberg et al., 1984; Korhonen et al., 1986b). Another proposed function of
phase variation is to coordinate expression of surface factors that are required in
complex micro-environments, such as the colonised epithelium (Holden and Gaily,
2004). Surface factors can block or hinder each other and so operons expressing
surface factors such as fimbrial adhesins, non fimbrial adhesins, flagella, outer-
membrane proteins and capsule are connected via a regulatory network that is driven
in part by phase variation (Hasman et al., 1999; Xia et al., 2000; Schembri et al.,
2001; Barnich et al., 2003). Phase variation frequencies, therefore, are not only
important in controlling expression levels of a specific local factor but also impact on




Genotypic and phenotypic characterisation of UPEC isolates
for P fimbriae
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The finding that homologouspap operons are differentially expressed under the same
or different environmental conditions prompted the investigation of the regulatory
sequence of pap operons from several UPEC clinical isolates, with the aim to
identify sequence variation that has an effect on the regulation and expression of P
fimbriae. This chapter describes the characterisation of selected UPEC clinical
isolates for the presence of pap operons and P fimbrial expression. The final part
presents the strategy for obtaining the sequence of pap regulatory regions and
identifying areas of nucleotide conservation or divergence.
4.1 Pap genotypic and phenotypic characterisation of clinical UPEC isolates
Fifty seven E. coli isolates from different UTI clinical syndromes were collected for
this study. The collection contained UPEC strains isolated from 17 cases of
asymptomatic bacteriuria (ABU), 15 cases of cystitis and 25 cases of pyelonephritis,
including the three prototype strains: CFT073 (Mobley et al., 1990), J96 (Hull et al.,
1981), and 536 (Berger et al., 1982). For a detailed description of all isolates used in
this study see section 2.1.2.
4.1.1 PCR detection ofpap genes
Source information suggested all isolates were positive for genetic carriage of pap.
This was confirmed for 54 of the 57 isolates by PCR screening using PfamA and B
primers (Table 2.3) for the detection of papF gene (Fig. 4.1). Two cystitis isolates,
AUTI3 and AUTI16, and the pyelonephritis isolate AP5 were negative for the
presence ofpapF (Fig. 4.1 II and III).
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I. Asymptomatic Baeteriuria (ABU) isolates
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 M M 1 4 5 10 11 M
Lane M: DNA ladder (500 bp marked)
Lane 1: DNA blank (PCR control)
Lane 2: AAEC185 (negative control)
Lane 3-5: CFT073, J96, 536 (positive controls)
Lane 6-11: U43, U68, U105, U113,
U126, U151
Lane 12 - 14: BR2-V1, BR10-V8, BR20-V1
II. Cystitis Isolates
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 M
Lane M: DNA ladder (500 bp marked)
Lane 1: DNA blank (PCR control)
Lane 2: AAEC185 (negative control)
Lane 3: CFT073 (positive control)
Lane 4-11: HU1690, HU1691, HU1740,
HU1751, HU1756, HU1757,
HU1758, HU1761
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Lane M: DNA ladder (400 bp marked)
Lane 1: DNA blank (PCR control)
Lane 2: AAEC185 (negative control)
Lane 3-5: CFT073, J96, 536 (positive controls)
Lane 6 - 14: AUTI3, AUTI4, AUTI7, AUTI12, AUTI16, AUTI19, AUTI31, AUTI36, AUTI43
Lane 15-20: AUTI47, AUTI48, AUTI62, AUTI64, AUTI66, AUTI72
III. Pyelonephritis isolates
M 1 2 3 4 5 6 7 8 9 10 11 12 13 M
Lane M: DNA ladder (400 bp marked) Lane M:
Lane 1: DNA blank (PCR control) Lane 1 - 4:
Lane 2: Negative control: AAEC185 Lane 5:
Lane 3-5: CFT073, J96, 536 Lane 6 - 14:
Lane 6-13: AUTI8, AUTI11, AUTI20,
AUTI67, AUTI68, AUTI69, Lane 15:
AUTI70, AUTI71
DNA ladder (400 bp marked)
AP4, AP5, AP7, API8
KS71
IHE1041, IHE1049, IHE1086, IHE1108, IHE
IHE1152, IHE1268, IHE1402, IHE1431
DNA blank (PCR control)
Fig. 4.1 PCR screening for papF gene in 57 E. coli isolates. (I) 17 asymptomatic bacteriuria (ABU),
(II) 15 cystitis and (III) 25 pyelonephritis isolates were screened for the amplification of 431 bp of
papF gene using primers PfamA and PfamB (Table 2.3). Isolates AUTI3, AUTI16 (II) and AP5 (III)
were negative. Prototype isolates CFT073, J96 and 536 were used as positive controls and E. coli K-
12 strain AAEC185 served as a negative control. A PCR negative control (DNA blank) was also
performed in every screen.
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Further screening using primers papBl and papB2 (Table 2.3) for the amplification
of papB gene also suggested a pop-negative status for these three isolates and
subsequently, they were excluded from the study. Reference E. coli isolates CFT073,
J96 and 536 were used as positive controls in all PCR screens and the K-12 strain
AAEC185 that does not contain a pap operon was used as a negative control. Weak,
non-specific amplification products were observed in AAEC185 PCR reactions, but
no amplification product of the correct size was present (431 bp).
4.1.2 Determination of the number ofpap operons present in UPEC isolates by
Southern hybridisation
E. coli isolates causing UTI have been shown to possess multiple P fimbrial operons.
For instance, the first sequenced pyelonephritis isolate CFT073 was found to contain
two pap operons, PI and P2 (Welch et al., 2002). In order to determine the number
of pap operons present in each of the 54 E. coli isolates Southern hybridisation
analysis was performed, as described in section 2.3.9. Genomic DNA digests
(Hindlll or BglW) were electrophoretically separated, transferred to a nylon
membrane, and hybridised to fluorescein-dUTP labelled DNA probes
complementary to papB. Detection of multiple pap operons was verified with
reference UPEC isolates CFT073, J96 and 536, since the number of pap operons
present in each is known: two, two and one, respectively (Welch et al., 2002; Hull et
al., 1986; Hacker et al., 1990). Plasmid pPap5 contains the complete pap operon
{papI-G) from isolate J96 (Lindberg, et al., 1984) and was used as a positive control,
whereas genomic DNA from strain AAEC185 was used as a negative control.
Southern blot images are shown in Figure 4.2 and the number of pap operons
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detected in each isolate is listed in Table 4.1A.
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Fig. 4.2 Southern hybridisation for the detection of pap operons in 54 UPEC isolates. Genomic
DNA digests {HindiII top - fig/I I bottom) from 54 clinical isolates were screened for the number of
papB gene copies. Detection specificity was verified with reference strains CFT073, J96 and 536,
shown in the final blots, for which 2, 2 and 1 copies were detected, respectively. Control plasmid
DNA (pPap5) and AAEC185 genomic DNA digests were also included in each blot. Fainter bands
were not counted as they probably represent papB homologues, such as sfaB and focB encoded by S
and F1C fimbrial operons, respectively. Note, the second BglW blot (marked with the white asterisk)
failed to develop in the majority of lanes and results were obtained from the corresponding Hindlll
blot.
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Table 4.1 Summary of Southern hybridisation analysis. (A) Number of pap operons present in 54 E.
coli isolates from cases of ABU, cystitis and pyelonephritis, as determined by Southern hybridisation
analysis. (B) Frequency of asymptomatic and symptomatic isolates with one or multiple (2 or 3) pap
operons. Evidence of association between isolate clinical origin and the number of pap operons it
contains was obtained by chi-square test (/?=().04).
ABU Cystitis Pyelonephritis
U43 3 AUTI4 2 CFT073 2
U68 1 AUTI7 1 J 96 2
U105 AUTI12 1 536 1
U113 1 AUTI19 2 AUTI8 2
U126 AUTI31 1 AUTI11 1
U151 1 AUTI36 1 AUTI20 2
BR2-V1 1 AUTI43 1 AUTI67 3
BR10-V8 1 AUTI47 1 AUTI68 2
BR20-V1 1 AUTI48 2 AUTI69 2
HU1690 AUTI62 1 AUTI70 1
HU1691 1 AUTI64 3 AUTI71 2
HU1740 1 AUTI66 1 AP4 2
HU1751 AUTI72 2 AP7 2
HU1756 1 AP18 2
HU1757 1 KS71 2
HU1758 1 IHE1041 1









Number of pap operons
Isolate clinical origin One Multiple (2 or 3) Total
Asymptomatic 12 5 17
Symptomatic 15 22 37
Total 27 27 54
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The frequency of isolates with one or multiple (two or three) pap operons was
determined with respect to clinical origin (asymptomatic or symptomatic) and is
presented in Table 4.IB. Analysis by chi-square test provided evidence of association
between the clinical origin of an isolate and the number of pap operons it contains
(p<0.05). Symptomatic isolates were significantly more likely to contain multiple
operons than isolates from asymptomatic cases, despite the selective bias for the
presence of at least one pap operon in each UPEC isolate examined. Generally, a
smaller proportion of asymptomatic isolates contain P fimbrial operons than
symptomatic isolates (Plos et al., 1989, 1990).
4.1.3 Quantification of P fimbrial expression in UPEC isolates by
immunofluorescence and flow cytometry.
The observation that symptomatic isolates tend to possess multiple pap operons
suggests that they may contain a higher proportion of P-fimbriate bacteria in their
populations than asymptomatic isolates. This could be responsible for the generation
of disease symptoms and acute pathology, due to the inflammatory potential of P
fimbriae. In order to investigate whether the number of pap operons carried by an
isolate affects the proportion of P-fimbriate bacteria in its population, P fimbriation
in UPEC isolate populations was examined using polyclonal anti-P sera. E. coli
isolates were grown overnight at 37°C on CFA agar to promote P fimbriation (Evans
et al., 1977). The bacterial cells were subsequently incubated with a mix of three
anti-P rabbit polyclonal sera for primary detection of P fimbriae, followed by
secondary detection using Alexa Fluor 488, a commercial green-fluorophore protein
conjugate to goat anti-rabbit IgG (Molecular Probes). Three anti-P sera (OM12, OM5
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and 0M15) were kindly provided by Prof. T. Korhonen and each was raised against
purified P fimbriae from three test strains (IH11002, IH11024, IH11062, respectively)
that were selected to represent common UPEC serotypes and contained only one P
fimbrial variant (Pere et al., 1987). All three antisera were shown to be broadly
cross-reactive and stained in total 98% of 92 P-fimbriate isolates from major
pyelonephritis-associated serogroups (Pere, 1989). In this study we used an
equimolar mix of the three anti-P sera to ensure recognition of a broad spectrum of P
fimbrial variants encoded by the 54 UPEC isolates examined. The proportion of P-
fimbriate bacteria in the population of twelve asymptomatic isolates was determined
by immunofluorescence staining and flow cytometry (FC), as described in sections
2.4 and 2.5.1, respectively, and is graphically presented in Figure 4.3. The extent of P
fimbriation in the examined set of ABU isolates ranged from 3% to 90%. A
proportion of P-fimbriate bacteria as high as 90%, suggests that pap phase variation
occurs at extremely high frequencies (>10~2 ceir'generation"1; see Fig. 3.2) and
would argue against the role of phase-variation in immune evasion and conservation
of bacterial metabolic energy. It could be argued that isolates with multiple pap
operons could generate high P-fimbriate bacterial proportions, if all operons phase-
vary at high frequencies and if all P fimbrial types are recognised by the anti-P mix
used. However, the P-fimbriate proportion measured in each isolate population does
not seem to correlate with the number ofpap operons it contains. It therefore seemed





Fig. 4.3 Proportion of P-fimbriate bacteria in populations of 12 asymptomatic UPEC isolates.
Immunofluorescence staining of P fimbriae was performed using a mix of three anti-P sera and the
secondary fluorophore-IgG conjugate Alexa Fluor 488. Quantification of fluorescent bacteria was
performed by flow cytometry in populations of constant size (20,000 cells), as described in section
2.5.1. Results are presented as mean proportions of fluorescent bacteria (± s.e.) of three biological
replicates.
Examination of the FC data and fluorescence microscopy images revealed that the
high number of stained cells observed for some UPEC isolates is due to cross-
reaction of the anti-P antibody mix, probably with non-P surface antigens present on
some but not all UPEC isolates tested. Figure 4.4A compares the fluorescence
histograms obtained by FC for one UPEC population with low proportion of P-
fimbriate cells (U68 - 3%) and one with high (BRIO - 67%). In the case of isolate
U68 the majority of the bacteria are not stained by the anti-P mix and only 3% of the
population appears positive for fluorescence (counts within marker Ml). In contrast,
the majority (67%) of bacteria in the population of isolate BRIO appear to be stained.
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Most stained BRIO cells however, show low fluorescence intensities (FL1-Height
<10 ) with only the right-hand skew of the distribution demonstrating high FL1-
Height values. It therefore appears that most bacteria in the BRIO population react
'mildly' with the primary antibody mix and do not fluoresce as brightly as the
positive U68 cells. This observation was confirmed by examination of fluorescence
microscopy images of the two isolate populations (Fig. 4.4B). For U68 the majority
of cells are unstained and appear as dark background, with the minority of stained
cells fluorescing brightly. In contrast, in the BRIO population most cells fluoresce
moderately creating a low-fluorescence background and only some of the cells
fluoresce as brightly as the stained U68. A similar pattern was observed for other
isolates with high numbers of stained cells, which suggests that the anti-P mix binds
to non-P surface structures in an isolate-specific manner.
Non-specific binding of the primary antibody mix to surface structures other than P
fimbriae was further tested by immunofluorescence staining of isolates that either do
not contain P fimbrial operons (P~) or are isogenic fimbrial knock-out mutants.
Staining of two P" cystitis isolates, AUTI1 and AUTI73 (Keegan, 2001) with the
anti-P antibody mix resulted in 10% and 0% P-fimbriate subpopulations, respectively.
This result provides supportive evidence for the lack of antibody specificity to P
fimbriae and suggests that non-specific binding is isolate-specific.
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(A)
Fig. 4.4 Comparison of" flow cytometry data and fluorescence microscopy images for two
asymptomatic UPEC isolates with different proportions of P-fimbriate bacteria. Asymptomatic
isolates U68 and BRIO were stained with a mix of three anti-P sera and the secondary fluorophore-
IgG conjugate Alexa Fluor 488. (A) Flow cytometry histograms showing the fluorescence intensity of
each cell in the examined population. The proportion of fluorescent bacteria is shown at the top right
corner. (B) Phase contrast and immunofluorescence microscopy of the two isolates employing the
anti-P sera mix. Different staining patterns and higher background staining for isolate BRIO were
observed.
Further evidence was provided by comparing immunofluorescence staining of isolate
536 and isogenic fimbrial knock-out mutants (Table 2.1 A). This reference
pyelonephritis isolate encodes for P-related fimbriae (prf), S fimbriae (sfa), and type
1 fimbriae (fim) (Brzuszkiewicz et al., 2006). Each strain was labelled with the anti-P
mix (Fig. 4.5A) and with each anti-P serum separately (Fig. 4.5B), in order to
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determine which of the three accounts for the non-specific binding. The anti-P mix
resulted in high numbers of antibody-labelled bacteria in the 536 isolate population
and all the fimbrial mutants, including the prf deletion strain, suggesting non-specific
binding to a non-P structure on the surface of 536 (Fig. 4.5A). Anti-P serum OM5
appeared to be mainly responsible for the high levels of non-specific binding, as it
stained an equal proportion of bacteria with the anti-P mix (Fig. 4.5B). Anti-P sera
OM12 and OM15 resulted in much lower proportions of stained bacteria, but both
failed to specifically detect the 536 P fimbrial variant, as similar proportions were
found in populations of 536 wild-type and 536 prf ' (Fig. 4.5B). Fluorescence
microscopy confirmed a similar staining pattern between 536 wild-type and the
fimbrial mutants with the anti-P mix or each of the anti-P sera separately.
Reactivity of each anti-P serum was finally tested using reference isolates CFT073
and J96. Immunofluorescence staining results from FC and microscopy further
supported the observed trend that each anti-P serum reacts in a different way with the
surface of different uropathogenic E. coli isolates. Interestingly, anti-P serum OM12
was found to be specific for P fimbriae of the model isolate CFT073 as it failed to
cross-react with an isogenic P fimbrial mutant strain (ZAP965). It was therefore
concluded that the three anti-P sera are unsuitable for measuring the P-fimbriate
proportions in diverse UPEC isolate populations, and specific detection of P fimbriae
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Fig. 4.5 Proportion of antibody-labelled bacteria in populations of E. coli 536 and isogenic
fimbria! knock-out mutants. (A) Seven isogenic fimbrial mutant strains were compared to 536 wild-
type (w.t.) for staining with a mix of three anti-P sera. Results are presented as mean proportions (±
s.e.) of three biological replicates. (B) Three isogenic fimbrial mutants were compared to 536 wild-
type for staining with three separate anti-P sera (OM12, OM15, OM5) or an equimolar mix of the
three (anti-P mix).
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4.1.4 Quantification of P fimbrial expression in UPEC isolates by mannose-
resistant haemagglutination (MRHA).
Due to the lack of a specific anti-P serum, P-fimbriate bacterial proportions for each
UPEC isolate were assessed by MRHA of human red blood cells (RBCs), a measure
of P-fimbrial binding capacity (Norgern et al., 1984). Assays were performed by
Miss E. Mahler in a parallel study investigating cross-talk between P and type-1
fimbriae in UPEC clinical isolates (Holden et al., 2006, Appendix B). P fimbrial
adhesins (PapG) recognise the P bloodgroup antigens present on human erythrocytes
and binding leads to agglutination. Mixing of equal concentrations of RBCs with
serially-diluted bacteria allowed the quantification of P fimbrial expression for each
isolate. Assays were performed in the absence and presence of mannose to
differentiate between agglutination caused by P and type-1 fimbriae, as the latter is
sensitive to mannose. The agglutination titre was determined as the highest bacterial
dilution that prevented formation of a defined RBC pellet and the reciprocal value
determined for each UPEC isolate is listed in Table 4.2.
Levels of MRHA were investigated with respect to isolate clinical origin and number
of pap operons and are presented as boxplots in Figure 4.6. Analysis of variance
(ANOVA) suggested that symptomatic isolates exhibit significantly higher levels of
MRHA than asymptomatic isolates (p<0.05). There was also statistically significant
evidence suggesting that the number of pap operons present in an isolate has a
positive effect on the level of MRHA (pcO.OO l).
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Isolate ID Total HA MRHA No. of pap operons
HU1690 32 16 3
HU1691 0 0 1
HU1740 8 2 1
HU1751 4 2 3
HU1756 16 16 1
HU1757 2 1 1
HU1758 1 1 1
HU1761 4 2 1
U43 64 8 3
U68 0 0 1
U105 64 64 2
U113 2 2 1
U126 16 16 2
U151 0 0 1
BR2 8 4 1
BR20 16 16 1
AUTI4 64 64 2
AUTI7 16 8 1
AUTI12 0 0 1
AUTI19 32 32 2
AUTI31 16 16 1
AUTI36 2 2 1
AUTI43 16 16 1
AUTI47 16 16 1
AUTI48 32 32 2
AUIT62 8 8 1
AUTI64 16 16 3
AUTI66 4 4 1
AUTI72 32 32 2
AUTI8 16 8 2
AUTI11 8 8 1
AUTI20 16 16 2
AUTI67 16 16 3
AUTI68 16 16 2
AUTI69 16 16 2
AUTI70 64 64 1
AUTI71 16 16 2
AP4 8 8 2
AP7 64 64 2
AP18 0 0 2
IHE1041 8 8 1
IHE1049 2 2 2
IHE1086 32 32 3
IHE1106 0 0 1
IHE1152 0 0 1
IHE1190 8 8 2
IHE1268 8 8 2
IHE1402 64 64 2
IHE1431 8 8 1
KS71 64 64 2
Table 4.2 Levels of MRHA of human
RBCs induced by UPEC isolates. Total
agglutination and mannose-resistant
haemagglutination (MRHA) titres are
expressed as the reciprocal value of the
highest bacterial dilution that prevented
formation of a defined RBC pellet. The
number ofpap operons present in each
isolate is also listed. The table is
divided in three sections containing
isolates from distinct clinical UTI
syndromes: ABU {top), cystitis

















Fig. 4.6 MRHA levels of UPEC clinical isolates. Boxplots showing the level of MRHA for clinical
isolates as a function of their clinical origin (asymptomatic vs. symptomatic; left) or the number of
pap operons they contain (one vs. multiple; right). MRHA levels are expressed as log2 of the
maximum agglutination titre and the mean was significantly higher in the symptomatic group of
isolates {p= 0.01) and the group containing multiple pap operons and (/><().001).
Taken together the results demonstrate that symptomatic UPEC isolates are more
likely to contain multiple pap operons in their chromosome and higher proportions of
P-fimbriate cells in their populations than asymptomatic isolates. Moreover, these
two attributes appear to be linked, suggesting that the genetic carriage and functional
expression ofmultiple pap operons could impact on the isolate's pathogenic potential
and fitness in the urinary tract.
4.2 Cloning of the regulatory region ofpap operons from UPEC isolates
Having identified the number ofpap operons present in each of the 54 UPEC isolates,
the aim was to obtain and examine the sequence of their regulatory regions. PCR was
used to amplify the pap regulatory regions present in each isolate with primers
designed complementary to highly conserved regions at the 3' end ofpapl and the 5'
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end ofpapA [CFTP1+2 for and rev] (Table 2.3). An enzyme mix containing Taq and
the proof-reading DNA polymerase Tgo (Roche) was used for high fidelity
amplification (section 2.3.4). PCR products were subsequently cloned into the
pCR4®-TOPO® vector as described in section 2.3.11. Recombinant plasmid clones
were screened for the presence of an inserted pap regulatory region by digestion with
EcoRl restriction endonuclease. Screening of several clones from each reaction
revealed the presence of inserts with small size differences, confirming the
successful amplification and cloning of different pap regulatory regions from the
same isolate. An example is shown in Figure 4.7 for isolate IHE1086 that was shown
to contain three pap operons by Southern blot analysis (Table 4.1A). Six ifcoRI-
digested clones are shown with small differences in insert size.
4.3 —
2.3 —
— pCR4 -TOPO vector
— insert
Fig. 4.7 Screening of six IHE1086 TOPO® clones for the presence of insert by EcoRl digestion.
Differences in insert sizes are visible between clones 1, 2, 3 and 4, 5, 6. Lane M: X Hindlll DNA
ladder with 4.3 and 2.3 Kb reference bands shown.
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43 Sequencing ofpap regulatory regions from UPEC isolates
The TOPO®-cloned pap regulatory regions from each isolate were sequenced by
MWG-Biotech, as described in section 2.3.12. The number of sequenced clones per
isolate was determined by and was in excess of the number ofpap operons detected
in each isolate by Southern hybridisation (Table 4.1A); two clones were sequenced
for isolates containing one pap operon, five for isolates containing two, and eight for
isolates containing three operons. Reference strain CFT073 served as a control for
the reliability of this rule, as the sequence of each pap regulatory region (PI and P2)
was represented by two TOPO®-clones. Double-stranded sequences were assembled
for each regulatory region using high-quality sequence data from four individually-
primed sequencing reactions that covered both directions. Base quality was
thoroughly checked particularly for singletons.
All sequenced clones per isolate were compared by multiple sequence alignment
(msa) to identify regulatory regions belonging to the same or different pap operons.
The number of pap operons identified in each isolate by sequencing of their
regulatory regions is listed in Table 4.3A. One caveat of sequencing only the
regulatory region of each pap operon was that it would be impossible to identify two
operons with identical regulatory regions, so the total number of identified operons
could be underestimated. Nevertheless, there was little discrepancy between the
number of pap operons identified in each isolate by Southern hybridization analysis
and by sequencing of the regulatory regions (compare Tables 4.1A and 4.3A). For
the majority of isolates, sequence information was obtained for every pap regulatory
region detected by Southern hybridization. The regulatory region sequence of 8 pap
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operons identified by Southern blotting was not obtained (n/a; AUTI4, AUTI8,
AUTI20, AUTI71, AP4, API 8, IHE1268, KS71), and there were two cystitis isolates
for which an extra pap operon was identified by sequencing (AUTI43, AUTI66).
Table 4.3B lists the number ofpap operons present in each of the 54 UPEC isolates,
as determined by combination of Southern hybridisation and sequencing analyses.
These data were used in all subsequent analyses. It is important to note that the
association between isolate clinical origin and number of pap operons was still
evident in the revised dataset (/?=0.042).
Table 4.3 Number of pap operons present in 54 E. coli isolates from cases of ABU, cystitis and
pyelonephritis, as determined (A) by sequencing of regulatory regions and (B) by combining the
results of Southern hybridisation and sequencing analyses.
(A) ABU Cystitis Pyelonephritis
U43 3 AUTI 4 1 CFT073 2
U68 1 AUTI 7 1 J96 2
U105 2 AUTI 12 1 536 1
U113 1 AUTI 19 2 AUTI 8 1
U126 2 AUTI 31 1 AUTI 11 1
U151 1 AUTI 36 1 AUTI 20 1
BR10-V8 1 AUTI 43 2 AUTI 67 3
BR20-V1 1 AUTI 47 1 AUTI 68 2
83972 2 AUTI 48 2 AUTI 69 2
HU1690 3 AUTI 62 1 AUTI 70 1
HU1691 1 AUTI 64 3 AUTI 71 1
HU1740 1 AUTI 66 2 AP 4 1
HU1751 3 AUTI 72 2 AP 7 2
HU1756 1 AP 18 1
HU1757 1 KS71 1
HU1758 1 IHE 1041 1









Table 4.3 - continued
ABU Cystitis Pyelonephritis
U43 3 AUTI 4 2 CFT073 2
U68 1 AUTI 7 1 J96 2
U105 2 AUTI 12 1 536 1
U113 1 AUTI 19 2 AUTI 8 2
U126 2 AUTI 31 1 AUTI 11 1
U151 1 AUTI 36 1 AUTI 20 2
BR10-V8 1 AUTI 43 2 AUTI 67 3
BR20-V1 1 AUTI 47 1 AUTI 68 2
83972 2 AUTI 48 2 AUTI 69 2
HU1690 3 AUTI 62 1 AUTI 70 1
HU1691 1 AUTI 64 3 AUTI 71 2
HU1740 1 AUTI 66 2 AP 4 2
HU1751 3 AUTI 72 2 AP 7 2
HU1756 1 AP 18 2
HU1757 1 KS71 2
HU1758 1 IHE 1041 1








4.4 Sequence analysis ofpap regulatory regions from UPEC isolates
In total, sequence information was obtained for 82 pap regulatory regions from 54
UPEC clinical isolates. The sequenced regions included the papl and papB genes,
their intergenic region {pap switch) and the papB-A intergenic sequence up to the
first codon of papA. Comparison by msa revealed conserved and variable regions,
which are depicted in Figure 4.8. Conserved regions, not surprisingly, contained sites
known to play a key role in the reversible operation of the pap epigenetic switch,
suggesting the importance of preserving their function. In contrast, the presence of
sequence variation, both in sites of the pap switch and the two regulators papl and
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papB. suggested potential changes in their function that could affect pap expression.
In this chapter the sequence of important features of the pap regulatory region is
described. Observed sequence variation was investigated in the context of the clinical
isolate combining infonnation on isolate clinical origin, number ofpap operons and
level of P fimbriation. Sequence variation in the papl gene and the PapB binding site
1 is described in greater detail separately in chapters 5 and 6, respectively, together
with the major findings from analysing their effect on pap expression.




Fig. 4.8 The pap regulatory region. The -1.2 Kb sequenced region from pap operons present in 54
UPEC isolates is shown schematically, including the papl, papB and beginning ofpapA genes. The
three PapB, one CAP and six Lrp binding sites present in the papI-B intergenic region (pap switch)
are shown along with the -35 and -10 hexamers of the two divergent promoters (pi and pBa)- Two
Dam methylation sites (GATCp'oxlmal and GATCd,stal) are shown overlapping Lrp sites 2 and 5,
respectively. A sequence variation bar below the pap regulatory region marks roughly areas of
nucleotide conservation (black bar) and variation (white bar) identified by msa of 82 sequenced pap
regulatory regions. The length of genes, intergenic regions and the distance between protein binding
sites are not drawn to scale.
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4.4.1 pi and pBA promoters
The pap switch contains two divergent promoters, pi and pBA driving transcription of
papl and the pap operon, respectively. The sequence of the putative -10 and -35 pi
elements was conserved in all sequenced switches (Fig. 4.9), suggesting that
expression of the Papl regulator is not modulated through sequence variation in
regions interacting with the a70 subunit of RNA polymerase. The -35 and -10
hexamers of the divergent pBA promoter were also highly conserved (Fig. 4.9). In
particular, the -35 element was conserved in 100% of the sequenced switches,
whereas the sequence of the -10 box contained one variable base: TAa/cCTT.
Cytosine at position -11 was only observed in 5 pap switches (6%) that also had a










Fig. 4.9 Sequence of pi and piiA promoter elements. The conserved hexamer sequence of -10 and -
35 promoter elements found in 82 pi and pBA promoters from UPEC isolates is shown together with
the consensus sequences found in strong E. coli promoters (Busby and Ebright, 1994). The -10
element sequence of pBA contained one variable base 11 bp upstream of the transcription start site that
was observed in 6% of the promoter sequences examined. Both p) promoter elements were 84%
identical to the consensus sequences, whereas -10 and -35 elements of pBA promoter were 50% and
84% identical to consensus, respectively.
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4.4.2 Dam and Lrp binding sites
The mechanism of pap phase variation relies on the competition between Dam and
Lrp for access to two overlapping binding regions present within the pap switch: one
proximal to the main operon promoter pBA and one distal (Fig. 4.8). The on and off
methylation patterns of the pap switch are generated by Dam recognition and
adenine methylation of one of the two GATC signal sequences and are established by
Lrp binding to the other, non-overlapping region. Both GATC signal sequences are
therefore important for the reversible operation of the pap switch and mutations in
both have been shown to lock the switch to either phase (Braaten et al., 1994; Nou el
al., 1995). This was reflected by the conservation observed for these sequences
among UPEC isolates. Of the 82 sequenced pap switches only two were found to
contain mutations in the GATC methylation signals. In both cases GATCproximal was
mutated to GATT (Fig. 4.10), a transition that will abort recognition of the site by
Dam and prevent subsequent adenine methylation. This point mutation is also
predicted to disrupt Lrp binding to site 2 since Lrp was shown to come to close
contact with the first and last guanosine residues within GATCproximal (one in the top
and one in the bottom DNA strand) (Nou et al., 1995). Moreover, a 6 bp substitution
mutation over GATCproximal that disrupted Lrp binding to site 2 was shown to lock the
pap switch on (Nou et al., 1995). Interestingly, in this study both pap switches found
to contain the GATCproximaI mutation belonged to UPEC isolates that demonstrated
high MRHA levels (see AUTI48 and AP7 in Table 4.2), indicating high levels of P
fimbriation. Both isolates are of symptomatic clinical origin and contained a second
pap operon with both Dam signal sequences intact. In contrast to GATCproximal, the
sequence of GATCdlstal overlapping Lrp binding site 5 was conserved in all pap
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switches examined (Fig. 4.10), indicating that Dam methylation and Lrp binding to











Fig. 4.10 Sequence of Lrp and Dam binding sites in the pap regulatory region. The sequence of
Lrp sites 3, 4, and 5 was identically conserved in 100% of the pap switches examined. Variable bases
identified in Lrp sites 1, 2 and 6 are underlined and the sequence of every variant is shown together
with the frequency with which it was observed. The two GATC signal sequences for Dam methylation
overlapping Lrp sites 2 and 5 and are shown in bold. The sequence upstream of Lrp site 5 is part of
the Papl 'response element' and is shown in lower case. Sequence variation between sites 6 and 1 is
not shown.
The flanking sequences of both pap GATC sites are important in determining Dam's
methylation ability and processive catalysis of the two sites (Peterson and Reich,
2006). All pap switches examined contained identical GATC flanking sequences
(gacGATCdlstttt and aaaGATCproxgtt) which are poorly preferred for methylation by
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Dam (Peterson and Reich, 2006), indicating that Dam methylation kinetics are
conserved among pap operons and do not serve as targets for modulating pap
expression. The conserved sequence immediately upstream of GATCdlstal (Fig. 4.10)
is also part of the Papl 'response element' ACGATC, which was shown to be
required for Papl-dependent binding of Lrp to site 5 and therefore off-to-on pap
transition (Hernday et al., 2003).
Each of the two Lrp binding regions in pap DNA contains three separate binding
sites (sites 1-3 are located proximal to the pBA promoter and sites 4-6 distal, see
Figure 4.8). All six Lrp binding sites present in the pap switch are important for the
reversible operation of the switch and were found to be highly conserved. The
sequence of each site is shown in Figure 4.10 together with sequence variation
observed in sites 1 and 6 and the frequency with which they occurred. Variation in
site 6 involved the guanosine residue of the consensus Lrp binding sequence for pap
DNA 'Gnn(n)TTTt' (Nou et al., 1995). A transition to adenine was observed in 7
pap operons, all of symptomatic clinical origin. It is difficult to predict the impact of
this point mutation on pap expression as the role of Lrp site 6 in phase variation is
not completely clear. Even though the consensus 'G' residue of all six binding sites
has been shown to come in close contact with Lrp, the complete substitution of site 6
sequence barely affected pap off-to-on transition frequency (Nou et al., 1995),
suggesting that site 6 does not play a significant role in the regulation of pap
expression. Variation in site 1 was more commonly observed, but did not involve any
of the conserved residues in the consensus Lrp binding site 'Gnn(n)TTTt'.
Nevertheless, the observed sequence variation could affect Lrp binding to site 1,
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which is essential for pap transcription since the translocation of Lrp from proximal
to distal binding sites has been proposed to require the interaction of Papl with Lrp
bound at site 1 (Nou et al., 1995; Kaltenbach et al., 1995). The region between sites
6 and 1 was also found to contain some variable residues that could have a
modulatory effect on the regulation ofpap expression. Evidence indicating that this
region could play a positive role in regulation ofpap transcription was provided by a
6 bp substitution mutation between sites 6 and 1 that resulted in a locked off
phenotype (Nou et al., 1995).
4.4.3 CAP binding site
Expression of P fimbriae is repressed by glucose metabolism (Baga et al., 1985).
During glucose starvation E. coli synthesises cyclic AMP (cAMP) which is bound by
catabolite activator protein (CAP). CAP was shown to bind pap DNA in a cAMP-
dependent manner at a site centred at 215.5 bp upstream of the pba transcription start
site and binding was essential for activation of pap transcription (Goransson et al.,
1989b; Forsman et al., 1992; Weyand et al., 2001). The region of CAP binding was
proposed to function as an upstream activating sequence for both pi and pba
promoters (Goransson et al., 1989b) and was conserved among the pap switches
examined in this study. Figure 4.11 shows the sequence variants of the CAP binding
site found in 82 pap switches together with their associated frequencies. All variable
bases identified were not part of the consensus CAP binding site sequence 5'-
AAnTGTGAnnTnnnTCAnATW-3' (Ebright et al., 1984) suggesting that the
observed sequence variation is unlikely to alter CAP binding affinity. Interestingly,
the first variable base was observed with high frequency (35%) and associated with
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other sequence variation upstream and downstream of the CAP site. This could
indicate a potentially altered interaction between CAP and RNA polymerase via the
C-terminal domains of its a subunits (aCTD), since possible aCTD binding sites in
pap DNA could be the AT-rich sequences flanking the CAP site. The second
variable base identified within the CAP site was found in almost 10% of the
sequenced switches, whereas the final variable base was only observed in the pap
switch of the reference isolate J96.
Fig. 4.11 Sequence of the CAP binding site in the pap regulatory region. The variable bases
identified are underlined and the sequence of each variant site is shown together with the frequency it
was observed among the 82 pap switches examined. Bases identical to the consensus CAP binding
site 5'-AAnTGTGAnnTnnnTCAnATW-3' are shown in bold (W is either A or T; Ebright et al., 1984).
4.4.4 PapB binding sites
Binding studies demonstrated the presence of three pap DNA regions with affinity
for the pap-encoded regulator PapB (Forsman et al., 1989). Named in the order of






papBA transcription start site and directly adjacent to the CAP binding site, site 2
overlapped the -10 pba promoter element and site 3 was localised within the papB
gene (see Fig. 4.8). The position of each site, its affinity for PapB, and the finding
that high PapB protein levels repressed pap expression, led to the proposition that
PapB acts both as an activator and a repressor of pap transcription and that its
autoregulatory role is achieved by differential binding to the three sites (Forsman et
al., 1989). The sequence of the PapB binding sites is AT-rich and contains conserved
bases (Forsman et al., 1989; Xia et al., 1998). PapB site 1 was the most variable
region identified within the pap switch and analysis of its sequence variation is the
research focus of the following chapter. In contrast, the sequence of PapB sites 2 and
3 was highly conserved. In particular, site 3 was 100% identical in all the examined
switches and site 2 contained a few variable bases at non-conserved positions. The
sequences of the three different PapB site 2 variants and of site 3 are shown in Figure
4.12 together with their associated frequencies.
AATTTCACTTATTGCGTTAAGAGTGTTT (6%)
AATTTAACTTATTGCATGAAGAGTATTT (13%)
Site 3: GAAATGCGTTTTTGCTGAATATACGCGA (100%)
Fig. 4.12 Sequence of PapB binding sites 2 and 3 in the pap regulatory region. The variable bases
identified are underlined and the sequence of site 2 variants is shown together with their occurrence
frequency among the 82 pap switches examined. Identical bases between sites 2 and 3 are shown in
bold (Forsman et al., 1989).
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4.4.5 papB gene
The first cistron to be transcribed from the main pap operon promoter is papB. The
gene encodes for one of the two transcriptional regulators ofpap expression that was
shown to have autoregulatory function (Forsman et al., 1989). Comparing the
sequence of 82 papB genes obtained from pap operons belonging to 54 UPEC
isolates by msa revealed the presence of mutations. In 22% of the genes examined
were the same frameshift mutation was found that introduced a premature stop codon
resulting in a truncated PapB protein. The resulting 35 amino acid polypeptide is
predicted to be non-functional as it is lacking both the DNA binding and
oligomerisation regions required for PapB to function as a transcriptional regulator
(Xia and Uhlin, 1999, see Fig. 4.13). Investigation of the isolates encoding for the
mutant papB genes revealed that the great majority contained multiple pap operons
and therefore wild-type copies of papB that could complement the mutant operon
(Table 4.4). In fact, five of the six isolates found to have 3 pap operons contained at
least one with a mutant papB gene, but no isolate had all its copies ofpapB mutated.
Isolates with a single pap operon were rarely found to carry a mutated papB gene
(/?<0.05), as this would abolish P fimbrial expression, unless other fimbrial operons
encoding for PapB homologues, such as SfaB, were present in the same isolate.
Indeed, three of the four isolates that contained a mutated papB gene in their only
pap operon exhibited very low MRHA levels (see FUJI740, U68 and AUTI12 in
Table 4.2). Interestingly, these isolates although rare, tended to be of asymptomatic
clinical origin, suggesting that the papB gene mutation could be part of the general
'taming' of pathogenicity demonstrated by E. coli isolates causing ABU, such as
isolate 83972 (Hull et al., 1999; Graham et al., 2001; Klemm et al., 2006). This
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prototype asymptomatic UPEC strain was shown to encode for a non-functional
PapG (Klemm et al., 2006) and in this study, a second pap regulatory region was
identified containing a mutantpapB gene.
Table 4.4 Frequency of mutant papB genes in 54 UPEC isolates. UPEC isolates with multiple pap
operons (2 or 3) were found to be more likely to contain at least one mutant papB gene by a chi-square
test of association (/>=().036).
Number of UPEC isolates with:
1 pap operon 2 pap operons 3 pap operons Total
mutant papB 4 8 5 17
wild-type papB 20 16 1 37
Total 24 24 6 54
The sequence of the remaining majority of papB genes was intact and highly
conserved. Thirteen single nucleotide polymorphisms (SNPs) were observed
generating 11 haplotypes with an estimated nucleotide diversity (II) of 0.007%
±0.002%. Eight of the SNPs led to synonymous amino acid substitutions and the
remaining 5 in replacements. Translation of the papB alleles resulted in three protein
variants designated B.1-B.3 (Fig. 4.13). Interestingly, variant B.3 was only found in
the operon of prototype UPEC strain 536 and contained four of the five observed
amino acid replacements. Similarly, variant B.2 was present only in one operon and
differed in a single amino acid residue from variant B.l, which represents the
sequence encoded by the great majority (96%) of operons (Fig. 4.13). The amino
acid sequence of the three variants is homologous and the observed amino acid
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substitutions are not predicted to change the overall structure of the protein.
Moreover, the observed amino acid changes involved non-conserved residues of
PapB family members (Xia and Uhlin, 1999; Holden et al., 2001).
10 20 30 Ai 40
B.i : mahhevisrsgnafllniresvHlpgsmsBmhSf|lli|g|issihs
B.2 : MAHYEVISRSGNAFLLNIRES V L LPG SMS EMHEFLLIGISSIHS
























































Fig. 4.13 Amino acid sequence alignment of PapB protein variants. All pap operons containing
intact papB genes were found to encode for protein variant B.I, except for one operon from isolate
IHE1268 (B.2) and the prf operon from reference UPEC 536 (B.3). The observed amino acid
substitutions (shaded) did not involve residues conserved among members of the PapB regulator
family (boxed) or consensus residues required for DNA binding (black circle) and oligomerisation
(black triangle) previously identified (Xia and Uhlin , 1999).
In summary, the sequence of regulatory features of the pap epigenetic switch was
conserved among UPEC isolates with little sequence variation tolerated suggesting
that the reversible function of the switch is highly conserved. The sequence ofpapB
gene, encoding one of the operon's transcriptional regulators, was also found to be
highly conserved, signifying the importance of maintaining PapB's regulatory
function, as well as the limited tolerance for amino acid replacements, since most
SNPs resulted in synonymous changes and the most frequent mutation resulted in
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loss of protein function. Sequence variation that could result in modulation of pap
regulation and expression was identified in the papl regulator and PapB binding site
1, described in chapters 5 and 6.
4.5 Discussion
In this study a selection of 54 UPEC clinical isolates was used as a source of 82 pap
operons with the aim to investigate the sequence of their regulatory regions. The
isolates used originated from asymptomatic or symptomatic UTI cases and their
clinical origin was found to correlate with the number ofpap operons they contained,
as well as the level of functional expression of P fimbriae. Specifically, symptomatic
isolates were significantly more likely to possess two or more pap operons compared
to asymptomatic isolates and displayed higher levels of P fimbriation, as assessed by
MRHA. These findings were in agreement with previous studies that report increased
pap operon carriage in symptomatic UPEC isolates, as well as lower functional
expression of P fimbriae in asymptomatic isolates (Plos et al., 1989, 1990;
Andersson et al., 1991; Blanco et al., 1997). Moreover, the results from this
phenotypic and genotypic characterisation provided the basis for investigating for the
first time regulatory cross-talk between P and type 1 fimbriae in clinical UPEC
isolates (Holden et al., 2006, Appendix B). Type 1 fimbrial expression correlated in
an inverse manner with P fimbrial expression and was significantly reduced in the
group of symptomatic UPEC isolates that exhibited the highest levels of P fimbrial
expression.
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Despite chromosomal carriage of at least one pap operon in all E. coli isolates
examined, the asymptomatic group had the highest proportion of isolates displaying
no clear MRHA, implying either that expression of P fimbriae is repressed in these
isolates or that mutations preventing expression have occurred in operon genes. This
is consistent with asymptomatic strains not expressing factors that can trigger an
inflammatory response in the host (Hull et al., 1999; Graham et al., 2001; Lim et al.,
1998). Attenuation of pathogenicity through inactivating mutations has recently been
demonstrated in the prototype asymptomatic E. coli isolate 83972 for several of its
fimbrial operons: type 1 and P (Klemm et al., 2006), and F1C (Roos et al., 2006b).
Several lines of evidence, including multilocus sequence typing (MLST) and the
possession of FimH and PapA alleles associated with virulent UPEC strains, suggest
that strain 83972 originated from a pyelonephritis UPEC isolate (Klemm et al., 2006).
In this study strain 83972 was found to possess a novel pap regulatory region with
several sequence differences to the published pap sequence (Klemm et al., 2006).
Interestingly, nucleotide variation was observed in both pap-encoded regulators;
papl contained unique base changes resulting in two amino acid replacements in the
protein sequence and papB contained the commonly-observed frameshift mutation
resulting in PapB protein truncation and inactivation. This finding further supports
the notion that E. coli 83972 has evolved from an ancestral pyelonephritis UPEC
isolate as it contains two pop operons, while the presence of inactivating mutations in
both operons reflects the strain's lifestyle transition and need to inactivate genes that
are no longer compatible with the novel lifestyle. Assessing this possibility for each
of the asymptomatic isolates used in this study would require extensive sequence
analysis of complete pop operons, which would be outside the scope of the current
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analysis. It is therefore possible that any of the 82 pap operons investigated contains
mutations in operon genes that could abolish functional expression of P fimbriae.
The research focus of this study was directed in the regulatory region of the detected
pap operons, with the aim of examining modulation of pap regulation through
sequence changes. The most prominent areas of sequence variation identified in the
82 sequenced pap regulatory regions involved the papl gene, encoding for the pap
transcriptional activator, and PapB site 1, the binding site with the highest affinity for
the pap autoregulator PapB (Forsman et al., 1989). Investigating the effect of these
variable sequence regions on pap regulation and expression constitutes the remainder
of this thesis and is presented and discussed in chapters 5 and 6.
In this chapter regions of sequence conservation were described and were found to
include sites known to be important for the phase-variable expression of the pap
operon. In particular, the two GATC sites targeted by Dam and required for the
formation of differential methylation patterns that govern pap expression were highly
conserved. In addition, pap autoregulation seemed to be highly conserved through
sequence conservation of PapB sites 2 and 3 that are responsible for repressing pap
expression (Forsman et al., 1989). In contrast, the sequence of site 1 was highly
variable, involving insertion/deletion of 9 bp sequences, which suggested that
activation of pap expression is subject to modulation, whereas repression is highly
conserved and occurs at much higher frequencies (Blyn et al., 1989; Holden et al.,
2007). This signifies the importance of tightly controlling pap expression, as P
fimbriae are metabolically expensive for the bacterium, as well as targets for the host
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immune system.
Minor sequence variation was also identified in other features of the pap regulatory
region, such as protein binding sites and the papB gene. These observations provide
insights into the extent of sequence variability that naturally occurs in pap regulatory
regions and could be part of future research. For example, the effect of sequence
variation in Lrp binding sites 1 and 6 (see Fig. 4.10) on the affinity of Lrp binding
could be investigated using electrophoretic mobility shift assays. Changes in Lrp
affinity could alter the sensitivity of pap transcription to leucine (Ernsting et al.,
1993), potentially explaining the differential effect of amino acid-containing medium
on the off-to-on transition frequency of PI and P2 operons (see section 3.5 and Table
3.1). Additionally, future work could investigate the pap operons observed to contain
mutant papB genes and integrate them in single-copy into the chromosome of
CFT073 wild-type and its isogenic P fimbrial mutant ZAP965 to test for
complementation by wild-type papB copies in a clinical isolate genetic background.
Previous studies suggested that complementation of papB mutants can occur upon
expression of wild-type PapB from plasmid-based systems (Baga et al., 1985;
Goransson et al., 1989b; Morschhauser et al., 1994), but it will be interesting to
determine whether phase-variable expression ofpap operons containing mutant papB
genes can be restored by wild-type PapB levels found in the same UPEC isolate.
The finding that pap operons with mutant papB sequences frequently occur in UPEC
isolates containing intact papB genes in other pap operons, together with the
sequence conservation observed among intact papB genes, is particularly interesting
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when considering regulatory cross-talk within UPEC isolates, as it provides a
possible mechanism for modulating expression of homologous pap operons found in
the same isolate. Expression of a pap operon carrying a mutant papB gene will rely
on the regulatory action of wild-type PapB protein expressed from other operons that
have to be higher in the regulatory hierarchy. Assuming that the concentration of
PapB regulator required for stimulating self as opposed to related pap operons is
different, then this mechanism would preclude co-expression of homologous pap
operons and increase the probability of them being sequentially expressed at the
single-cell level and under identical environmental conditions. The presence of
sequence variation in other sites of the pap switch as well as the pap transcriptional
activator papl, could be serving a similar role in modulating pap expression, and
together with papB mutations it could provide a mechanism for coordinating
expression of homologous P fimbrial operons in UPEC isolates. These possibilities
are explored further in the remaining chapters.
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Chapter 5
Sequence variation in PapB binding site 1 and effects
pap phase variation
This chapter describes the sequence variation observed in a high-affinity PapB
binding site present in pap regulatory regions from UPEC isolates of different
clinical origin (asymptomatic vs. symptomatic UTI). The sequence variation was
examined in the context of each UPEC isolate, the number ofpap operons it contains
and its clinical origin. Formulated hypotheses regarding the role of PapB site 1
sequence variation in pap operon phase-variable expression are described, together
with the in vitro and in vivo methods used to test them and the associated findings.
5.1 Variation in PapB site 1 sequences from UPEC isolates
The most variable region identified in the 82 pap switches sequenced in this study
(see sections 4.3 and 4.4) involved a protein binding site for the /?op-encoded
regulator PapB. This is the first of three PapB binding sites present in the regulatory
region of the pap operon and was shown to have the highest affinity for PapB and to
act as an activating site for pap transcription (Forsman et al., 1989). The sequence of
PapB site 1 is AT-rich and contains multiple 9 bp sequences with (T/A)3 at
conserved positions and repeating with 9 bp periodicity (Xia et al., 1998). PapB
protein has been proposed to recognise these repeats via minor groove interactions
and bind in an oligomeric fashion. Site 1 mutagenesis studies have demonstrated the
importance of the repeated (T/A)3 sequences and their periodicity in PapB binding
capacity and pap transcriptional activation (Xia et al. 1998). Sequencing of 82 pap
regulatory regions from 54 UPEC strains as described in chapter 4 of this thesis,
revealed variation in the number of 9 bp sequence repeats present in PapB site 1.
Five naturally-occurring site 1 sequence variants containing 4, 6, 7, 8 or 9 repeats
were identified (Fig. 5.1).
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■1 -35 and -10 promoter elements
i I PapB binding site
10 20 30 40 50 60 70 80 90~"~---..
TTTTTATTCTCTATGTTTG CTTTATTTGTTCAAl^AGTGAAtTTGCTTTTT : 52
TTTTTATTCTCTGTGTTTGCTGTGTTTGCTGTGTTTG CTTTATTTGTTCAATTTAGTGAATTTGCTTTTT : 70
TTTTTATTCTCTGTGTTTGCTGTGTTTGCTGTGTTTGCTGTGTTTG CTTTATTTGTGCAATTTAGTGAATTTGCTTTTT : 79
TTTTTATTCTCTGTGTTTGCTGTGTTTGCTGTGTTTGCTGTGTTTGCTGTGTTTG CTTTATTTGTGCAATTTAGTGAATTTGCTTTTT : 0 0
TTTTTATTCTCTGTGTTTGCTGTGTTTGCTGTGTTTGCTGTGTTTGCTGTGTTTGCTGTGTTTGCTTTATTTGTGCAATTTAGTGAATTTGCTTTTT : 97
•jst 2nd 3rd 4th 5th gth 7th gth gth
Fig. 5.1 Alignment of PapB site 1 sequence variants from UPEC isolates. Five natural sequence
variants ofPapB site 1 were identified in 82 sequenced pap regulatory regions from 54 UPEC isolates.
Sequence variation involved the number of 9 bp repeats (underlined) containing (T/A)3 at conserved
positions (shaded grey). The variants are designated 4, 6-9 according to the number of 9 bp repeats
they contain. The minimum site I identified was 52 bp long and contained four 9 bp repeats, and the
maximum was 97 bp with nine repeats. Note that the second, third, fourth, fifth and sixth 9 bp repeats
have identical sequence: 5'-CTGTGTTTG-3', which is also shared by the first repeat present in sites
with >4 repeats (6, 7, 8, or 9). Sites with 4 repeats were found to contain base differences in non-
conserved positions and one variable base can be seen in the first 9 bp repeat of variant 4.
Longer site 1 variants appeared to result from insertion of additional 9 bp sequences
between the first and second 9 bp repeats of the smallest site 1 variant (4 repeats).
The sequence of the additional 9 bp repeats was identical in 100% of the sites
examined (5'-CTGTGTTTG-3') and identical to the sequence of the first 9 bp repeat.
A few variable nucleotides were also identified in the first and penultimate 9 bp
sequence repeats, but involved non-conserved positions and did not alter the
important (T/A)3 feature or the 9 bp periodicity.
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Each pap operon in the UPEC isolate collection was characterised for the number of
9 bp repeats present in its PapB site 1 sequence (Table 5.1 A). The majority (62%) of
site 1 sequences examined contained 4 repeats, whereas sites with > 4 repeats (6, 7, 8,
and 9) were less frequent among the pap operons, with each variant occurring in
approximately 10% of the sequences (Table 5. IB).
Table 5.1 PapB site 1 sequence variants in pap operons from UPEC clinical isolates. (A) Fifty four
UPEC isolates divided in three clinical groups (ABU-top, cystitis-middle, pyelonephritis-bottom) are
listed together with the number of pap operons contained in each one, as determined by Southern
hybridisation and sequencing of regulatory regions (see Table 4.3B). Every pap operon present in
each isolate was scored for the number of 9 bp repeats (4, 6, 7, 8, or 9) within its PapB site 1 sequence.
Isolates containing a pap operon detected by Southern hybridisation, for which the sequence of the
regulatory region was not obtained. (5) Frequency of each PapB site 1 sequence variant (with 4, 6, 7,
8 or 9 repeats) among the 82 pap regulatory regions examined.
Isolate No. of pap No. of 9 bp repeats in PapB site 1
ID operons 4 6 7 8 9
HU1690 3 2a 1
HU1691 1 1
HU1740 1 1a







U105 2 1a 1
U113 1 1








AUTI19 2 1 1
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AP7 2 ia 1
AP18* 2 1
IHE1041 1 1
IHE1049 2 1 1
IHE1086 3 1 2
IHE1106 1 1
IHE1152 1 1
IHE1190 2 1a 1
IHE1268* 2 1
IHE1402 2 1a 1
IHE1431 1 1
KS71* 2 1
CFT073 2 1 1
J 96 2
536 1 1
*pap operon with mutant papB gene encoding for truncated PapB (see section 4.4.5)
No. of 9 bp repeats Frequency among pap








The majority of isolates with a single pap operon (75%) contained a site 1 variant
with 4 repeats, although this observation was not statistically significant (Table 5.2A).
It is important to note though that in the UPEC collection studied, asymptomatic
isolates are significantly more likely to contain a single pap operon (£><0.05; see
Table 4.3B). These observations are suggestive of a trend between asymptomatic
isolates, a single pap operon and a site 1 sequence with 4 repeats. Similarly, the
majority of isolates with two pap operons (75%) contained a combination of site 1
variants with 4 and >4 repeats (Table 5.2B). Alternative combinations (4 and 4, or >4
and >4) were rare; only one isolate was found to contain a >4-repeat site variant in
both operons, and three isolates contained two 4-repeat site variants. Interestingly,
two of the latter carried mutant papB gene copies in one of the two pap operons.
Furthermore, the great majority (87.5%) of isolates with two pap operons in the
UPEC collection studied are of symptomatic clinical origin.
Table 5.2 Frequency of PapB site 1 sequence variants in (A) 24 UPEC isolates with a single pap
operon and (B) 16 UPEC isolates with 2 pap operons, for which sequence information was obtained
for both regulatory regions. PapB site 1 variants were grouped into sequences with 4 or >4 repeats (6,
7, 8 or 9). The expected frequencies were estimated from the overall frequency of site 1 variants (see
Table 5.IB) and were compared to the observed frequencies using the chi-square goodness of fit test.
(A: x2= 1-67 on 1 degree of freedom, p>0.05; B: /2= 5.025 on 2 degrees of freedom, p>0.05).
(A) No. of 9 bp repeats
in PapB site 1
Observed frequency among
isolates with one pap operon
Expected
frequency
4 repeats 18 14.927
>4 repeats 6 9.073
(B) Combination of PapBsite 1 variants
Observed frequency among













To test for a potential association between the number of repeats in PapB site 1
sequence and the extent of P fimbriation in an E. coli isolate, the level ofMRHA of
UPEC isolates with a single pap operon (see Table 4.2) was examined in relation to
the number of repeats present in its PapB site 1 sequence (4 or >4). It appeared that
isolates with a single pap operon containing sites with 4 repeats tended to display









4 repeats >4 repeats
PapB site 1
Fig. 5.2 MRHA levels of UPEC clinieal isolates with one pap operon. Boxplots showing the
distribution of MRHA levels of isolates with a single pap operon containing 4 or >4 repeats in their
PapB binding site 1 sequence. MRHA levels are expressed as log2 of the maximum agglutination titre.
Equality of median values (middle line in boxplots) was tested using the Kruskal-Wallis non-
parametric test and median MRHA levels were not found significantly different (p= 0.2).
Based on the observed trends in UPEC isolates and the current knowledge on the
function of PapB site 1 (Forsman et al., 1989; Xia el al., 1998), the observed
sequence variation was hypothesised to alter the mode of PapB interactions with pap
DNA and subsequently influence pap phase variation and P fimbrial expression.
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5.2 Effect of PapB site 1 sequence variation on PapB protein binding
PapB protein was shown to bind to site 1 with high affinity (Forsman et al., 1989).
To investigate whether the observed sequence variation in site 1 altered the PapB
binding ability, gel mobility shift assays were carried out, as described in section 2.7.
Due to the tendency of PapB protein to form large, insoluble aggregates, whole-cell
extracts containing over-expressed PapB were used. These were generated by
transformation of E. coli NEC11 (Table 2.1A) with pNJH36, a pETll-based
expression vector containing the papB gene (Table 2.2). Control extracts were
obtained similarly from transformation of E. coli NEC11 with vector pETll. DNA
fragments containing the natural site 1 sequence variants with 4, 6, 7, 8 or 9 repeats
were labelled with 32P-dATP during PCR amplification using primers papBsitel_F
and papBsitel_R (Table 2.3). Sequenced TOPO®-clones containing the
corresponding pap regulatory regions were selected for PCR amplification templates.
Figure 5.3 depicts a sequence alignment of the different DNA fragments used in the
electrophoretic mobility shift assays (EMSAs). Isogenic DNA fragments for site 1
variants 7, 8 and 9 were amplified from the TOPO®-cloned regulatory regions
AUTI72.1, HU1761.2 and IHE1086.2 respectively, but no naturally isogenic
regulatory regions were found for site 1 variants 4 and 6. Instead, PapB site 1
variants with 4 and 6 repeats were amplified from PI and P2 pap operons of the
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CAP site ' Lrp site 4 papBsite1_R
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4_ (TOPO_ CFTD73 PI) ATGCTG (207)
6_ (TOPO__CFT073_P2) ATGCTG (225)
7_ (TOPO_ AUTI72.1) ATGCTG (234)
8_ (TOPO_ HU1761.2) ATGCTG (243)
9_ (TOPQ_"iHE108 6.2) ATGCTG (252)
Fig. 5.3 Alignment of DNA fragments used in EMSAs. The sequence of five DNA fragments
containing different PapB site I variants (grey bar) is shown together with some other important
sequence features: PCR primers papBsitelF and papBsitel R (black arrows), the region containing
P! promoter elements (double dotted arrow), the CAP binding site (white bar), and Lrp binding site 4
(black bar). The fragments are designated 4, 6, 7, 8 or 9 according to the number of 9 bp repeats
present in their PapB site 1 sequence and the plasmid template used for their amplification is shown in
parenthesis. Sequence differences outside PapB site 1 are shaded in grey. Note: Fragments 7, 8 and 9
are isogenic PapB site 1 variants, whereas fragments 4 and 6 represent the PapB site 1 sequence found
in the two pap operons (PI, P2) from E. coli CFT073 and contain further base differences.
For all EMSA reactions an equal amount of each DNA fragment was incubated with
serial dilutions of PapB cell extract (NEC1 lpNJH36) and reactions were subjected to
gel electrophoresis. Negative reactions were performed for each DNA fragment
using either control cell extract (NEC1 IpETl 1) or no cell extract (free DNA). Figure
5.4 illustrates representative autoradiographs of EMSA reactions using DNA



















Fig. 5.4 Electrophoretic mobility shift assays (EMSAs) of PapB binding to site 1 variants with 4
or 9 repeats. DNA control samples (no cell extract) are shown in the first lane of both gels and a
sample mix of DNA and the control cell extract NECllpETll is shown in the second lane. The 8
final lanes contain sample mixes of DNA with serial dilutions of cell extract containing over-
expressed PapB (NECllpNJH36). The free DNA and DNA-protein complex bands are marked in
each gel. Images are autoradiographs of representative experiments.
The loss of free DNA was quantified and relative PapB binding affinities for each
site 1 variant are shown in Figure 5.5. The results demonstrate that higher protein
concentrations are required for 50% occupancy of longer site 1 variants. Similarly,
comparison of the proportion of shifted DNA at mid-range protein concentrations
(e.g. protein dilutions 0.0313 and 0.0625) suggested that longer site 1 variants (8 and
9) have lower relative affinities for PapB compared to shorter sites (4 and 6), as they
demonstrated a lower proportion of shifted DNA. At high relative PapB
concentrations, the majority (90-100%) of shorter site 1 variants was shifted, whereas
>20% of DNA fragments with 8 and 9 repeats remained free. Interestingly,
investigation of binding at low protein concentrations (0.0078) showed a higher
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proportion of shifted DNA for longer site 1 variants compared to sites with 4 and 6
repeats. This small difference could be indicative of a potential difference in initial
PapB binding to site 1 variants. Since two PapB molecules have been shown to
occupy each 9 bp sequence present in site 1 (Xia et al. 1998), it was hypothesised
that longer site 1 variants will have a higher probability of interacting with PapB due
to the higher number of 9 bp repeats present in their sequence. Consequently, site 1
variation could be affecting the sensitivity of activation of pap operons and their
phase variation frequencies.
0 0.0078 0.0156 0.0313 0.0625 0.125 0.25 0.50 1.00
relative [PapB]
Fig. 5.5 Relative PapB binding affinity of natural PapB site 1 sequence variants. Binding of five
DNA fragments containing PapB site 1 sequences with variable number of 9 bp repeats (4, 6-9) was
carried out using serial dilutions of whole cell extract containing over-expressed PapB
(NEC1 lpNJH36). The relative amount of DNA shifted at every relative PapB concentration was
estimated for each DNA fragment and the mean of 4-6 independent experimental replicates is
graphically presented.
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5.3 Effect of PapB site 1 sequence variation on pap phase transition frequencies
The requirement for different PapB concentrations suggested that sequence variation
in site 1 can have an effect on pap phase variation and regulation of P fimbrial
expression. In order to investigate the effect of site 1 sequence variation on pap
phase transition frequencies, pap regulatory regions containing natural site 1 variants
were fused to the lacZ reporter gene. Pap regulatory regions containing site 1
variants with 4, 6, 7, 8, or 9 repeats were selected from sequenced TOPO®-clones
and sub-cloned into BamHl-Kpnl of the pIB307-based vector pKC29 (Table 2.2) for
construction of translational lacZ fusions. The reporter gene was placed under the
control of the main operon promoter pBA and both papl and papB regulators were
included in the fusion. Regulatory regions with 7, 8 and 9 repeats were isogenic site
1 variants, whereas PI and P2 regulatory regions from UPEC CFT073, which were
used to represent natural site 1 variants with 4 and 6 repeats, contained further single-
base changes. All fusions were subsequently exchanged into the lac chromosomal
locus of the pyelonephritis E. coli isolate CFT073 generating strains ZAP838 (4),
ZAP1137 (6), ZAP1000 (7), ZAP1002 (8) and ZAP1003 (9) (Table 2.1C; for
construction of E. coli strains see section 2.3.15). E. coli CFT073 was selected as the
appropriate genetic background for regulatory integration of the fusions, as it
provided a relevant context in which to assess pap expression. Work presented in
chapter 1 of this thesis has shown that reporter expression levels from pBA promoter
fusions in an E. coli K-12 background are lower than the clinical isolate background
(Holden et al., 2007). Pap phase transition frequencies of CFT073 strains carrying
single-copy lacZ fusions were determined by switching assays, as described in
section 2.6.
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In rich defined medium the off-to-on transition frequencies of strains containing
fusions with longer PapB site 1 variants were higher than the on-to-off frequency
displayed by the strain containing a site 1 sequence with 4 repeats (£><0.001, Fig. 5.6-
top). In addition, off-to-on switching of pap regulatory regions with 7 repeats in site
1 was occurring at significantly lower frequencies than switching of isogenic variants
with 8 or 9 repeats (£><0.001). Switching frequencies in the opposite direction (on-to-
off transition) were measured under identical culture conditions and were found to be
slightly lower in CFT073 strains containing isogenic fusions with 7, 8 or 9 site 1
variants (£>=0.001, Fig. 5.6-bottom). On-to-off frequencies were more than 100-fold
higher than off-to-on for all CFT073 strains tested.
Switching frequencies under different culture conditions however were less affected
by sequence variation in PapB site 1. Off-to-on phase transition frequencies on a rich
complex medium considered to be optimal for P fimbrial expression (CFA; Evans et
al., 1977), appeared to be high for all tested fusions (Fig. 5.7-top). Significant
differences were still observed in the mean frequency displayed by the different
CFT073 strains (p><0.001, ANOVA), but they were more prominent between strains
with 4 and 9 repeats (minimum and maximum site 1 variants). The on-to-off
transition frequencies were also determined on CFA medium and were found to be
similarly high to rich-defined M9 medium (Fig. 5.7-bottom). The CFT073 strains
containing longer site 1 variants (6, 7, 8 or 9 repeats) had equally high mean on-to-
off transition frequencies, whereas the strain with 4 repeats in site 1 switched off at a
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papA::lacZ
Fig. 5.6 Phase transition frequencies of E. coli CFT073 strains containing single-copy papA::lacZ
fusions with natural PapB site 1 variants in rich defined medium (M9 AA glycerol). CFT073
strains ZAP838/1137/1000/1002/10003 contain single-copy lacZ fusions to pap regulatory regions
with 4, 6, 7, 8, or 9 repeats in PapB site 1, respectively. Off-to-on (top graph) and on-to-off (bottom
graph) transition frequencies (cell-1 generation"1) were determined under identical culture conditions
(M9 RD glycerol, 37°C) by switching assays, as described in section 2.6, and are presented as mean
frequencies (± s.e.). On average, 6500 colonies of each CFT073 strain were assayed for estimating the
off-to-on transition frequency and 1000 colonies for the on-to-off frequency. Due to lack of normality
in the distribution of the observed frequencies (both directions), the conservative non-parametric
Kruskal-Wallis test was used to compare the median frequency displayed by each CFT073 strain.
There was supportive evidence for differences among the median frequencies (both directions) of the
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Fig. 5.7 Phase transition frequencies of E. coli CFT073 strains containing single-copy papA::lacZ
fusions with natural PapB site 1 variants in rich complex medium (CFA). CFT073 strains
ZAP838/1137/1000/1002/10003 contain single-copy lacZ fusions to pap regulatory regions with 4, 6,
7, 8, or 9 repeats in PapB site 1, respectively. Off-to-on (top graph) and on-to-off (bottom graph)
transition frequencies (cell"' generation"1) were determined under identical culture conditions (CFA,
37°C) by switching assays, as described in section 2.6, and are presented as mean frequencies (± s.e.).
On average, 1400 colonies of each CFT073 strain were assayed for estimating the off-to-on transition
frequency and 650 colonies for the on-to-off frequency. Equality ofmean frequencies (both directions)
was tested by ANOVA (normally distributed data) and significant evidence of differences among the
tested strains was found for both off-to-on and on-to-off mean frequencies (p<0.001 and /?=0.004,
respectively).
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In summary, it appears that under certain conditions pap operons with longer site 1
sequences switch on and potentially remain on more frequently than operons
containing site 1 sequences with 4 repeats. Since pap phase variation frequencies
determine the proportion of P-fimbriate bacteria in the population, it was
hypothesised that the overall fimbrial output of a UPEC isolate can vary depending
on the PapB site 1 sequence present in the pap operons it contains. The differential in
sensitivity of activation among the tested regulatory regions was less apparent under
growth conditions considered optimal for P expression (CFA agar, 37°C), suggesting
that this mechanism might be of relevance in limiting conditions for pap expression.
In the system described above, phase variation of each fusion was potentially
regulated by Papl and PapB encoded by the regulatory region fused to the lacZ
reporter, as well as the regulators present in the two CFT073 native pap operons (PI
and P2). Both Papl and PapB regulators have been shown to activate pap operons in
trans, suggesting that the lacZ fusions in the CFT073 wild-type background were
subject to higher levels of Papl and PapB regulators, especially under culture
conditions that will stimulate P expression. Assuming that sequence variation in site
1 is affecting the sensitivity of transcriptional activation of pap operons, it was
interesting to assess the variant fusions in a genetic background with limiting
concentrations of regulators. In order to investigate the differential sensitivity of
regulatory regions containing site 1 variants, the same papAr.lacZ fusions were
introduced in single-copy into the lac chromosomal locus of the CFT073 double
papIB deletion strain (ZAP964), generating strains ZAP843 and ZAP595-598 (Table
2.1C). Deletion of the regulators and regulatory regions of both native pap operons in
CFT073 permitted the regulation of lacZ fusions only by the pop-encoded regulators
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present in the promoter fusion, while the fusions were still integrated in a relevant
genetic background of a clinical UPEC isolate.
Switching assays performed in rich defined medium revealed a step-wise increase in
the off-to-on transition frequency of strains containing fusions with increasing
number of repeats in site 1 (pcO.OOl, Fig. 5.8-top). Isogenic strains containing site 1
variants with 7, 8 and 9 repeats displayed significantly higher off-to-on transition
frequencies. Overall, off-to-on frequencies were lower for all tested fusions in the
CFT073 P background than in the CFT073 wild-type background, with the highest-
fold decrease observed for the fusion containing the P2 regulatory region with 6
repeats. In contrast, on-to-off transition frequencies were not affected by genetic
background but displayed significant differences among the strains tested (Fig. 5.8-
bottom). Strains containing fusions with 8 and 9 repeats switched off at lower
frequencies than the strain carrying the fusion with 4 repeats (p<0.001). The results
confirmed the frequency differences observed for the same lacZ fusions in the
CFT073 wild-type background.
Taken together, the results suggest that sequence variation in PapB site 1 has an
effect on pap phase transition frequencies, with longer site 1 variants switching on at
higher frequencies than shorter site 1 variants and potentially remaining in the on

























Fig. 5.8 Phase transition frequencies of E. coli CFT073 P" strains containing single-copy
papA::lacZ fusions with natural PapB site 1 variants in rich defined medium (M9 AA glycerol).
CFT073 P" strains ZAP843/595/596/597/598 contained single-copy lacZ fusions to pap regulatory
regions with 4, 6, 7, 8, or 9 repeats in PapB site 1, respectively. Off-to-on (top graph) and on-to-off
{bottom graph) transition frequencies (cell-1 generation"1) were determined under identical culture
conditions (M9 RD glycerol, 37°C) by switching assays, as described in section 2.6, and are presented
as mean frequencies (± s.e.). On average, 4200 colonies of each CFT073 P" strain were assayed for
estimating the off-to-on transition frequency and 1900 colonies for the on-to-off frequency. The
conservative, non-parametric Kruskal-Wallis test was used to compare the median frequency
displayed by each CFT073 P" strain. There was supportive evidence for differences in the median
frequencies of the tested strains (off-to-on, pO.001 and on-to-off, p<().()() I).
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5.4 Effect of PapB site 1 sequence variation on papl expression
The effect of site 1 sequence variation on pap phase transition frequencies was
proposed to be the result of a direct effect of this site on expression of the positive
regulator Papl. PapB binding site 1 lies approximately 70 bp upstream from the
transcription start site of papl, a reasonable distance for a transcriptional activator.
Moreover, there is evidence to suggest that PapB binding to site 1 activates papl
transcription (Goransson et al., 1989b). In order to investigate whether sequence
variation in site 1 affects expression ofpapl, pi promoter regions containing the five
observed site 1 variants were amplified by PCR using primers [papl 15_KpnI (F)]
and [papl prom_CAP_BglII (R)] (Table 2.3) and fused transcriptionally to the gfp+
reporter gene. The pi promoter regions included the upstream CAP binding site, the
PapB site 1 variant and the sequence up to the second proposed papl translation start
site, but excluded PapB sites 2 and 3 to prevent any possible repressor effects from
PapB binding. The pi promoter fusions to gfp+ were constructed using vector pKC48
(Table 2.2), which is a low-copy temperature-sensitive vector used for allelic
exchange into the E. coli K-12 chromosomal lac locus. The fusions were
subsequently introduced in single-copy into the chromosome of E. coli K-12 by
allelic exchange generating strains ZAP611 (4), ZAP612 (6), ZAP613 (7), ZAP616
(8) and ZAP614 (9) (Table 2.1C; for construction of E. coli strains by allelic
exchange see sections 2.3.14-15). Expression of GFP was examined under P-
promoting growth conditions (CFA, 37°C) in the absence or presence of PapB. E.
coli K-12 does not contain papB genes, so each fusion strain was transformed with
the inducible vector pNJH20, which is a pBAD18-based construct carrying papB
under the control of the pBAD promoter (Table 2.2; Holden et al., 2001). Control
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transformations with the pBAD18 vector were also performed for all strains.
Fluorescence levels were relatively low for all E. coli K-12 strains and their plasmid-
containing transformants, as demonstrated by fluorescence microscopy and flow
cytometry. Examination of the bacterial populations after induction of PapB
expression revealed however a small but reproducible increase in the mean
population fluorescence intensity of K-12 strains containing promoter fusions with
>4 repeats, but not in the mean fluorescence intensity of the K-12 population
carrying the 4-repeat fusion (Fig. 5.9).
For more sensitive detection of GFP the K-12 strains were examined by
immunoblotting using a commercial anti-GFP antibody (BD Biosciences), as
described in section 2.8.4. Each E. coli K-12 strain and its pBAD18 (control) and
pNJH20 (PapB) transformants were cultured in CFA medium at 37°C. In the absence
of PapB no GFP protein could be detected. Expression of PapB in trans activated
GFP expression only in strains with fusions containing the longer PapB site 1
variants (Fig. 5.10). These findings were consistent with the flow cytometry data and
taken together, the results suggest that pap operons with longer PapB site 1




MG1655 p,::GFP+ / pBAD18
MG1655 p,::GFP+ / pBADpapB (pNJH20)
Fig. 5.9 Population fluorescence intensity histograms of E. coli K-12 strains containing single-
eopy pupl::gfp+ fusions with natural PapB site 1 variants in the presence or absence of PapB. E.
coli K-12 strains ZAP611-614 and ZAP616 carry single-copy gfp+ fusions to p, promoter regions
containing PapB site 1 sequence variants with 4, 6, 7, 9 and 8 repeats, respectively. Fluorescence
intensity (FL1-Height) histograms obtained by flow cytometry were overlayed for populations of each
K-12 strain (black line) and its plasmid-containing transformants (pBAD18: green line/ pNJH20: pink






































Fig. 5.10 Western hybridisation analysis of GFP expression in E. coli K-12 strains containing
single-copy papl::gfp+ fusions with natural PapB site 1 variants in the presence or absence of
PapB. E. coli K-12 strains ZAP611/612/613/614 and ZAP616 are designated 4, 6, 7, 9, and 8,
respectively, according to the number of 9 bp repeats present in the p, promoter region fused to gfp+.
All strains were cultured in CFA medium overnight with 0.2% (w/v) arabinose added to pBAD18
(vector control) and pNJH20 (PapB) transformants. Protein extracts were prepared for Western
hybridisation analysis, as described in section 2.8.1 and immunoblotting was carried out using a
mouse anti-GFP monoclonal antibody (JL-8; BD Biosciences Clontech) and an HRP-conjugate rabbit
anti-mouse IgG secondary antibody (DAKO), as described in section 2.8.4. GFP bands (-27 KDa)
were detected for strains 6, 7, 8 and 9 in the presence of PapB.
In order to determine whether the complete lack of GFP expression in E. coli strain
ZAP611 is a direct consequence of the 4-repeat PapB site 1 variant and not other
sequence changes present in the promoter region, an E coli K-12 strain containing a
single copy gfp+ fusion to the pi promoter from the pap operon of E. coli isolate J96
(ZAP610) was constructed in a similar manner. The regulatory region of the papm
operon also has 4 repeats in PapB site 1, but contains different sequence variation to
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Fig. 5.11 Alignment of p, promoter regions containing natural PapB site 1 variants. The DNA
sequence of the six pi promoter regions used for the construction of E. coli K-12 strains ZAP610-
614/616 is shown, with important sequence features marked: PCR primers [papl 15_Kpnl (F)] and
[papl promCAP Bglll (R)] (black arrows), the region containing pi promoter elements (double
dotted arrow), PapB binding site 1 (grey bar), and the CAP binding site (white bar). The DNA
fragments are designated 4, 6, 7, 8 or 9 according to the number of 9 bp repeats present in their PapB
site 1 sequence. The two fragments designated 4, represent DNA sequences found in the pap operon
of E. coli isolate J96 and the PI operon of E. coli isolate CFT073, and while both contain 4 repeats in
PapB site 1, base changes can be seen both in site 1 and in the rest of the fragment. Fragment 6
represents the DNA sequence from the P2 operon of E coli isolate CFT073, and fragments 7, 8 and 9
are isogenic PapB site 1 variants. Single base differences are shaded in grey.
It was hypothesised that if the level ofpapl activation is solely determined by the
number of repeats present in PapB site 1, E. coli strain ZAP610 would be predicted
not to express GFP, similarly to strain ZAP611 that also contains 4 repeats in PapB
site 1. Analysis of GFP expression in strain ZAP610 in a similar manner performed
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for strains ZAP611-614 and ZAP616, revealed however a different outcome. GFP
expression was stimulated by the J96 pi promoter in the presence of PapB, to a
similar extent demonstrated by promoters with longer PapB site 1 variants. This was
shown both as an increase in the mean fluorescence intensity of a ZAP610pNJH20
population and by immunodetection of GFP protein production (Fig. 5.12). It
therefore appears that variation in repeat number in PapB site 1 is not solely
responsible for determining the levels ofpapl expression and that sequence changes











MG1655 p,::GFP+ MG1655 p,::GFP+ / pBAD18 •MG1655 p,::GFP+ / pBADpapS (pNJH20)
Fig. 5.12 Population fluorescence intensity and GFP expression in E. coli K-12 strain ZAP610 in
the presence or absence of PapB. E. coli strain ZAP610 contains a single-copy gfp+ reporter fusion
to the papl promoter region from E. coli isolate J96. which contains 4 repeats in PapB site 1.
Fluorescence intensity (FL1-Height) histograms obtained by flow cytometry are shown (left), and
were overlayed for population comparisons between strain ZAP610 (black line). pBADl 8-containing
transformants (green line) and pNJH20-containing transformants (pink line). The PapB-induced
increase in mean population fluorescence intensity was 30%. The GFP immunoblot (right) shows
GFP expression in E. coli ZAP610 only in the presence of PapB.
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In conclusion, the results suggest that a longer site 1 sequence could increase the
probability of initial PapB binding, potentially increase the sensitivity of papl
expression, and subsequently increase the frequency of off-to-on phase transition. A
longer site 1 sequence can also occupy a higher total number of PapB molecules
before reaching saturation, which under limiting PapB concentrations could restrict
PapB from binding to autoregulatory sites 2 and 3 that will ultimately repress
transcription from the pba promoter.
5.5 Discussion
The aim of this work was to investigate the effect of a highly variable regulatory site
in the pap epigenetic switch on pap regulation and expression. The sequence of the
high-affinity PapB binding site 1 was found to differ greatly among the 82 sequenced
pap regulatory regions, mainly due to multiple insertion/deletion events of a 9 bp
sequence. This variation explains the size differences observed in TOPO®-clones
containing pap regulatory regions from UPEC isolates, described in chapter 4 (see
Fig. 4.7). In total, five natural site 1 variants were observed with 4, 6, 7, 8 or 9
repeats of 9 bp sequences, increasing the extent of sequence variation previously
reported for this site (Blyn et al., 1989; Xia et al., 1998). Interestingly, no site
variants with 5 repeats were observed in this study, suggesting that operons similar to
the pap-21 operon from E. coli isolate C1212 (Blyn et al., 1989) are rare and
potentially unstable. Earlier work has demonstrated that PapB recognises a DNA
structure containing (T/A)3 repeats with 9 bp periodicity rather than a specific
sequence in pap DNA, and mutagenesis experiments suggested that these repeats as
well as their periodicity are important for PapB binding and pap expression (Xia et
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al., 1998). The sequence variation in site 1 identified in this study did not alter these
important features, suggesting that it can function as a modulator ofpap expression.
Binding of PapB to natural site 1 variants was investigated in vitro and longer sites
were shown to require higher protein concentrations for 50% site occupancy. These
findings were in agreement with previous work reporting that site 1 variants with 6
repeats require four more PapB molecules to cover the binding site than sites with 4
repeats (Xia et al., 1998). It was therefore hypothesised that longer site 1 variants
have a higher probability of initially interacting with PapB molecules, simply
because they contain a higher number of repeats that can be recognised by PapB. The
hypothesis was partly supported by the observation that at low protein concentrations
a slightly higher proportion of the longer site variants was protein-bound.
The differential PapB affinity demonstrated for site 1 variants was shown to have an
effect on pap phase transition frequencies. Under certain conditions, pap switches
with longer site 1 variants displayed higher on-to-off phase transition frequencies
than switches containing the short site 1 variant with 4 repeats. This differential
sensitivity in activation ofpap expression was however less apparent in rich complex
medium for reasons that remain unclear. It is highly possible that other sequence
changes present in the regulatory region of the PI operon, which was used to
represent a natural minimum site 1 variant, is responsible for the media-induced
increase in off-to-on switching frequency. The construction of isogenic strains with 4
and 9 repeats in site 1 could aid in resolving this. It is important to note, however,
that investigating the regulation of such isogenic switches might not be biologically
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relevant, as no naturally-occurring isogenic switches containing site 1 variants with 4
and >4 repeats were observed among the 82 switch sequences examined.
On-to-off phase transition frequencies were also investigated and were overall higher
than off-to-on frequencies (increase range of 5 to 400-fold, depending on the fusion
strain and growth conditions). This was consistent with previous studies reporting
100-fold frequency differences (Blyn et al., 1989) and supports the general notion
that fimbrial expression is promptly repressed when it does not provide an advantage
to bacterial fitness. Variation in the number of repeats in site 1 did not appear to
affect off-to-on transition frequencies greatly. A small decrease in switching off
frequencies was observed for longer site 1 variants in both CFT073 wild-type and
papIB mutant backgrounds, but this subtle differential was less apparent in assays
performed in rich complex medium (CFA). The reason for this effect is unclear, but
the observation that pap phase transition frequencies in both directions were
generally higher on CFA than other growth media could indicate that at high
switching frequencies, cues over and above local pap regulators are responsible for
pap repression. One potential candidate could be the cytoplasmic response regulator
CpxR of the two-component CpxAR envelope stress system, which when
phosphorylated was shown to specifically bind to the pap regulatory region and
inhibit pap transcription and P fimbriation (Hemday et al., 2004).
The effect of site 1 sequence variation on papl expression was also investigated, as
previous studies have demonstrated that binding of PapB to site 1 activates
transcription from both divergent pap promoters (Forsman et al., 1989; Goransson et
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al., 1989b). Moreover, increased Papl expression from regulatory regions with
longer site 1 variants could explain the higher off-to-on frequencies observed in this
study, as Papl is essential for the translocation of Lrp to distal sites in the pba
promoter and activation ofpap operon transcription. Promoter regions containing site
1 variants with >4 repeats stimulated Papl expression at low levels, but no expression
was detected from a promoter containing 4 repeats in site 1 (PI from UPEC CFT073).
It is possible that a very low level of GFP expression from the PI promoter fusion
failed to be detected by the employed methods and this could be investigated further
with more sensitive transcript-detection methods, such as qRT-PCR. Investigation of
a different natural promoter with 4 repeats {pap from UPEC J96) demonstrated that
the number of repeats present in PapB site 1 does not affect the level of Papl
expression and suggested that other sequence changes may be limiting papl
expression from the PI operon. Sequence comparison of pi promoter regions from
P1CFT073 and PapJ96 identified single-base changes in CAP binding site and its
upstream sequence as potential candidates. The finding however that papl encoded
by the PI operon from E. coli CFT073 failed to be activated in the presence of PapB,
raised questions as to how this operon transitions from the off-to-on phase to allow
expression of PI fimbriae. Moreover, the lack of papl activation from the PI pi
promoter does not explain how the divergent pBA promoter in the same operon can
switch on, even at relatively low frequencies (Fig. 5.6-8). Comparison of the results
however requires caution, as activation of the two divergent promoters was assayed
in different genetic backgrounds (E. coli K-12 for pi vs. CFT073 for pBa), which were
shown in chapter 3 of this thesis, to provide a different regulatory context for papl
gene expression. This is further supported by the fact that the very low off-to-on
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transition frequency presented in section 3.3 for the PI pba promoter in the E. coli K-
12 background (ZAP992) is consistent with the lack ofpapl expression from the PI
pi promoter in the same background that was described here. Alternatively, it is
possible that differences in papl expression levels exist between different pap
operons in the same genetic background and that they are linked to papl sequence
variation. For example, P1cfto73 and papS(t operons that differ greatly in papl
activation levels contain sequence changes in papl resulting in different Papl proteins.
These findings are analysed and discussed further in the following chapter.
The observation that pap operons display differential sensitivity of activation is
proposed to be physiologically significant for UPEC isolates that contain multiple
copies of pap and pap-related operons. Sequence variation in PapB site 1 is
hypothesised to provide a mechanism for differential responsiveness of homologous
pap operons to activation and possibly coordinated timing of P fimbrial expression in
single cells. This hypothesis is supported by the finding that almost all UPEC isolates
with two pap operons examined in this study were found to contain operons with
different site 1 variants, with the combination of minimum (4) and maximum (9)
length sites being the most common. Based on this finding, PapB site 1 sequence
variation is proposed to have the potential of a diagnostic tool. PCR amplification
over the variable site 1 sequence would be a fast and simple method to gain good




Sequence variation in papl genes from UPEC isolates and effects on
regulation ofpap expression
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This chapter describes the extent of natural sequence divergence observed in papl
genes from UPEC clinical isolates associated with different UTI clinical syndromes.
Sequence divergence was investigated with respect to isolate clinical origin and pap
operon copy number, in order to link allelic variation to isolate pathogenic potential.
Sequence variation in papl was also investigated with respect to other variable
regions identified in the pap epigenetic switch and described in chapters 4 and 5.
Lastly, the function of different Papl protein variants as transcriptional activators was
examined on differentpap operons and homologous fimbrial operons from E. coli.
Papl is the positive transcriptional regulator of the pap operon. It is a small protein
(8.8 KDa) encoded by the papl gene, which is located ~ 400bp upstream of papB and
is divergently transcribed from its own promoter (pi). Papl is essential for pap phase
variation. Early studies investigated the possibility of Papl exerting its regulatory
function by binding pap DNA sites specifically, but obtained no evidence to suggest
that the protein was interacting with pap DNA independent of Lrp (Forsman et al.,
1989; Nou et al., 1993; Kaltenbach et al., 1995). It was later shown that Papl was
required for the transition of the pap switch from off to on by a mechanism involving
the E. coli global regulators Lrp and Dam and specifically, that Papl favoured Lrp
binding to distal promoter sites when proximal sites were methylated by Dam, thus
promoting formation of the on transcriptional phase (Kaltenbach et al., 1995;
Hemday et al., 2003). Recently, the structure of Papl has been solved and the
proposed fold resembled that of the winged helix-turn-helix (wHtH) family of DNA-
binding proteins (Kawamura et al., 2007). In the same study the ability to bind DNA
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non-specifically was also demonstrated in the absence of Lrp, providing new insights
into Papl's mode of action as a regulator ofpap transcription.
6.1 Sequence variation in papl genes from UPEC isolates
The sequence of papl genes present in 82 pap operons from 54 UPEC isolates was
obtained as described in section 4.3. Comparison of papl sequences by multiple
sequence alignment (msa) revealed novel polymorphism within the population of
UPEC clinical isolates (Fig. 6.1). Twenty one single nucleotide polymorphisms
(SNPs) were identified in the 234 bp coding region resulting in 16 papl alleles.
Unlike papB, no papl gene was found to contain frameshift mutations that led to
protein truncation and higher nucleotide diversity was displayed by papl than full-
length papB sequences (Jlpapi = 0.034 ± 0.008% vs. npapB = 0.007 ± 0.002%). Twelve
of the observed SNPs were synonymous (S) substitutions, whereas the remaining
nine were nonsynonymous (N) and resulted in amino acid replacements. The number
of synonymous substitutions per synonymous site (dS) and the number of
nonsynonymous substitutions per nonsynonymous site (dN) were determined and
compared by a codon-based Z-test using the Nei-Gojobori method (Nei and Gojobori,
1986). The test revealed significant evidence for positive selection acting on papl
genes (dN>dS,p<0.05).
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AUT172.6 G [ 69]
IHE1106.1 G [ 69]
IHE1152 .1 G [ 69]












AUT164 .1 [ 69]
BR20.1 [ 69]
U68.1 [ 69]
IHE1190.2 A [ 69]
U43.3 [ 69]
API8 .1 G G [ 69]
AUT119.1 G G [ 69]
AUT 120.3 G G [ 69]
AUT147.1 G G [ 69]
AUT17.1 G G [ 69]
IHE1402 .1 G G [ 69]
IHE1431.1 G G [ 69]
CFT073_P1 G G [ 69]
Hul 690.3 G [ 69]
Hul751.1 G [ 69]
Hul751.2 G [ 69]
IHE1402 . 3 G [ 69]
KS71.1 G [ 69]
CFT073_P2 G [ 69]
AUT8.2 G G [ 69]
AP7.1 G G [ 69]
AUT119.4 G G [ 69]
AUT148.2 G G [ 69]
AUTI67.3 G G [ 69]
AUT171.1 G G [ 69]
U126.3 G G [ 69]
AP4.1 G G [ 69]
AUT 111.1 ; G G [ 69]
AUT 14 3.2 ' G G [ 69]
AUTI62.1 G G [ 69]
AUT172.2 G G [ 69]
Hul740.1 G G [ 69]
Hul756.1 G G [ 69]
Hul761. 2 G G [ 69]
IHE1041.1 G G [ 69]
IHE1086. 2 G iG [ 69]
IHE1268 .2 G G [ 69]
U105.2 G G [ 69]
Hul758.2 [ 69]
IHE1049 . 3 G G [ 69]
U151.2 [ 69]
AUT143.1 [ 69]
AUT164.5 G G [ 69]
AUT166.1 G G [ 69]
AUTI67.1 [ 69]
AUT168.4 G G [ 69]
AUT169.4 G G [ 69]
IHE1086 .1 G G [ 69]
IHE1190 .1 G G [ 69]
Fig. 6.1 Multiple sequence alignment (msa) of 82 papl genes from 54 UPEC clinical isolates. Dots
represent nucleotides identical to the first DNA sequence listed, while polymorphic bases are shown.
DNA sequences were aligned using ClustalX 1.83 (Thompson et ai, 1997).
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AUT172.6 A C C [138
IHE1106.1 A C C [138
IHE1152 .1 A C C [138

















AP18.1 A C C C. ... [138
AUT119.1 A C C C. ... [138
AUT120.3 A C C C. ... [138
AUT147.1 A C C C. ... [138
AUT17.1 A C C C. ... [138
IHE1402 .1 A C C C. ... [138
IHE1431.1 A C C C. ... [138
CFT073_P1 A C C C. ... [138
Hul 690 . 3 A C C C. ... [138
Hul751.1 A C C C. ... [138
HU1751.2 A . C C C. ... [138
IHE1402 . 3 A C C C. ... [138
KS71.1 A C C C. ... [138
CFT073_P2 A C C C. ... [138
AUT 8 .2 C C C. ... [138
AP7.1 C C C. ... [138
AUT 119.4 C C C. ... [138
AUT 14 8.2 C C C. ... [138
AUT 167 . 3 C C C. ... [138
AUT 171.1 C C C. ... [138
U126.3 C C C. ... [138
AP4.1 C C C. ... [138
AUT 111.1 C C C. ... [138
AUT143.2 C C C. ... [138
AUT162 .1 C C C. ... [138
AUT172.2 C C C. ... [138
HU1740.1 C C C. ... [138
HU1756.1 C C C. ... [138
HU1761.2 C C C. ... [138
IHE1041.1 C C C. ... [138
IHE1086.2 C C C. ... [138
IHE1268 .2 C C C. ... [138
U105.2 C C C. ... [138
Hul758 .2 C [138
IHE1049 . 3 C C C. ... [138
U151.2 C [138
AUT 143.1 C [138
AUTI64.5 C C C. ... [138
AUT 166.1 C C C. ... [138
AUT167 .1 [138
AUT168.4 C C C. ... [138
AUT169.4 C C C. ... [138
IHE1086.1 C C C. ... [138
IHE1190 .1 C C C. ... [138
Fig. 6.1 - continued (papl bases: 70-138)
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AUT136.1 T. . [207]






Hul757.1 A . .G T. . [207]
IHE1086.4 A [207]
J96 pap A . .G T. . [207]
J96 prs A . .G T. . [207]
AUT172.6 T . . [207]
IHE1106.1 T. . [207]
IHE1152.1 T. . [207]
U126.1 T. . [207]
83972.1 ... C.. A [207]
AP7.2 ... C.. A [207]
AUT148.1 ... C.. A [207]
AUTI67.2 ... C.. A [207]
AUTI68.2 ... c.. A [207]
Hul690.5 [207]
Hul751.8 [207]
U105.3 ... c.. A [207]
U43. 6 ... c.. A [207]
AUT112.1 ... c.. A [207]
AUT14.1 ... c.. A [207]
AUT164.1 ... c.. A [207]
BR20.1 ... c.. A [207]
U68.1 ... c.. A [207]
IHE1190.2 ... c.. G. .A [207]
U43.3 . . A [207]
API8.1 A ..A ... A . .G A [207]
AUT119.1 A ..A ... A . .G A [207]
AUT120.3 A ..A ... A . .G A [207]
AUT147.1 A ..A ... A . .G A [207]
AUT17.1 A ..A ... A . .G A [207]
IHE1402.1 A ..A ... A . .G A [207]
IHE1431.1 A ..A ... A . .G A [207]
CFT073 PI A ..A ... A . .G A [207]
HU1690.3 A ..A ... A . .G A [207]
Hul751.1 A ..A ... A . .G A [207]
Hul751.2 A ..A ... A . .G A [207]
IHE1402.3 A ..A ... A . .G A [207]
KS71 .1 A ..A ... A . .G A [207]
CFT073 P2 A ..A ... A . .G A [207]
AUT8.2 A ..A ... A . .G A [207]
AP7.1 A ..A ... A . .G ... c.. A [207]
AUT119.4 A ..A ... A . .G ... c.. A [207]
AUT148.2 A [207]
AUT167.3 A ..A ... A . .G ... c.. A [207]
AUT171.1 A ..A ... A . .G ... c.. A [207]
U126.3 A ..A ... A . .G ... c.. A [207]
AP4.1 A ..A ... A . .G ... c.. A [207]
AUT111.1 A ..A ... A . .G ... c.. A [207]
AUT143.2 A [207]
AUT162.1 A [207]
AUT172.2 A ..A ... A . .G ... c.. A [207]
Hul740.1 A [207]
Hul756.1 A ..A ... A . .G ... c.. A [207]





HU1758.2 A . .G T. . [207]
IHE1049.3 A ..A ... A . .G ... c.. A [207]
U151.2 A . .G T. . [207]
AUT143.1 A [207]
AUT164.5 A ..A ... A . .G ... c.. A [207]
AUT166.1 A ..A ... A . .G ... c.. A [207]
AUT167.1 ... c.. A [207]
AUT168.4 A ..A ... A . .G ... c.. A [207]
AUT169.4 A ..A ... A . .G ... c.. A [207]
IHE1086.1 A ..A ... A . .G ... c.. A [207]
IHE1190.1 A ..A ... A . .G ... c.. A [207]
Fig. 6.1 — continued (papl bases: 139-207)
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536.1 GGA CAG AGC TGT TCT TCC ACA ACT TAA [234
83972.2 A .A [234
AUT170.1 A .A [234
Hul690 .4 A .A [234
U43.1 A .A [234
IHE1049.1 A .A. .C [234
AUT131.2 A .A [234
AUT136.1 A .A [234
Hul691.1 A .A [234
U113.1 A .A [234
AUTI66.2 A .A [234
AUT164 . 3 A .A [234
AUT169.1 A .A [234
BRIO. 1 A .A [234
HU1757.1 A .A [234
IHE1086. 4 A .A [234
J96_pap A .A [234
J96_prs A .A [234
AUT172.6 A .A [234
IHE1106.1 A .A [234
IHE1152.1 A .A [234
U126.1 A .A [234
83972.1 ..G ... .A [234
AP7.2 ..G ... .A [234
AUT 14 8.1 ..G ... .A [234
AUTI67.2 . .G ... .A [234
AUTI68.2 . .G . . . .A [234
Hul 690.5 ..G ... .A [234
HU1751.8 ..G ... .A [234
U105.3 ..G ... .A [234
U43.6 ..G ... .A [234
AUT112.1 ..G [234
AUT14.1 ..G [234













Hul 690.3 ..G [234
Hul 7 51.1 ..G [234









AUT 171.1 ..G [234
U126.3 ..G [234
AP4.1 ..G T [234
AUT 111.1 ..G T [234
AUT143.2 ..G T [234
AUT162 .1 ..G T [234
AUT172.2 ..G T [234
HU1740.1 ..G T [234
Hul756.1 ..G T [234
Hul7 61.2 ..G T [234
IHE1041.1 ..G T [234
IHE1086.2 ..G T [234
IHE1268.2 ..G T [234
U105.2 ..G T [234
Hul758 .2 A .A [234
IHE1049.3 ..G T [234
U151.2 A .A [234
AUT14 3.1 A .A [234
AUTI64.5 ..G [234
AUT166.1 ..G T [234
AUT167 .1 . .G ... .A [234
AUT168.4 ..G [234
AUT169.4 ..G [234
IHE1086.1 ..G T [234
IHE1190.1 ..G T [234
Fig. 6.1 - continued (papl bases: 139-234)
164
Translation of the 16 papl alleles resulted in 11 protein variants, denoted 1.1 -1.11
(Fig. 6.2). Six of the identified variants were novel and the remaining five matched
Papl sequences available in public sequence databases belonging to either sequenced
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Fig. 6.2 Multiple sequence alignment (msa) of 11 Papl protein variants identified in 54 UPEC
clinical isolates. The identified Papl variants were designated I.l-I.ll. The sequence of five variants
is identical to Papl protein sequences from sequenced E. coli isolates (CFT073, 536, UTI89) and
prototype strains (J96, 83972). Variable residue positions are shaded grey. The CONSERV line
indicates the degree of conservation in each column, with '* ^identically conserved, ':'=contains only
very conservative substitutions and '.'=contains mostly conservative substitutions. The SS line shows
the secondary structure elements of Papl (H, a-helix; S, (3-strand) as proposed by Kawamura and
colleagues (Kawamura et a/., 2007).
Colour-mapping of the 9 observed amino acid replacements onto the protein
structure of Papl (PBD ID 2HTJ; Kawamura et al., 2007) was performed using the














Fig. 6.3 Diagram showing the location of identified amino acid replacements in Papl structure.
The winged helix-turn-helix (wHtH) structure of Papl consists of a HtH («l-a2-turn-a3). followed by
the wing (pi-loop-p2) (Kawamura et al., 2007). Helices are shaded in green and are marked by arrows,
coils are shaded in red and strands are shaded in blue and are also marked by arrows. The loop
between the two P strands is marked by an arrow and labelled "wing tip". Variable residues are shaded
in yellow with the position and residue replacement labelled. The ribbon diagram of Papl structure
(PDB ID: 2HTJ; Kawamura et al., 2007) was obtained from the Protein Data Bank (RCSB PDB;
Berman et al., 2003) and editing was performed using the MBT Protein Workshop (Moreland et al.,
2005).
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Most changes were located within coil structures and the C-terminal tail. One change
was found in the first helix (al) and was only observed in variant 1.9, which in turn
was found in a single pap operon (see Table 6.1 below). A phenylalanine
replacement by leucine was more commonly observed and localised in the highly
hydrophobic second strand (P2) of the antiparallel p-sheet, but it is not predicted to
change the overall hydrophobicity of the strand. Interestingly, the sequence of the
third helix (a3), known as the recognition helix and proposed to be the major surface
contacting DNA in wHtH proteins (Kawamura et al., 2007), was identically
conserved. A similar role was proposed for the tip of the wing, which is the loop
between the P-strands, which was also conserved among the identified variants.
To examine the evolutionary relationships of the papl gene sequences phylogenetic
analysis was performed using the neighbor-joining method, which uses distances
between pairs of taxa (eg. number of nucleotide differences between sequence pairs
in msa) to construct an evolutionary tree (Fig. 6.4; Saitou and Nei, 1987). Distance
methods, such as the neighbor-joining, are the most suitable for phylogenetic
analysis of the large number of sequences analysed in this study, whereas parsimony
or maximum-likelihood methods are limited to smaller datasets. To evaluate the
reliability of branch topology in the constructed phylogenetic tree the bootstrap
method was used (Felsenstein, 1988). This method operates by randomly resampling
vertical columns from the aligned sequences to produce several sequence alignments
of the same size. In each new dataset some of the original data could be represented
more than once and others not at all. A minimum-length tree is produced for each
alignment of resampled sequences and the predicted topology of the original tree is
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Fig. 6.4 Phylogenetic tree of Papl amino
acid sequences from UPEC isolates.
Translated papl gene sequences from 54 UPEC
isolates were compared by msa (BLOSUM62
scoring matrix) and evolutionary relationships
were predicted using the neighbor-joining
distance method. The Papl protein variant
designations I.I - I.II corresponding to each
group of sequences is shown with the clinical
origin of every sequence colour-coded
(blue=asymptomatic, red=symptomatic). The
predicted tree topology was tested using the
bootstrap method (1000 replicates) and branch
frequencies are shown in bold. Phylogenetic
and molecular evolutionary analyses were
conducted using MEGA version 3.1 (Kumar et
a/., 2004).
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Table 6.1 lists the Papl protein variant encoded by each pap operon from the UPEC
isolates examined. The information on isolate clinical origin, number ofpap operons
and PapB site 1 repeat number is also included in the table to enable examination of
papl polymorphism in the context of the clinical isolate.
Table 6.1 Papl protein variants in pap operons from UPEC clinical isolates. The papl alleles present
in the pap operons from each UPEC isolate were translated and assigned a protein variant number
(I.l-I.ll). Each of the 54 UPEC isolates is listed along with the number ofpap operons it contains and
the Papl protein variant found in each operon. The PapB site 1 repeat number found in the sequence of
each corresponding operon is also listed in the final column.
(*) Isolates containing a pap operon that was detected by Southern hybridisation but for which the
sequence of the regulatory region was not obtained (N/O).
{a ) Papl protein variants that were found only in one pap operon.
{h) Papl protein variants encoded by a pap operon with a mutant papB gene (see section 4.4.5).
Isolate ID No. of pap operons Papl variant PapB site 1 repeat number
HU1690 3 1.11", 1.3, 1.8 4, 7,4
HU1691 1 1.8 4
HU1740 1 1.1* 8
HU1751 3 1.3, 1.3, 1.11" 7, 7,4
HU1756 1 1.1 9
HU1757 1 1.6 4
HU1758 1 1.6 4
HU1761 1 1.1 8
U43 3 1.8, l.4a, 1.11* 4, 4,4
U68 1 1.1 o" 4
U105 2 1.11*, 1.1 4,8
U113 1 1.8 4
U126 2 1.8, 1.1 4,6
U151 1 1.6 4
BR10 1 1.6 4
BR20 1 1.10* 4
83972 2 1.11*, 1.8 4, 4
AUTI4* 2 1.10*. N/O 4, N/O
AUTI7 1 1.2 4
AUTI12 1 1.10" 4
AUTI19 2 1.2, 1.1 4,6
AUTI31 1 1.8 4
AUTI36 1 1.8 4
AUTI43 2 1.6, 1.1 4, 9
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Table 6.1 - continued
AUTI47 1 1.2 4
AUTI48 2 l.11b, 1.1 4,8
AUTI62 1 1.1 7
AUTI64 3 l.10b, 1.6, 1.1 4, 4, 7
AUTI66 2 1.8, 1.1 4,9
AUTI72 2 1.8, 1.1 4,7
AUTI8* 2 1.2, N/O 6, N/O
AUTI11 1 1.1 7
AUTI20* 2 1.2, N/O 4, N/O
AUTI67 3 1.11", 1.11", 1.1 4, 4,4
AUTI68 2 1.11", 1.1 4,4
AUTI69 2 1.6, 1.1 4,9
AUTI70 1 1.8 4
AUTI71* 2 1.1, N/O 8, N/O
AP4* 2 1.1, N/O 8, N/O
AP7 2 1.11", 1.1 4,8
AP18* 2 1.2, N/O 4, N/O
IHE1041 1 1.1 9
IHE1049 2 1.7s , 1.1 6,7
IHE1086 3 1.6, 1.1, 1.1 4, 9, 9
IHE1106 1 1.8 4
IHE1152 1 1.8 4
IHE1190 2 l.9a,b, 1.1 4,9
IHE1268* 2 1.1, N/O 9, N/O
IHE1402 2 l.2b, 1.3 4,6
IHE1431 1 1.2 4
KS71* 2 1.3, N/O 6, N/O
CFT073 2 1.2, 1.3 4,6
J96 2 1.6, 1.6 4, 4
536 1 1.5* 4
54 90 82 82
The occurrence of each Papl protein variant in the pap operons of the isolate
collection was recorded and then analysed on the basis of i) isolate clinical origin
(asymptomatic or symptomatic), ii) isolate pap copy number (one or multiple) and iii)
PapB site 1 repeat number (4 or >4) (Table 6.2). Regression analysis provided
evidence for the association of certain protein variants with the clinical origin of the
isolate (p=0.03). Interestingly, the most common Papl sequence found in pap
operons, 1.1, is a novel variant and was found to associate with isolates causing
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symptomatic disease. Variant 1.2 also associated with symptomatic disease but
generally occurred less frequently in the examined operons. The sequence of this
variant is identical to Papll from the PI fimbrial operon of E. coli CFT073 and was
not found in any pap operons of asymptomatic clinical origin. Papl variants were
also significantly associated with the copy number of pap operons in each isolate
(/?<0.001). Protein variants 1.1,1.2 and 1.6 were predominantly found in isolates that
contained multiple pap operons, and Papl variants 1.3 and 1.11 were never observed
in lone pap operons. These results are supportive of the association of certain
variants, such as 1.1,1.3 and 1.6, with symptomatic disease since in the studied UPEC
collection isolates of symptomatic disease origin are more likely to possess multiple
pap operons (see Table 4.3B). A very strong association was also detected between
Papl variants and the repeat number in PapB site 1 sequence present in the same pap
operon (/?=10~10). In particular, the commonest variant 1.1 was almost exclusively
found in operons with longer site 1 sequences (>4 repeats). In fact, all operons with
site 1 sequences containing 8 or 9 repeats encoded for Papl variant 1.1 (see Table 6.1).
Similarly, 1.3 was always associated with operons containing longer site 1 sequences,
although this protein variant was fairly uncommon among the isolates studied. In
contrast, variants 1.2,1.6,1.8,1.10 and 1.11 were associated with operons containing a
PapB site 1 sequence with 4 repeats. The results indicate that certain combinations of
Papl variants will be commonly encountered in isolates with multiple pap operons.
Interestingly, the occurrence of mutations in papB genes also appeared to correlate
with certain Papl variants. In particular, all pap operons encoding for Papl variants
1.9, 1.10 and 1.11 also encoded for truncated PapB proteins (Table 6.1), due to the
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frameshift mutation described in section 4.4.5. These operons also had the minimum
(4) number of 9 bp repeats in their PapB site 1 sequence (Table 6.2).
Table 6.2 Frequency of Papl protein variants in 82 pap operons from 54 UPEC clinical isolates. The
total number of pap operons encoding for each Papl protein variant is listed in the first frequency
column (total number of examined pap operons: 82). The frequency of each Papl variant was then
investigated depending on whether the encoding pap opcrons belonged to (1) an asymptomatic or
symptomatic isolate, (2) an isolate with a single or multiple pap operons and (3) depending on
whether the encoding pap operon contained a PapB site 1 sequence with 4 or >4 repeats. Logistic
regression analysis on variants with more than 6 occurrences provided significant evidence that
variants 1.1 and 1.2 are found more often in pap operons from symptomatic isolates (marked with *,
p=0.03). Similarly, variants 1.1, 1.2, 1.3, 1.6 and 1.11 were encoded more frequently in pap operons
from isolates that contained multiple pap operons (marked with *, pcO.OOl). A Fisher exact test
provided very strong evidence of an association between Papl variants and PapB site 1 repeat number,
with variants 1.2,1.6,1.8,1.10 and 1.11 frequently coinciding with PapB site 1 sequences containing 4
repeats and variants 1.1 and 1.3 associating with >4-repeat sites (marked with *, /?=10"').
Frequency
(no. of pap
Frequency (no. of pap operons) examined by:
2. Isolate pap 3. No. of repeats
copy number in PapB site 1
1. Isolate clinical origin
Papl variant operons) asymptomatic symptomatic one multiple 4 >4
1.1 25 5 20* 6 19* 2 23*
1.2 9 0 9* 3 6* 8* 1
1.3 6 3 3 0 6* 0 6*
1.4 1 1 0 0 1 1 0
1.5 1 0 1 1 0 1 0
1.6 10 4 6 4 6* 10* 0
1.7 1 0 1 0 1 0 1
1.8 13 6 7 7 6 13* 0
1.9 1 0 1 0 1 1 0
1.10 5 2 3 3 2 5* 0
1.11 10 5 5 0 10* 10* 0
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The presence of positive Darwinian selection acting on papl genes found in UPEC
isolates suggests that the observed sequence variation could be a mechanism for
modulating the protein's regulatory function on the pap operon. Papl has been shown
to complement fimbrial regulators from homologous operons (Goransson et al., 1988;
van der Woude and Low, 1994; Morschhauser et al., 1994; Nicholson and Low,
2000), so the observed mutations could also be affecting the protein's cross-talk
potential. If the hypothesis holds true then the presence of certain Papl combinations
in isolates could result in different fimbrial expression outputs due to different
regulatory interactions between the isolate's homologous fimbrial operons.
6.2 Effect ofpapl sequence variation on P fimbriation and pap expression
In order to investigate the effect of Papl polymorphism on P fimbriation inducible
plasmids encoding for different Papl variants were transformed into an E. coli K-12
strain (ZAP594; see Table 2.1C) engineered to chromosomally contain a single copy
of the complete F13 pap operon (papI-papG) from E. coli J96 (Linberg et al., 1984).
Bacteria expressing P fimbriae on their surface were detected by
immunofluorescence using a PapA-specific polyclonal antiserum supplied by Prof.
B.E. Uhlin (Nilsson et al., 1996) and the Alexa Fluor 488 IgG conjugate (Molecular
Probes) and were subsequently enumerated by flow cytometry, as described in
sections 2.4 and 2.5.1. The specificity of the antibody for P fimbriae of the F13
serotype was tested using the E. coli K-12 strain MG1655 as a negative control and
MG1655pPap5 as a positive control. The pPap5 plasmid is a pBR322-based
construct that contains the complete F13 pap operon from J96 (Linberg et al., 1984).
Transformation of E. coli MG1655 with this multi-copy plasmid and staining with
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the anti-P serum resulted in a mean of 86% (± 3.5%) fluorescent bacteria, of which
only a negligible fraction (0.07%) was due to non-specific binding to MG1655
surface components (Fig. 6.5). It was therefore concluded that the tested anti-P serum
recognised F13 P fimbriae specifically.
The proportion of P-fimbriate bacteria detected in a population of E. coli ZAP594
was very low (0.26 ± 0.02%) in the absence of Papl added in trans (Fig. 6.5).
Induced expression of three different Papl variants (1.2, 1.3 and 1.6) increased the
proportion of P-fimbriate bacteria in the population to 2.1%, 9.5% and 12.8%,
respectively (Fig. 6.6). The papl genes encoding variants 1.2 and 1.3 were cloned
under the control of the pBAD promoter in the pBAD18 vector generating plasmids
pKCl and pKC2, respectively (Table 2.2), whereas the papl gene for 1.6 was cloned
into pACYC184 under the control of the lac promoter, making vector pHMG98
(Table 2.2; Forsman et al., 1989). Papl variants 1.3 and 1.6 had a significant positive
effect on ZAP594 P fimbriation compared to their corresponding vector controls
pBAD18 and pACYC184 (p<0.001), whereas variant 1.2 had a marginal effect. The
three Papl variants tested differed in one (1.2 and 1.3), four (1.2 and 1.6) and three (1.3
and 1.6) amino acid residues (Fig. 6.2). These results indicate that sequence variation
in Papl affects P fimbriation and the mechanism is predicted to involve changes in
the protein's ability to regulate pap operon expression.
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Fig. 6.5 Proportion of P-fimbriate bacteria in populations of E. coli J96 and K-12 strains. Phase
contrast and immunofluorescence microscopy images of bacterial cells stained with anti-P (F13)
serum and the secondary fluorophore-IgG conjugate Alexa Fluor 488 (Molecular Probes) are shown
for E. coli isolate J96 and K-12 strains MG1655, MG1655pPap5, ZAP594 and ZAP589. Fluorescence
histograms obtained by flow cytometry are shown for each population (left), with the proportion of
fluorescent bacteria indicated in the top right-hand comer. The gate for fluorescence detection is
shown by Ml and was set as defined in section 2.5.1. Microscopy images and fluorescent histograms
are representatives of one immunofluorescence experiment. At least three biological replicates were
performed. For ZAP594 and ZAP589 images, multiple fields had to be scanned to detect a single




Fig. 6.6 Effect of different Papl variants on P fimbriation in E. coli ZAP594. Inducible expression
of Papl variants 1.2 and 1.3 in ZAP594 by transformation with plasmids pKCl and pKC2 resulted in
2.1% and 9.5% P-fimbriate bacteria, respectively. The effect of variant 1.2 was marginal compared to
pBAD18 (control vector), whereas the fimbriate proportion induced by 1.3 was significantly higher
(pcO.Ol). Similarly, expression of Papl variant 1.6 from the inducible plasmid pHMG98 significantly
increased the proportion of P-fimbriate bacteria (12.8%) compared to the pACYC184 (control vector;
/?<().001). P-fimbriate bacteria were detected by immunofluorescence using an anti-P serum specific
for the F13 serotype (Nilsson et al., 1996) and Alexa Fluor 488 IgG conjugate (Molecular Probes).
Proportions of fluorescent bacteria in the population were quantified by flow cytometry, as described
in section 2.5.1. Results are presented as mean proportions (± s.e.) of three biological replicates.
The same activating trend was observed for the three Papl variants when tested on an
E. coli K-12 strain engineered to contain a chromosomal single-copy fusion of the
F13 pap regulatory region to the egfp reporter (ZAP589; see Table 2.1C). This
translational fusion placed the egfp reporter gene under the control of the pBA
promoter and included papl, papB and the first 23 codons of papA. Fluorescence
microscopic examination of a ZAP589 population grown under P-promoting
conditions (CFA medium, 37°C) revealed that F13 pap expression in the K-12
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background is phase variable but at very low frequencies (Fig. 6.5). The mean
proportion of fluorescent bacteria in ZAP589 populations was 0.15% (± 0.5%), as
determined by flow cytometry and was consistent with the low proportion of P-
fimbriate bacteria detected by immunofluorescence in ZAP594 populations grown
under identical conditions (see Fig. 6.5). This suggested that pap expression in the
two systems is regulated in a similar manner.
Induced expression of Papl variants 1.2, 1.3 and 1.6 significantly increased the
proportion of fluorescent bacteria in the population compared to control vectors
pBAD18 and pACYC184, respectively (Fig. 6.7). Similar to their effect on P
fimbriation, Papl variant 1.6 caused a ~470-fold increase in pap expression, while 1.3
induced a higher-fold increase than variant 1.2 (~85-fold and ~35-fold, respectively).
The results confirmed that sequence variation altered Papl's capacity to activate pap
operon expression. Moreover, the activation trend of the three Papl variants was the
same for both the complete F13 pap operon strain and that containing the
translational reporter fusion to the operon's regulatory region. This suggested that
expression of pba reporter fusions reflects P-fimbriate bacterial proportions in the E.
coli K-12 background and therefore single-copy reporter fusions to pap regulatory
regions can be used instead of the complete operons for studying pap expression.
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pBAD18 I.2 I.3 pACYC184 I.6
Fig. 6.7 Effect of different Papl variants on pap expression in E. coli ZAP589. Induced expression
of Papl variants 1.2 and 1.3 in ZAP589 by transformation with plasmids pKCl and pKC2 resulted in
17.7% and 44.6% eg/p-expressing bacteria, respectively. Both variants resulted in a significant
increase compared to pBAD18 (control vector; p<0.001). Similarly, expression of Papl variant 1.6
from the inducible plasmid pHMG98 significantly increased the proportion of eg/p-expressing
bacteria (70.3%) compared to pACYC184 (control vector; p<0.001). Quantification of fluorescent
bacteria was performed by flow cytometry, as described in section 2.5.1. Results are presented as
mean proportions (± s.e.) of three biological replicates.
Taken together the results suggest that Papl sequence variation has an effect on the
proportion of P-fimbriate bacterial in the population and pap expression. There is
evidence to suggest that such an effect is due to altered pap phase variation
frequencies and not elevated transcription from the pBA operon promoter. Firstly, the
fluorescence intensity of strain ZAP589 remained the same in the absence and
presence of multi-copy Papl but the number of eg/p-expressing bacteria increased
after addition of Papl. This differentiation was possible by using flow cytometry
instead of other population-based fluorescence detection systems, since the former
allows fluorescence examination at the single-cell level. Moreover, additional
laboratory findings (Miss K. Catherwood, unpublished data) using an E. coli K-12
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strain (ZAP593) that contains a single-copy lacZ reporter fusion to the regulatory
region of the F13 pap operon, showed that different Papl variants differentially
increased the off-to-on transition frequency of the pap operon. These findings were
in agreement with the effect observed on P fimbriation and pap expression of strains
ZAP594 and ZAP589, respectively.
6.3 Effect ofpapl sequence variation on positive cross-talk between homologous
fimbrial operons
Papl has been shown to cross-activate homologous fimbrial operons, such as sfa and
daa (van der Woude and Low, 1994; Morschhauser et al., 1994). The difference in
activator potential observed for Papl variants 1.2 and 1.3 using the F13 pap operon
and the fact that these two variants are present in the same E. coli strain (the first
sequenced UPEC, CFT073) indicated that different cross-talk scenarios can take
place in UPEC isolates. In order to investigate the ability of different Papl variants to
cross-regulate homologous fimbrial operons, three E. coli K-12 strains were
constructed, containing chromosomal single-copy egfp fusions to three homologous
pap regulatory regions. The selected homologous operons were papl,pap2 and foe
encoding for PI, P2 and F1C fimbriae, respectively and belonged to the same E. coli
strain (CFT073), in order to investigate the Papl cross-regulatory network present in
a single well-characterised UPEC isolate. The papl, pap2, and foe regulatory regions
were fused to egfp and then introduced in single-copy into the E. coli K-12 lac
chromosomal locus generating strains ZAP714, ZAP955 and ZAP715, respectively
(Table 2.1C), in a manner similar to ZAP589. The cross-activating potential of the
two CFT073 Papl variants (1.2 and 1.3) was investigated on the three operon fusions
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contained in strains ZAP714, ZAP955 and ZAP715. Transformation of plasmids
pKCl and pKC2, carrying the two CFT073 Papl variants into each K-12 strain and
induction of Papl expression resulted in different proportions of eg/p-expressing
bacteria in each population (Fig. 6.8). Papl variant 1.3 was able to cross-activate all
three CFT073 operons to an equal extent (~10-fold). In contrast, Papl variant 1.2 was
able to activate the native papl operon and foe, but failed to cross-regulate the pap2
operon fusion.
1.3
Fig. 6.8 Effect of CFT073 Papl variants on cross-regulation of CFT073 homologous fimbrial
operons in E. coli ZAP714 (papl), ZAP955 (papl) and ZAP715 (foe). Expression of Papl variant
1.2 from inducible plasmid pKC 1 resulted in a mean 6.7-fold, 1.8-fold and 11.4-fold increase of egfp-
expressing bacteria in strains ZAP714 (papl), ZAP955 (papl) and ZAP715 (foe), respectively.
Expression of Papl variant 1.3 from inducible plasmid pKC2 resulted in a mean 8.5-fold, 4.9-fold and
9.8-fold increase of eg$?-expressing bacteria in strains ZAP714 (papl), ZAP955 (papl) and ZAP715
(foe), respectively. The effect of 1.2 on the pap2 operon was significantly lower than its effect on the
other two CFT073 operons (p=0.016, marked as *). In addition, the effect of 1.2 on the pap2 operon
was significantly lower than the effect of 1.3 variant on the same operon (p=0.012). Quantification of
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fluorescent bacteria was performed by flow cytometry, as described in section 2.5.1. Results are
presented as mean proportions (± s.e.) of at least three biological replicates.
The protein sequence of Papl variant 1.2 differs from 1.3 by a single amino acid
residue at position 17 (D17N). In order to confirm the profound effect of this
replacement change on Papl's ability to activate the pap2 operon fusion, the papl,
pap2 and foe regulatory regions, as well as the papl genes cloned in plasmids pKCl
and pKC2 were checked by sequencing and no sequence errors were detected. To
further verify the observed difference in Papl function, the pap2 operon fusion was
remade using a sequenced TOPO®-clone for CFT073 carrying the pap2 regulatory
region (see sections 4.2 and 4.3) and the brighter reporter variant gfp+. The fusion
was introduced in single-copy into the chromosome of E. coli K-12 generating strain
ZAP615 (Table 2.1C). Transformation of plasmids pKCl and pKC2 into E. coli
ZAP615 and induced expression of the different Papl variants confirmed the inability
of variant 1.2 to cross-activate the pap2 operon from UPEC CFT073 (Fig. 6.9).
In summary, the results demonstrated that naturally-occurring Papl variants differ in
their ability to activate transcription of the same pap operon leading to different
proportions of P-fimbriate bacteria in the population. Moreover, it was shown that
pap operons have different sensitivities to activation by the same Papl variant, as
























Fig. 6.9 Effect of CFT073 Papl variants on CFT073 pap2 operon expression in E. coli ZAP615.
Expression of Papl variants 1.2 and 1.3 from inducible plasmids pKCl and pKC2 in ZAP615 resulted
in 0.76% and 7.5% ^-expressing bacteria, respectively. Variant 1.2 failed to affect pap2 expression,
while 1.3 resulted in a significant increase of expression compared to the pBAD18 (control vector;
p<0.001). Quantification of fluorescent bacteria was performed by flow cytometry, as described in
section 2.5.1. Results are presented as mean proportions (± s.e.) of seven biological replicates.
6.4 Discussion
The aim of this work was to investigate the sequence variability in papl genes from
multiple UPEC isolates. Papl plays a central role in the regulation of P fimbriae
expression in uropathogenic E. coli through a phase variation mechanism that relies
on the synergistic action of Dam methylase, Lrp and Papl regulatory proteins on pap
DNA (Hernday et al., 2002). More specifically, Papl was shown to be required for
the transition of the pap operon to the transcriptionally 'on' phase by binding to Lrp-
pap DNA complexes and increasing the affinity of Lrp for pBA promoter distal
binding sites (Kaltenbach et al., 1995; Nou et al., 1995; Hernday et al., 2003).
Further insight into Papl's mode of action as a pap transcriptional activator was
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gained from the recent solution structure, which identified Papl as a winged helix-
turn-helix (wHtH) DNA-binding protein (Kawamura et al., 2007).
The extent of nucleotide diversity identified in this study using 82 papl gene
sequences from 54 UPEC isolates was greater than that predicted from the few papl
sequences previously available in public databases. In total, eleven Papl protein
variants were identified, of which six were novel. The point amino acid replacements
in Papl were acquired at a high rate and driven by positive (adaptive) selection
(dN/dS>l). Recently, the adhesive P fimbrial subunit PapG was also reported to be
under strong positive selection and to acquire structural mutations (Weissman et al.,
2006). The authors proposed that the identified PapG mutations were pathoadaptive
functional modifications of the adhesin's receptor binding properties, similar to the
functionally adaptive amino acid replacements discovered in FimH, the tip adhesin
of type-1 fimbriae (Sokurenko et al., 2004; Weissman et al., 2006). P fimbriae are
surface structures with demonstrated immunogenic potential and the finding that
their regulation is under adaptive selective pressure, targeted to the transcriptional
activator Papl, hinted that the observed Papl mutations reflect functional differences.
Moreover, certain Papl variants were found to associate with cases of symptomatic
infections and specific Papl variant combinations were frequently occurring in
isolates of symptomatic clinical origin. This association also suggested a functionally
adaptive role for the observed amino acid replacements. An association was also
observed between Papl variants and other variable regions of the pap switch
identified in this study and described in previous chapters, but this was partly
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expected since the pap operons under investigation are present in pathogenicity
islands that spread as complete genomic units among E. coli strains through
horizontal gene transfer (Hacker et al., 1999).
Papl acts as a transcriptional activator of the pap operon that encodes for it, but has
also been shown to affect expression of homologous fimbrial operons, such as sfa (S
fimbriae) and daa (F1845 fimbriae) (Goransson et al., 1988; van der Woude and
Low,1994; Morschhauser et al.,1994). The effect of Papl sequence variation in the
protein's role as a fimbrial transcriptional activator has not been examined. Here,
certain Papl variants were shown to differ in their ability to activate pap expression.
The effect of sequence variation on Papl's mode of action was examined using K12
strains containing a chromosomal copy of a complete pap operon or different pBA
promoter fusions to the lacZ reporter gene. Differences in regulatory function
between selected Papl protein variants were demonstrated using the same pap
regulatory sequence fusion in the same genetic background, indicating that the
mechanism by which amino acid replacements in Papl affect pap phase variation is
likely to involve altered Papl interactions with the Lrp-pap DNA complex. There is
only one amino acid difference between variants 1.2 and 1.3 (D17N), yet variant 1.2 is
much less efficient in activating transcription of the same pap operon promoter. The
amino acid replacement is located within the structural loop joining the first two
helices (al and a2) in Papl, which is not proposed to interact with DNA (Kawamura
et al., 2007). However, loops tend to lie on the protein surface and interact with the
surrounding aqueous environment and other proteins, so it is likely that this residue
is interacting with Lrp. Variant 1.6 contains further amino acid replacements, which
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could be playing a role in the elevated activating potential observed for this protein
compared to variants 1.2 and 1.3. However, this result should be interpreted with
caution as 1.6 was expressed from a different inducible vector than 1.2 and 1.3
(pACYC184-based vs. pBAD18-based), which could be the reason for the observed
difference in activation levels. Future work could investigate the interaction kinetics
of different Papl variants with Lrp on pap regulatory DNA using competition
electrophoretic mobility shift assays, in order to identify specific amino acid residues
that play a role in this interaction.
The ability of Papl to cross-activate homologous fimbrial operons was also shown to
be affected by observed amino acid replacements. This aspect of Papl function was
investigated using homologous operons from E. coli CFT073, in order to investigate
the Papl cross-regulatory network present in a single well-characterised UPEC
isolate. Variant 1.2 failed to cross-activate the P2 operon from CFT073, while it had a
positive effect on the isolate's two other operons (PI and F1C), as well as the pap
operon from UPEC J96. Variant 1.3 differs in a single amino acid residue from 1.2
(N17D) and was able to cross-activate all operons tested. This difference was again
suggestive of residue 17 playing a role in Papl interactions with Lrp-DNA complexes.
Interestingly, the results showed that the extent of pap operon activation is not only
dependent on the Papl protein sequence, but the DNA sequence of the regulatory
region as well. The pap operon from J96 appeared more sensitive to activation than
PI and P2 operons from CFT073, as evident from the higher fold-increase of
ZAP589 fluorescent bacteria upon 1.2 and 1.3 expression compared to ZAP714 and
ZAP955. The regulatory region of the J96 pap operon is 95.8% and 94.9% identical
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to PI and P2 regulatory regions, respectively. Sequence differences exist in the
region of Lrp binding sites and although Papl alone was shown to lack DNA
substrate specificity (Kawamura et al., 2007) the nucleotide differences could be
accounting for differences in affinity of Papl-Lrp complexes, which were reported to
have specificity for DNA sequence (Hernday et al., 2004). It is therefore proposed
that sequence changes in all three interacting factors can impact on their ability to
activate pap expression (Fig. 6.10), without however precluding the possibility that
other unknown factor(s), also required for pap phase switching, might play a role too.
Fig. 6.10 Diagrammatic representation of interdependent sequence relationships between Papl,
Lrp and the pap regulatory region. The depicted triangle is composed of three known factors
involved in pap off-to-on phase transition: Papl, Lrp and pap regulatory DNA. The double arrows
indicate interdependent relationships between the sequence (DNA or protein) of all factors. Evidence
supporting that Papl and pap regulatory DNA sequence changes affect pap activation was presented in
this study, while Lrp mutations affecting pap off-to-on transition were demonstrated in Kaltenbach et
al., 1998. The role of Dam is not included in this diagram.
In conclusion, the results indicate that UPEC clinical isolates can encode for Papl
regulators that may or may not cross-activate homologous fimbrial operons present
in the same isolate. Moreover, the extent of activation can differ between different
pap regulatory DNA
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Papl regulators and different pap operons. Depending on the Papl combinations and
the responsiveness of each operon to activation, it is predicted that each isolate can
have different fimbrial outputs and that papl sequence variation could be part of the
mechanism by which uropathogens achieve different surface-presentations required





P fimbriae are important virulence factors of uropathogenic Escherichia coli (UPEC)
for bacterial colonisation of the human urinary tract and play a key role in the
development of symptomatic urinary tract infections (UTIs). Expression of P
fimbriae, like the majority of E. coli adhesins, is regulated by phase-variation and the
frequencies at which this mechanism occurs are linked to the proportion of P-
fimbriate bacteria in the population. As the expression of P fimbriae triggers pro¬
inflammatory responses in the host (Wullt et al., 2001a, b; Samuelsson et al., 2004),
a relationship is likely to exist between the proportion of P-fimbriate bacteria and the
severity of disease. Such a relationship would argue that P fimbrial phase transition
frequencies are virulence factors in their own right and therefore mechanisms for
modulating them might have evolved. Some supportive evidence comes from studies
reporting repressed fimbrial expression in UPEC isolates from asymptomatic
infections (Andersson et al., 1991; Graham et al., 2001; Hull et al., 1998, 1999;
Stenqvist et al., 1987; Lim et al., 1998; Klemm et al., 2006; Roos and Klemm, 2006;
Roos et al., 2006a, b). Moreover, the ability of type 1 fimbriae to phase-vary was
proposed to be advantageous to UPEC survival in the murine urinary tract (Snyder et
al., 2006). The aim of this study was to investigate the regulation of P fimbrial phase
transition frequencies in multiple UPEC isolates of different clinical origin, and the
investigation was focused on the regulatory sequence ofpap operons.
In the present study, P fimbrial phase transition frequencies were measured in a
clinical isolate genetic background. Previous studies have assessed pap phase
variation in the E. coli K-12 genetic background (Blyn et al., 1989, 1990; White -
Ziegler et al., 1990) that is non-native as it does not normally contain pap operons.
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The isolate genetic background proved to be a more relevant regulatory context for
assessing pap phase variation, as it allowed it to occur in high enough frequencies to
account for the level of P fimbriation observed for UPEC isolates in this study.
Phase variation frequencies measured under identical growth conditions and in the
same genetic background were found to be different between homologous pap
operons from different UPEC isolates. Similar findings have been reported for
homologous pap operons belonging to the same UPEC isolate (Blyn et al., 1989). In
the present study, differential expression of homologous pap operons from the same
UPEC isolate was also observed under certain environmental conditions. These
observations suggested that mechanisms for modulating pap phase variation
frequencies exist in UPEC isolates. Prior to this work, DNA sequence information
for only a few regulators and regulatory regions from pap and pap-related fimbrial
operons was available, but contained sequence differences with a predicted potential
to affect pap phase variation. An interesting example is the pap operon from E. coli
isolate J96 that was shown in this study to phase-vary at higher off-to-on transition
frequencies than PI and P2 operons from E. coli CFT073. Its regulatory region is
95.8% and 94.9% identical to the PI and P2 regulatory regions, respectively, and
sequence differences exist in the papl gene and the pap DNA region containing PapB
site 1, CAP and Lrp binding sites. The factors involved in the increased phase
transition frequency of the Papj96 operon are unknown, but sequence variation in the
local regulatory proteins and/or the pap regulatory DNA region was proposed to play
a role. The remainder of this chapter discusses the evidence provided by this study
supporting the hypothesis that sequence variation in pap regulatory regions has an
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impact on phase transition frequencies and the regulation of pap expression, and
presents a hypothesis for the potential implications of this mechanism on fimbrial
expression in UPEC isolates.
To investigate sequence variation to a greater extent, 82 pap regulatory regions
belonging to 54 UPEC clinical isolates were sequenced in this study. Evidence of
sequence differences that can affect pap phase variation and subsequently P fimbrial
expression was presented for a protein binding site in pap regulatory DNA, as well as
for the papl and papB genes encoding for the local transcriptional regulators Papl
and PapB. Interestingly, the sequence variation identified in the pap transcriptional
activator Papl was shown to be driven by positive selection, providing strong
supportive evidence that mechanisms for modulating phase variation of homologous
pap operons have evolved in UPEC isolates. The pap adhesin PapG, the type 1
fimbrial adhesin FimH, and the Dr adhesin DraE, have also been shown to
accumulate functionally adaptive amino acid replacements under strong positive
selection forces (Sokurenko et al., 1998, 2004; Hommais et al., 2003; Weissman et
al., 2006; Korotkova et al., 2007), however this is the first demonstration of a
fimbrial regulator evolving in a similar manner.
PapB binding site 1, located near the pi promoter, was a highly variable region
observed among the sequenced pap switches and contained insertions/deletions of 9
bp sequence repeats. Naturally-occurring site 1 variants with 4, 6, 7, 8, or 9 repeats
were found to differ in their relative affinity for PapB binding. These results were in
agreement with previous investigation of PapB binding to site 1 sequences with 4
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and 6 repeats (Xia et al., 1998). The present study extended the investigation of this
finding to its impact on expression from both divergently transcribed pap promoters
(pi and Pba)- Overall, longer site 1 variants displayed higher off-to-on transition
frequencies than short site 1 variants, and this may be partly attributed to higher
levels ofpapl transcriptional activation, although differential papl activation was not
solely dependent on the number of repeats present in the upstream PapB site 1. The
differential in sensitivity of pap operon activation was subtle and appeared less
prominent in culture conditions considered to promote P fimbrial expression. The
reason for this remains unclear. The observation however that UPEC isolates with
two pap operons tend to differ in their site 1 sequences suggests that differential
sensitivity of activation generated by sequence change could be playing a role in
coordinating expression of homologous pap operons present in the same isolate.
Sequence changes were also identified in the genes encoding for the local pap
regulators. As both Papl and PapB are required for regulating P fimbrial expression,
it was tempting to speculate that the observed variation in amino acid sequence alters
protein regulatory function and represents adaptive changes that have evolved in an
isolate background-dependent manner to modulate pap phase variation. The variation
identified in PapB involved a single nucleotide deletion leading to a frameshift
mutation, which is more likely to prevent phase-variable expression of the encoding
pap operon, rather than modulate its phase transition frequencies. The resulting
truncated polypeptides were predicted to be nonfunctional as they lacked both the
DNA binding and oligomerisation regions required for PapB to function as a
transcriptional regulator (Xia and Uhlin, 1999). In contrast, amino acid replacement
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changes in Papl were demonstrated to alter the capacity of the regulator to activate
expression of the same pap operon. The molecular mechanism by which Papl
variants differentially affect pap operon expression was proposed to involve the
interaction of Papl with Lrp on pap DNA. This interaction appeared to be influenced
by changes in all three factors involved (see Fig. 6.10).
Previous work has established that Papl and PapB can work in trans to cross-regulate
homologous fimbrial operons (Goransson et al., 1988; van der Woude and Low,
1994; Morschhauser et al., 1994). It was therefore appreciated that the observed
sequence variation in pap-encodcd regulators could not only modulate phase
variation frequencies of the encoding pap operon, but could potentially affect phase
variation frequencies of homologous pap operons present in the same isolate through
positive cross-talk. Modulation of regulatory cross-talk potential was demonstrated
for certain Papl variants, which were commonly found in combination with other
Papl protein variants in UPEC isolates possessing multiple pap operons. The ability
of Papl variants to cross-activate the same pap operon was found to differ and the
extent of cross-activation also depended on the regulatory sequence of the operon.
Similarly, the observed deletions in papB were predominantly found in isolates that
contained homologous pap operons with intact papB copies. Full-length papB genes
encoded for highly conserved regulators. In the context of these UPEC isolates, such
mutations will reduce the papB copy number and potentially the level of the
regulator in the cell, which can have an effect on PapB cross-talk between the pap
operons of an isolate. Variation in PapB protein levels can prove more important in
modulating phase transition frequencies than protein sequence variation, since
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PapB's autoregulatory function is dependent on its expression level; PapB activates
pap expression at low levels and represses it at increasing concentrations (Forsman et
al., 1989).
Phase variation is generally considered to be a stochastic event with a switching
frequency that can in some cases be influenced by external inputs. This study
provides evidence that the phase variation frequencies determining P fimbriae
expression are not only modulated by external factors but are also influenced by
DNA sequence variation in the regulatory region and the regulators controlling the
pap switch. Variable regulatory DNA regions were shown to affect the sensitivity of
pap operon activation, while regulatory protein variants differed in their capacity to
activate expression of their own or homologous pap operons. Based on the findings
of this study, it was hypothesised that modulation of pap phase variation frequencies
via regulatory sequence changes has evolved as a mechanism for differential
activation of homologous pap operons present in the same UPEC isolate and
possibly for coordinating the timing of their expression. Therefore, a model can be
drawn predicting different scenarios of sequential expression of homologous pap
operons in a UPEC isolate (Fig. 7.1). A UPEC isolate with three homologous
fimbrial operons is considered in this model: two encoding for P fimbriae and one
encoding for F1C fimbriae. The two pap operons contain regulatory sequence
variation that was commonly encountered in the clinical UPEC isolates examined in
this study. Under certain environmental conditions and assuming a low level of PapB
regulator present, operon P2 will have a higher probability of switching on. This
probability is amplified further, as P2 will have a higher sensitivity of activation than
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Pi due to its longer PapB site 1 sequence. Expression of Papl variant 1.3 will ensure
P2 remains on but eventually, high local levels of PapB will repress expression.
Variant 1.3 has the potential to cross-activate Pi, which results in a fraction of
bacterial cells sequentially expressing Pi fimbriae on their surface after P2. The Papl
variant encoded by Pt (1.2) lacks the potential to re-activate P2 but can cross-activate
the homologous fimbrial operon F1C. Increasing local PapB levels will eventually
repress Pi operon expression and F1C fimbriae will be sequentially presented on the
bacterial cell surface after Pi. A distinct pathway of sequential fimbrial expression is
also presented in parallel, but this scenario is predicted to have a lower probability of
occurring in the bacterial population, due to the regulatory sequence differences
present in the P operons modelled.
Differential sensitivity to activation and differential ability of cross-activation by
homologous fimbrial regulators achieves a programmed set of switching events at the
single-cell level, and coordinates fimbrial expression in a hierarchical manner.
Sequential expression of related fimbrial structures may be of benefit for several
reasons. Firstly, it limits physical interference between surface structures. In addition,
the existence of a 'master' fimbrial operon which when stimulated by appropriate
environmental cues can initiate an activation relay by influencing the frequency of
activation of related fimbrial operons lower in the regulatory hierarchy, provides the
cell with the chance to display its entire repertoire of related fimbrial adhesins on its
surface. This could perhaps aid sequential occupation of different urinary tract niches,
due to slight differences in receptor specificity displayed by different adhesin alleles.
Lastly, fimbrial operons containing inactivating mutations in certain genes, as seen
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Fig. 7.1 Schematic diagram illustrating different scenarios of sequential expression of
homologous fimbrial operons in a UPEC isolate. The model UPEC isolate contains three
homologous fimbrial operons: Pb P2 encoding for P fimbriae and F1C encoding for F1C fimbriae.
Regulatory sequence differences between P, and P2 are shown in the encoded Papl variant (1.2 and 1.3)
and the number of 9 bp repeats present in the PapB binding site I sequence in each operon (4 and 9).
Activated operons are shaded green, while red represents no expression. The two depicted scenarios
have different probabilities (marked by arrow weight), due to (/) differential responsiveness of
homologous P fimbrial operons to certain environmental conditions, and (//) differential sensitivity of
PapB site 1 variant operons to activation in the presence of low PapB levels. Once expression of the
first operon is activated, the rules applied in the diagram are: i) the P2 operon is more likely to cross-
activate P,, than vice versa, due to differences in the potential of encoded Papl variants to cross-talk, if)
increasing local PapB/SfaB levels will repress expression of the encoding P/F1C fimbrial operon, and
Hi) F1C operon activation is likely to follow Pi or P2 expression due to Papfs cross-activating ability,
while SfaC is also capable of cross-activating P fimbrial operons (Goransson et al., 1988).
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This interplay between phase-varying pap operons becomes more important when
integrated into the entire regulatory network operating in clinical E. coli isolates and
controlling expression of multiple surface organelles, including fimbriae,
autotransporter proteins, capsule and flagella. Its existence into such a regulatory
context suggests a role in the dynamic bacterial adaptation and survival in changing
environments and supports the view that phase variation is not a random
uncontrolled process (Holden and Gaily, 2004; van der Woude, 2006).
Surface presentation of UPEC is expected to affect the strain's pathogenic potential
as most surface factors implicated in regulatory cross-talk are immunogenic. Testing
this hypothesis in vivo is a challenge, as subtle changes in fimbrial phase variation
resulting directly by a bacterial regulatory mechanism can be hard to distinguish
from selection forces driven by the host's immune system. One of the original aims
of this thesis was to test whether differences in P fimbrial phase transition
frequencies impact on the strain's pathogenic potential in vivo. Preliminary work,
which is not part of this thesis, tested the C3H/HeN mouse model of UTI for pro¬
inflammatory responses induced by isogenic P fimbrial mutants. The range of
induced responses was unsuitable for differentiating the effects of isogenic isolate
variants with subtle differences in P fimbrial phase transition frequencies (M. Totsika,
unpublished). Future work needs to identify a suitable in vivo model or an
appropriate in vitro cell system that will allow the study of fimbrial regulatory
variants in the context of clinical isolates in order to understand the biological
benefits of regulating the phase variation mechanism of P fimbrial expression.
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